Document:

exv10w33

 

Exhibit 10.33

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN

THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN

OMITTED AND FILED SEPARATELY WITH THE

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO

RULE 24B-2 OF THE SECURITIES EXCHANGE

ACT OF 1934, AS AMENDED

CO-DEVELOPMENT AND LICENSE AGREEMENT

This Co-Development and License Agreement (the “Agreement”) is made and entered into effective as
of December 19, 2005 (the “Effective Date”) by and between GPC Biotech AG, a German corporation,
having its place of business at Fraunhoferstrasse 20, 82152 Martinsried/Munich, Germany (“GPC
Biotech”); and Pharmion GmbH, a Swiss limited liability company and wholly-owned subsidiary of
Pharmion Corporation, a Delaware corporation, having a place of business at Aeschenvorstadt 71,
4051 Basel, Switzerland (“Licensee”). GPC Biotech and Licensee are sometimes referred to herein
individually as a “Party” and collectively as the “Parties.”

RECITALS

     WHEREAS, GPC Biotech has rights with respect to the platinum complex known as “Satraplatin”
and has commenced a Phase III registrational trial for the use of the same for the second-line
treatment of hormone-refractory prostate cancer;

     WHEREAS, Licensee and its Affiliates have specialized experience in, among other things, the
development and commercialization of pharmaceutical compounds for the treatment of cancer in the
Licensee Territory (as defined below); and

     WHEREAS, GPC Biotech desires to grant a license to Licensee, and Licensee desires to obtain a
license, to Develop and Commercialize (each as defined below) the above-mentioned pharmaceutical
compound in accordance with the terms and conditions set forth below.

     NOW, THEREFORE, in consideration of the foregoing premises, the mutual promises and covenants
of the Parties contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do
hereby agree as follows:

ARTICLE 1

DEFINITIONS

     Unless otherwise specifically provided herein, the following terms shall have the following meanings:

     1.1 “Additional Indication(s)” shall mean each indication, other than the Initial Indication.

     1.2 “Adverse Event Experience” shall have the meaning set forth in Section 9.2.

     1.3 “Affiliate” shall mean, with respect to a Party, any Person that, directly or indirectly,
through one or more intermediaries, controls, is controlled by or is under common control with such
Party. For purposes of this definition, “control” and, with correlative meanings, the terms
“controlled by” and “under common control with” shall mean (a) the

1

 

possession, directly or indirectly, of the power to direct the management or policies of a business
entity, whether through the ownership of voting securities, by contract relating to voting rights
or corporate governance, or otherwise, or (b) the ownership, directly or indirectly, of at least
fifty percent (50%) of the voting securities or other ownership interest of a business entity (or,
with respect to a limited partnership or other similar entity, its general partner or controlling
entity).

     1.4 “Agreement” shall have the meaning set forth in the preamble to this Agreement.

     1.5 “Alliance Manager” shall have the meaning set forth in Section 4.4.7.

     1.6 “ANDA Act” shall have the meaning set forth in Section 8.3.2.

     1.7 “ANZ Territory” shall mean the Commonwealth of Australia and New Zealand.

     1.8 “Applicable Law” shall mean applicable laws, rules and regulations, including any rules,
regulations, guidelines or other requirements of the Regulatory Authorities, that may be in effect
from time to time.

     1.9 “Arbitration Matter” shall have the meaning set forth in Section 15.7.4.

     1.10 “Arbitration Rules” shall have the meaning set forth in Section 15.7.4.

     1.11 “Arbitrator” shall have the meaning set forth in Section 7.12.

     1.12 “Breaching Party” shall have the meaning set forth in Section 14.2.

     1.13 “Business Day” shall mean a day other than a Saturday or Sunday on which banking
institutions in Munich, Germany are open for business.

     1.14 “Calendar Quarter” shall mean each successive period of three (3) calendar months
commencing on January 1, April 1, July 1 and October 1.

     1.15 “Calendar Year” shall mean each successive period of twelve (12) calendar months
commencing on January 1 and ending on December 31.

     1.16 “Change of Control” means, with respect to Licensee, its ultimate parent corporation or
any successor to the foregoing, (a) a merger, consolidation, share exchange or other similar
transaction involving such party and any Third Party which results in the holders of the
outstanding voting securities of such party immediately prior to such merger, consolidation, share
exchange or other similar transaction ceasing to hold more than fifty percent (50%) of the combined
voting power of the surviving, purchasing or continuing entity immediately after such merger,
consolidation, share exchange or other similar transaction, (b) any transaction or series of
related transactions in which any “person”, as such term is used in Sections 13(d) and 14(d) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), together with any of such
person’s “affiliates” or “associates”, as such terms are used in the Exchange Act, becomes the
beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding
securities of such party, or (c) the sale or other transfer to a Third Party of all or
substantially all of such party’s assets which relate to this Agreement.

2

 

     1.17 “Clinical Data” shall mean all information with respect to the Licensed Product and the
Licensed Compound, made, collected or otherwise generated in the performance of or in connection
with Clinical Studies or Post Approval Studies for the Licensed Product, including any data,
reports and results with respect thereto.

     1.18 “Clinical Studies” shall mean Phase I, Phase II, Phase III and such other tests and
studies in patients that are required by Applicable Law, or otherwise recommended by the Regulatory
Authorities, to obtain or maintain Regulatory Approvals, but excluding Post Approval Studies.

     1.19 “Collaboration Costs” shall mean the FTE Costs (charged in accordance with Sections
6.1.2, 6.1.3, 6.1.4 and 6.1.6) incurred, and the direct out-of-pocket costs recorded as an expense
in accordance with GAAP, by or on behalf of: a Party or any of its Affiliates on or after October
1, 2005 or during the term of and pursuant to this Agreement, in connection with (i) tasks that are
specifically identified in or reasonably allocable to the Development Plan and Budget or (ii) Joint
Commercialization Activities specifically identified in the applicable Commercialization Plan and
Budget. Except in the case of Collaboration Costs incurred in accordance with Section 1.19.5,
Collaboration Costs incurred on or after the Effective Date with respect to Development activities
or Joint Commercialization Activities shall be included in “Collaboration Costs” for the Licensed
Product only to the extent less than or equal to the amounts set forth in the applicable
Development Budget or Commercialization Budget for such activities (subject to permitted overruns
pursuant to Sections 2.3.2 and 3.10.2). Subject to the foregoing, Collaboration Costs shall
include such costs incurred in connection with the following activities:

          1.19.1 pre-clinical and non-clinical activities such as toxicology and formulation
development, test method development, stability testing, quality assurance, quality control
development and statistical analysis;

          1.19.2 Clinical Studies and Post Approval Studies for the Licensed Product, including (a) the
preparation for and conduct of clinical trials; (b) data collection and analysis and report
writing; (c) clinical laboratory work; and (d) regulatory activities in connection with such
studies, including adverse event recordation and reporting;

          1.19.3 the preparation of a regulatory dossier reasonably necessary to obtain Initial
Regulatory Approval for the Licensed Product in both the GPC Biotech Territory and the European
Union;

          1.19.4 Manufacturing Costs for (a) the Licensed Product for use in Clinical Studies, Post
Approval Studies or other Development activities for the Licensed Product and (b) the manufacture,
purchase or packaging of comparators or placebo for use in Clinical Studies or Post Approval
Studies for the Licensed Product (with the manufacturing costs for comparators or placebo to be
determined in the same manner as Manufacturing Costs are determined for any Licensed Product) and
(c) costs and expenses of disposal of drugs and other supplies used in such Clinical Studies, Post
Approval Studies or other Development activities;

3

 

          1.19.5 Losses incurred in connection with Third Party Claims described in Section 13.3 to the
extent such losses are to be included in Collaboration Costs pursuant to Section 13.3; and

          1.19.6 Costs for the development of the Manufacturing Process for the Licensed Product,
scale-up, Manufacturing Process validation, including validation batches, manufacturing
improvements and qualification and validation of Third Party contract manufacturers; provided,
however, as set forth in Section 3.1.3 of the Supply Agreement, Licensee’s share pursuant to
Section 6.1.1 of any such costs allocable to the Manufacture of any validation batch (or part
thereof) that is subsequently sold commercially by or on behalf of Licensee or any of its
Affiliates, Sublicensees or Distributors, shall be credited against the Supply Price for such
supply.

For the avoidance of doubt and notwithstanding the foregoing, Collaboration Costs shall not include
any (a) FTE costs or other costs and expenses that are specifically identifiable or reasonably
allocable to Unilateral Activities of either Party during the applicable Opt-Out Period, (b) filing
fees in connection with the filing of applications for Regulatory Approvals (c) Third Party
Payments or (d) intercompany payments or charges of a Party or its Affiliates (or between such
Affiliates).

     1.20 “Combination Product” shall mean a Licensed Product that contains the Licensed Compound
as an active ingredient together with one or more other active ingredients that are sold either as
a fixed dose or as separate doses in a single package.

     1.21 “Commercialization” shall mean any and all activities (whether before or after Regulatory
Approval) directed to the marketing, Detailing and promotion of the Licensed Product and shall
include pre-launch and post-launch marketing, promoting, Detailing, marketing research,
distributing, offering to commercially sell and commercially selling the Licensed Product,
importing, exporting or transporting the Licensed Product for commercial sale and regulatory
affairs with respect to the foregoing, but shall not include Post Approval Studies or
Manufacturing. When used as a verb, “Commercializing” means to engage in Commercialization and
“Commercialize” and “Commercialized” shall have corresponding meanings.

     1.22 “Commercialization Budget” shall mean the budget for the Joint Commercialization
Activities set forth in the Commercialization Plan, as provided in Section 3.2.1.

     1.23 “Commercialization Plan” shall mean the plan for the Commercialization of the Licensed
Product in the Field in the Licensee Territory and for the Joint Commercialization Activities in
support of the Commercialization of the Licensed Product in the Field in the Territory to be
developed and amended as provided in Section 3.2.1.

     1.24 “Commercialization Plan and Budget” shall mean the Commercialization Plan and the
Commercialization Budget.

     1.25 “Commercially Reasonable Efforts” shall mean, with respect to the Development or
Commercialization of the Licensed Product, as the case may be, efforts and

4

 

resources commonly used in the research-based pharmaceutical industry by companies similarly
situated to the applicable Party, but in no event less than those efforts and resources commonly
used by companies similarly situated to the applicable Party as of the Effective Date, for an
internally-developed product of similar commercial potential at a similar stage in its lifecycle.
Commercially Reasonable Efforts shall be determined on a market-by-market basis for the Licensed
Product without regard to the particular circumstances of a Party, including any other product
opportunities of such Party and, with respect to Licensee, without regard to any payments owed to
GPC Biotech under Articles 6 and 7. When used as an adjective, “Commercially Reasonable” shall
mean using Commercially Reasonable Efforts.

     1.26 “Committee” shall mean any one of the JEC, the JDC or the JCC and “Committees” shall mean
two or more of the JEC, the JDC or the JCC.

     1.27 “Competitive Program” means a clinical development program in a Phase II or Phase III
stage or later anywhere in the Territory in support of commercialization activities in the Licensee
Territory or commercialization activity (including marketing or promotion) in the Licensee
Territory that involves a compound or product (other than the Licensed Product) [...***...].

     1.28 “Complaining Party” shall have the meaning set forth in Section 14.2.

     1.29 “Complaint” shall have the meaning set forth in Section 9.1.

     1.30 “Completion Notice” shall have the meaning set forth in Section 2.5.6(b).

     1.31 “Compound Option Notice” shall have the meaning set forth in Section 5.4.

     1.32 “Confidential Information” shall have the meaning set forth in Section 11.1.

     1.33 “Control” shall mean, with respect to any item of Information, Drug Master File,
Regulatory Documentation, Patent or Intellectual Property Right, possession of the right, whether
directly or indirectly, and whether by ownership, license or otherwise (other than by

 

			
	***	 	Confidential Treatment Requested

5

 

     operation of the assignments, license and other grants in Article 5 and Sections 8.1.3 and 8.1.4 of
this Agreement), to assign or grant a license, sublicense or other right to or under, such
Information, Drug Master File, Regulatory Documentation, Patent or Intellectual Property Right as
provided for herein without violating the terms of any agreement or other arrangement with any
Third Party.

     1.34 “Corporate Names” shall mean (a) in the case of GPC Biotech, the Trademark “GPC BIOTECH”
and the GPC Biotech corporate logo or such other names and logos as GPC Biotech may designate in
writing from time to time and (b) in the case of Licensee, the Trademark “PHARMION” and the
Licensee corporate logo or such other names and logos as Licensee may designate in writing from
time to time, in each case ((a) and (b)) together with any variations and derivatives thereof.

     1.35 “Country Commercialization Plan” shall have the meaning set forth in Section 3.2.3.

     1.36 “Derivative Compound” means an analog or derivative of the Licensed Compound. For
clarity, a Derivative Compound is not an Improvement.

     1.37 “Detail” shall mean an interactive face-to-face contact of a sales representative, who is
fully equipped with, and knowledgeable of, applicable Promotional Materials and Product Labeling
for the Licensed Product, with a physician or other medical professional licensed to prescribe
drugs or other healthcare professional that has a significant impact or influence on prescribing
decisions, in which relevant characteristics of the Licensed Product are described by the sales
representative in a fair and balanced manner consistent with the requirements of this Agreement and
Applicable Law, and in a manner that is customary in the industry for the purpose of promoting a
prescription pharmaceutical product. When used as a verb, “Detail” means to engage in a Detail.

     1.38 “Developing Party” shall have the meaning set forth in Section 2.5.2(a).

     1.39 “Development” shall mean all activities related to research, preclinical and other
non-clinical testing, test method development and stability testing, toxicology, formulation,
process development, manufacturing scale-up, qualification and validation, quality
assurance/quality control related to the foregoing manufacturing activities, Clinical Studies and
Post Approval Studies, including manufacturing in support thereof, statistical analysis and report
writing, the preparation and submission of Drug Approval Applications, regulatory affairs with
respect to the foregoing and all other activities otherwise requested or required by a Regulatory
Authority as a condition or in support of obtaining or maintaining a Regulatory Approval. When
used as a verb, “Develop” shall mean to engage in Development.

     1.40 “Development Budget” shall mean the budget for the Development of the Licensed Product
agreed to by the Parties as of the Effective Date, as it may be amended from time to time in
accordance with Section 2.3.1. For clarity, the Development Budget shall not include budgets for
Unilateral Activities.

     1.41 “Development Lead” shall mean, with respect to a Development activity, the Party that (a)
is assigned primary responsibility for the day-to-day implementation of such

6

 

Development activity as provided in the Development Plan or (b) is the Developing Party for a
Unilateral Activity.

     1.42 “Development Plan” shall mean the plan for the Development of the Licensed Product in the
Field agreed to by the Parties as of the Effective Date, as it may be amended from time to time in
accordance with Sections 2.2.1 and 2.5.1. For clarity, the Development Plan shall not include any
Development plans for Unilateral Activities.

     1.43 “Development Plan and Budget” shall mean the Development Plan and the Development Budget.

     1.44 “Dispute” shall have the meaning set forth in Section 15.7.

     1.45 “Distributor” shall mean a Person, other than a Sublicensee or an Affiliate, in one or
more countries in the Licensee Territory that (a) purchases the Licensed Product in finished form
or in bulk capsule form (to be packaged or labeled by such Person in accordance with Applicable
Law) from the Licensee, its Affiliate or Sublicensee for such country(ies), (b) assumes
responsibility from the Licensee for all or a portion of the Commercialization of the Licensed
Product in such country(ies) and (c) sells Licensed Product in such country(ies).

     1.46 “Drug Approval Application” shall mean a New Drug Application (an “NDA”) as defined in
the FFDCA and the regulations promulgated thereunder, or any corresponding foreign application in
the Territory, including, with respect to the European Union, a Marketing Authorization Application
(a “MAA”) filed with the EMEA pursuant to the centralized approval procedure or with the
applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or
any other national approval procedure.

     1.47 “Drug Master File” shall mean any drug master files filed with the FDA with respect to
the Licensed Product and any equivalent filing in other countries or regulatory jurisdictions.

     1.48 “Effective Date” shall mean the effective date of this Agreement as set forth in the
preamble to this Agreement.

     1.49 “EMEA” shall mean the European Medicines Agency and any successor agency thereto.

     1.50 “Europe” shall mean the countries comprising the European Economic Area as it may be
constituted from time to time, which as of the date hereof, consists of the member countries of the
European Union, Iceland, Norway, Lichtenstein and Switzerland.

     1.51 “European Union” shall mean the economic, scientific and political organization of member
states as it may be constituted from time to time, which, as of the date hereof, consists of
Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary,
Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Slovakia,
Slovenia, Spain, Sweden and the United Kingdom of Great Britain and Northern Ireland and that
certain portion of Cyprus included in such organization.

7

 

     1.52 “Exchange Act” shall have the meaning set forth in Section 1.16.

     1.53 “Expert” shall have the meaning set forth in Section 15.7.4(b)(i).

     1.54 “Exploit” shall mean to make, have made, import, use, sell or offer for sale, including
to research, Develop, Commercialize, register, Manufacture, have Manufactured, hold or keep
(whether for disposal or otherwise), have used, export, transport, distribute, promote, market or
have sold or otherwise dispose of.

     1.55 “Exploitation” shall mean the act of Exploiting a product or process.

     1.56 “Exploratory Study” shall mean a Clinical Study other than any Registrational Study.

     1.57 “FDA” shall mean the United States Food and Drug Administration and any successor agency thereto.

     1.58 “FFDCA” shall mean the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time.

     1.59 “Field” shall have the meaning set forth in the Spectrum Agreement, as it may be amended from time to time.

     1.60 “Follow Up Registrational Study” shall mean the first Registrational Study, if any,
conducted by the Parties pursuant to the Development Plan to obtain Initial Regulatory Approval for
the Licensed Product in the United States and Europe with respect to an Additional Indication.

     1.61 “FTE” shall mean the equivalent of the work of one (1) employee full time for one (1)
Calendar Year (consisting of at least a total of eighteen hundred (1800) hours per Calendar Year,
or such other number as may be agreed by the JDC) of work directly related to the Development of
the Licensed Product or any other activities contemplated under this Agreement. No additional
payment shall be made with respect to any person who works more than eighteen hundred (1800) hours
per Calendar Year (or such other number as may be agreed by the JDC) and any person who devotes
less than eighteen hundred (1800) hours per Calendar Year (or such other number as may be agreed by
the JDC) shall be treated as an FTE on a pro-rata basis based upon the actual number of hours
worked divided by eighteen hundred (1800) (or such other number as may be agreed by the JDC).

     1.62 “FTE Cost” shall mean the FTE rate for employees who shall be performing services under
this Agreement which, as of the Effective Date, is equal to [...***...]. Such rate shall be
adjusted subsequently in accordance with Section 6.1.4.

     1.63 “GAAP” shall mean United States generally accepted accounting principles consistently
applied.

 

			
	***	 	Confidential Treatment Requested

8

 

     1.64 “Generic Product” shall mean, with respect to a Licensed Product in a country, any
product (a) that contains the Licensed Compound, (b) in the case of any country in the European
Union, is approved for sale in the Field pursuant to an application approved by the applicable
Regulatory Authorities in the European Union under Article 10.1 of Directive 2001/83/EC, and for
which the applicant is not required under Article 8.3(i) of Directive 2001/83/EC to have submitted
any preclinical and clinical data other than data from bioequivalence studies comparing such
product to such Licensed Product required under Article 10.1 of that Directive, and in the case of
any other country in the Licensee Territory, is approved for sale pursuant to any corresponding
application in such country, and (c) is sold for use or consumption in the Field by the general
public in such country by a Third Party, other than any Third Party that is a Sublicensee or
Distributor or otherwise sells such product pursuant to a (sub)license, distributorship or other
arrangement with Licensee, or pursuant to or in reliance on any right of reference granted to such
Third Party or any of its Affiliates by or on behalf of Licensee.

     1.65 “Global Strategy” shall have the meaning set forth in Section 3.1.3(a).

     1.66 “GPC Biotech” shall have the meaning set forth in the preamble to this Agreement.

     1.67 “GPC Biotech Activities” shall have the meanings set forth in Section 2.2.2(b).

     1.68 “GPC Biotech Counter-Party” shall mean a Third Party with which GPC Biotech has entered
into an agreement that includes Development and Commercialization rights or Commercialization
rights for the Licensed Product.

     1.69 “GPC Biotech Improvement” shall mean any Improvement conceived or used by or on behalf of
GPC Biotech or its Affiliates in connection with the Development of the Licensed Product under this
Agreement but excluding any Joint Improvement.

     1.70 “GPC Biotech Know-How” shall mean all Information, including any GPC Biotech Improvements
and Clinical Data, that is Controlled by GPC Biotech or its Affiliates as of the Effective Date or
during the term of this Agreement that is not generally known and (a) is developed or acquired by
or licensed to GPC Biotech or any of its Affiliates under or in connection with this Agreement or
otherwise used by or on behalf of GPC Biotech or any of its Affiliates in the Development or
Commercialization of the Licensed Product or (b) is necessary for the Development or
Commercialization of the Licensed Product, but excluding any Information to the extent covered or
claimed by published GPC Biotech Patents, published Joint Patents and any Joint Know-How.

     1.71 “GPC Biotech Patents” shall mean all of the Patents that GPC Biotech and its Affiliates
Control as of the Effective Date or during the term of this Agreement that are necessary (or, with
respect to Patent applications, would be necessary if such Patent applications were to issue as
Patents) for the Development or Commercialization of the Licensed Product or any Improvement
thereto, including those that claim or cover the Licensed Product or the Development or
Commercialization thereof, but excluding any Joint Patents. For the avoidance

9

 

of doubt, the GPC Biotech Patents include, as of the Effective Date, the Patents set forth on
Exhibit A.

     1.72 “GPC Biotech Territory” shall mean the entire world, other than the Licensee Territory
and including any countries or Major Market Regions in which this Agreement is terminated pursuant
to Article 14.

     1.73 “Improvement” shall mean any modification, variation or revision to a compound, product
or technology or any discovery, technology, device or process or formulation related to such
compound, product or technology, whether or not patented or patentable, including any enhancement
in the efficiency, operation, manufacture (including any manufacturing process), ingredients,
preparation, presentation, formulation, means of delivery, packaging or dosage of such compound,
product or technology, any discovery or development of any new or expanded indications for such
compound, product or technology or any discovery or development that improves the stability, safety
or efficacy of such compound, product or technology; provided that, Improvements shall exclude any
Derivative Compound.

     1.74 “Indemnification Claim Notice” shall have the meaning set forth in Section 13.4.

     1.75 “IND” shall mean an investigational new drug application filed with the FDA for
authorization to commence Clinical Studies or Post Approval Studies and its equivalent in other
countries or regulatory jurisdictions.

     1.76 “Indemnified Party” shall have the meaning set forth in Section 13.4.

     1.77 “Information” shall mean all technical, scientific and other know-how and information,
trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions,
skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings,
assembly procedures, computer programs, apparatuses, specifications, data, results and other
material, including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical
and analytical, pre-clinical, clinical, safety, manufacturing and quality control data and
information, including study designs and protocols; assays and biological methodology; (whether or
not confidential, proprietary, patented or patentable) in written, electronic or any other form now
known or hereafter developed, but excluding the Regulatory Documentation and the Drug Master File.

     1.78 “Initial Indication” shall mean the second-line treatment of hormone-refractory prostate
cancer.

     1.79 “Initial Opt-Out Threshold” shall have the meaning set forth in Section 2.6.1(b).

     1.80 “Initial Regulatory Approval” of the Licensed Product for an indication means (a) with
respect to the United States, the approval by FDA (whether through means of an NDA, subpart E, or
subpart H filing or otherwise); or (b) with respect to a country in a regulatory jurisdiction in
the Licensee Territory, the approval by the applicable Regulatory Authorities, of the Drug Approval
Application with respect to the Licensed Product for such indication in the

10

 

applicable regulatory jurisdiction (including, in the European Union, the approval by the EMEA of
an MAA filed pursuant to the centralized approval procedure, if applicable, or otherwise with
respect to the mutual recognition approval procedure on a country-by-country basis with the
applicable Regulatory Authority of a country in Europe).

     1.81 “Intellectual Property Rights” shall mean Trademarks, service marks, trade names,
registered designs, design rights, copyrights (including rights in computer software), database
rights, trade secrets and any rights or property similar to any of the foregoing (other than
Patents) in any part of the Territory whether registered or not registered together with the right
to apply for the registration of any such rights.

     1.82 “Invoiced Sales” shall have the meaning set forth in Section 1.114.

     1.83 “Joint Commercialization Activities” shall have the meaning set forth in Section 4.3.2.

     1.84 “Joint Commercialization Committee” or “JCC” shall have the meaning set forth in Section 4.3.1.

     1.85 “Joint Development Committee” or “JDC” shall have the meaning set forth in Section 4.2.1.

     1.86 “Joint Executive Committee” or “JEC” shall have the meaning set forth in Section 4.1.

     1.87 “Joint Improvement” shall mean any Improvement jointly conceived by or on behalf of GPC
Biotech or its Affiliates, on the one hand, and Licensee or its Affiliates or Sublicensees, on the
other hand.

     1.88 “Joint Intellectual Property Rights” shall have the meaning set forth in Section 8.1.5.

     1.89 “Joint Know-How” shall have the meaning set forth in Section 8.1.5.

     1.90 “Joint Patents” shall have the meaning set forth in Section 8.1.5.

     1.91 “Knowledge” shall mean the actual knowledge or good faith understanding of the vice
presidents, senior vice presidents, president or chief executive officer of a Party of the facts
and information then in their possession without any duty to conduct any investigation with respect
to such facts and information and “Knowingly” shall mean, with respect to any action, to take such
action with Knowledge.

     1.92 “Licensed Compound” shall mean the platinum complex
af-bis(acetato)-b-ammine-cd-dichloro-e-(cyclohexylamine)platinum(IV).

     1.93 “Licensed Product” shall mean any form, mode of administration or dosage of a
pharmaceutical composition or preparation that contains the Licensed Compound as an active
ingredient, including any Improvements thereto.

11

 

     1.94 “Licensee” shall have the meaning set forth in the preamble to this Agreement.

     1.95 “Licensee Activities” shall have the meaning set forth in Section 2.2.2(b).

     1.96 “Licensee Change of Control Notice” shall have the meaning set forth in Section 14.5.2.

     1.97 “Licensee Improvement” shall mean any Improvement conceived or used by or on behalf of
Licensee or its Affiliates in connection with the Development of the Licensed Product under this
Agreement, but excluding any Joint Improvement.

     1.98 “Licensee Initial Indication Study” shall have the meaning set forth in Section 2.6.2(b).

     1.99 “Licensee Know-How” shall mean all Information, including any Licensee Improvements and
Clinical Data, that is Controlled as of the Effective Date or during the term of this Agreement by
Licensee or any of its Affiliates or Sublicensees that is not generally known and (a) is developed
or acquired by or licensed to Licensee or any of its Affiliates or Sublicensees under or in
connection with this Agreement or otherwise used by or on behalf of Licensee or any of its
Affiliates or Sublicensees in the Exploitation of the Licensed Product or the Licensed Compound or
(b) is necessary for the Exploitation of the Licensed Product or the Licensed Compound, but
excluding any Information to the extent covered or claimed by published Licensee Patents, published
Joint Patents and any Joint Know-How.

     1.100 “Licensee Patents” shall mean all Patents Controlled by Licensee and any of its
Affiliates or Sublicensees that are necessary (or with respect to Patent applications, would be
necessary if such Patent applications were to issue as Patents) for the Exploitation of the
Licensed Product, the Licensed Compound or any Licensee Improvement thereto, including those that
claim or cover any Licensed Compound, Licensed Product, Licensee Know-How, any Licensee Improvement
thereto or the Exploitation of any of the foregoing, but excluding any Joint Patents.

     1.101 “Licensee Territory” shall mean Europe, the Middle East, the ANZ Territory and any
portion of Cyprus not otherwise included within Europe, and except for those countries in which
this Agreement is terminated pursuant to Article 14.

     1.102 “Losses” shall have the meaning set forth in Section 13.1.

     1.103 “MAA” shall have the meaning set forth in Section 1.46.

     1.104 “Major Market Country” shall mean (a) with respect to Europe, France, Germany, Italy,
Spain and the United Kingdom and (b) with respect to the ANZ Territory, the Commonwealth of
Australia and (c) with respect to the Middle East, Israel and the Republic of Turkey.

     1.105 “Major Market Region” shall mean each of Europe, the Middle East, and the ANZ Territory.

12

 

     1.106 “Major Meetings” shall mean meetings (in person or otherwise) scheduled with the Regulatory
Authorities in the United States or the Licensee Territory concerning the Licensed Product
(including advisory committee meetings and any other meetings of experts convened by a Regulatory
Authority concerning any topic relevant to the Licensed Product of which a Party has been notified)
that would constitute type “A,” “B” or “C” meetings in the United States, or the equivalent thereof
in the European Union, Pre-NDA meetings or meetings relating to Product Labeling.

     1.107 “Manufacture” and “Manufacturing” shall mean all activities related to the production,
manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of the
Licensed Product or any intermediate thereof, including process development, process qualification
and validation, scale up, pre-clinical, clinical and commercial manufacture and analytic
development, product characterization, stability testing, quality assurance and quality control.

     1.108 “Manufacturing Cost” shall mean GPC Biotech’s cost to Manufacture the Licensed Product
calculated in accordance with the method disclosed by GPC Biotech in its letter to Licensee dated
December 13, 2005.

     1.109 “Manufacturing Process” shall mean any process or step thereof that is necessary or
useful for Manufacturing the Licensed Product or any intermediate thereof.

     1.110 “Markings” shall have the meaning set forth in Section 3.4.2.

     1.111 “Merger Party” shall have the meaning set forth in Section 14.5.3.

     1.112 “Middle East” shall mean the following countries: Bahrain, Egypt, Iran, Iraq, Israel,
Jordan, Kuwait, Lebanon, Oman, the Palestinian Territories (including the West Bank and the Gaza
Strip) as they may be constituted from time to time and any successor state comprising such
territories, Qatar, the Republic of Turkey, Saudi Arabia, Syria, the United Arab Emirates and
Yemen; and any successor state comprising the territory of any such countries.

     1.113 “NDA” shall have the meaning set forth in Section 1.46.

     1.114 “Net Sales” shall mean, for any period, (a) the gross amount invoiced by Licensee and
its Affiliates or Sublicensees for the sale of Licensed Product in an arm’s length transaction
exclusively for money (the “Invoiced Sales”), after deduction of normal trade discounts and of any
credits actually given by Licensee for returned or defective products, as determined in accordance
with GAAP, and excluding or making proper deductions for any costs of packing, insurance, carriage
and freight and VAT or other sales tax and, in the case of export orders, any import duties or
similar applicable governmental levies or export insurance costs expressly subject in all cases to
the same being separately charged on customer invoices or (b) in any sale or other disposal of
Licensed Product otherwise than in an arm’s length transaction exclusively for money, the fair
market value (if higher) in the relevant country of disposal.

     Notwithstanding the foregoing, in the event that the Licensed Product is sold in conjunction
with another proprietary component so as to be a Combination Product (whether packaged together or
in the same therapeutic formulation), Net Sales shall be calculated by

13

 

multiplying the Net Sales of such Combination Product by a fraction, the numerator of which shall
be the fair market value of the Licensed Product if sold separately (determined in accordance with
GAAP) and the denominator of which shall be the aggregate fair market value of all the proprietary
active components of such Combination Product, including the Licensed Product, if sold separately.
In the event that no such separate sales are made by Licensee or its Affiliates or Sublicensees,
Net Sales of the Combination Product shall be calculated in a manner to be negotiated and agreed
upon by the Parties, reasonably and in good faith, prior to any sale of such Combination Product,
which shall be based upon the respective estimated commercial values of the proprietary active
components of such Combination Product.

     Licensee’s or any of its Affiliate’s or Sublicensee’s transfer of Licensed Product to an
Affiliate or Sublicensee shall not result in any Net Sales, unless the Licensed Product is consumed
by such Affiliate or Sublicensee in the course of its commercial activities.

     1.115 “Non-Approvable Study” shall mean, with respect to any Registrational Study for the
Initial Indication or any Additional Indication conducted pursuant to the Development Plan, that
such study was determined by the applicable Regulatory Authority, or mutually by the Parties, to be
insufficient to support Initial Regulatory Approval of the Licensed Product in the designated
jurisdiction in the absence of substantial additional data or investment.

     1.116 “Notice Period” shall have the meaning set forth in Section 14.2.

     1.117 “Opt-In” shall have the meaning set forth in Section 2.5.6(a).

     1.118 “Opt-In Exercise Notice” shall have the meaning set forth in Section 2.5.6(b).

     1.119 “Opt-In Exercise Period” shall have the meaning set forth in Section 2.5.6(a).

     1.120 “Opting-Out Party” shall have the meaning set forth in Section 2.5.2(a).

     1.121 “Opt-Out” shall have the meaning set forth in Section 2.5.2(a).

     1.122 “Opt-Out Period” shall mean, with respect to any Unilateral Activity, the period
commencing on the date on which an activity is deemed to be a Unilateral Activity pursuant to
Section 2.5.2(a) and ending on the earlier to occur of (a) the date of completion of such
Unilateral Activity or (b) the date on which the Opt-In Exercise Notice is received by the
Developing Party, as applicable.

     1.123 “Party” and “Parties” shall have the meaning set forth in the preamble to this
Agreement.

     1.124 “Patents” shall mean (a) all national, regional and international patents and patent
applications, including provisional patent applications, (b) all patent applications filed either
from such patents, patent applications or provisional applications or from an application claiming
priority from either of these, including divisionals, continuations, continuations-in-part,
provisionals, converted provisionals and continued prosecution applications, (c) any and all
patents that have issued or in the future issue from the foregoing patent applications ((a) and
(b)), including utility models, petty patents and design patents and certificates of invention, (d)
any

14

 

and all extensions or restorations by existing or future extension or restoration mechanisms,
including revalidations, reissues, re-examinations and extensions (including any supplementary
protection certificates and the like) of the foregoing patents or patent applications ((a), (b) and
(c)) and (e) any similar rights, including so-called pipeline protection or any importation,
revalidation, confirmation or introduction patent or registration patent or patent of additions to
any of such foregoing patent applications and patents.

     1.125 “Payments” shall have the meaning set forth in Section 7.8.1.

     1.126 “Person” shall mean an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust,
joint stock company, trust, unincorporated association, joint venture or other similar entity or
organization, including a government or political subdivision, department or agency of a
government.

     1.127 “Pharmacovigilance Agreement” shall have the meaning set forth in Section 9.3.

     1.128 “Phase I” shall mean a human clinical trial of the Licensed Product, the principal
purpose of which is a preliminary determination of safety in healthy individuals or patients or
similar clinical study prescribed by the Regulatory Authorities, including the trials referred to
in 21 C.F.R. §312.21(a), as amended.

     1.129 “Phase II” shall mean a human clinical trial of the Licensed Product, the principal
purpose of which is a determination of safety and efficacy in the target patient population or a
similar clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to
Applicable Law or otherwise, including the trials referred to in 21 C.F.R. §312.21(b), as amended.

     1.130 “Phase III” shall mean a human clinical trial of the Licensed Product on a sufficient
number of subjects that is designated to establish that a pharmaceutical product is safe and
efficacious for its intended use and to determine warnings, precautions and adverse reactions that
are associated with such pharmaceutical product in the dosage range to be prescribed, which trial
is intended to support marketing approval of the Licensed Product, including all tests and studies
that are required by the FDA from time to time, pursuant to Applicable Law or otherwise.

     1.131 “Post Approval Study” shall mean any human clinical study or other test or study with
respect to a product for an indication that (a) is conducted solely in support of pricing or
reimbursement for such product in a country or (b) is not required to obtain or maintain Regulatory
Approval for such product for such indication (for clarity, any human clinical study that is
intended to expand the Product Labeling for such product shall be a Clinical Study). Subject to
the foregoing, Post Approval Studies may include epidemiological studies, modeling and
pharmacoeconomic studies, post-marketing surveillance studies, investigator sponsored studies and
health economics studies.

     1.132 “Product Labeling” shall mean (a) the Regulatory Authority-approved full prescribing
information for the Licensed Product for that country, including any required patient

15

 

information; and (b) all labels and other written, printed or graphic matter upon a container,
wrapper or any package insert utilized with or for the Licensed Product.

     1.133 “Product Trademarks” shall mean (a) the Trademark(s) for the Licensed Product Controlled
by GPC Biotech during the term of this Agreement and used or intended for use in connection with
the Commercialization of Licensed Products, and (b) such other Trademarks designated by the JCC in
accordance with Section 3.4.4 and any registrations thereof or any pending applications relating
thereto.

     1.134 “Promotional Materials” shall mean all sales representative training materials with
respect to the Licensed Product and all written, printed, graphic, electronic, audio or video
matter, including journal advertisements, sales visual aids, direct mail, medical
information/education monographs, direct-to-consumer advertising, Internet postings, broadcast
advertisements and sales reminder aids (e.g., scratch pads, pens and other such items) intended for
use or used by a Party, its Affiliates or, with respect to Licensee, its Sublicensees or
Distributors, in connection with any promotion of the Licensed Product, except Product Labeling for
the Licensed Product.

     1.135 “Proposed Unilateral Activities” shall have the meaning set forth in Section 2.5.2.

     1.136 “Registrational Study” shall mean (a) in the case of a Clinical Study with respect to
which GPC Biotech is the Development Lead, a pivotal Clinical Study for the Licensed Product for
the Initial Indication or any Additional Indication that is designed to be sufficient to obtain
Initial Regulatory Approval by the FDA of the Licensed Product for such indication or (b) in the
case of a Clinical Study with respect to which Licensee is the Development Lead, a pivotal Clinical
Study for the Licensed Product for the Initial Indication or any Additional Indication that is
designed to be sufficient to obtain Initial Regulatory Approval by the applicable Regulatory
Authorities in a given country or countries in the Licensee Territory, or if applicable, the
European Union. For the avoidance of doubt, the SPARC Study shall be deemed to constitute a
Registrational Study for the Initial Indication.

     1.137 “Registrational Study Budgeted Funding Commitment” shall mean [...***...].

     1.138 “Regulatory Approval” shall mean, with respect to a country in the Territory, any and
all approvals (including Drug Approval Applications), licenses, registrations or authorizations of
any Regulatory Authority necessary to commercially distribute, sell or market the Licensed Product
in such country, including, where applicable, (a) pricing or reimbursement approval in such
country, (b) pre- and post-approval marketing authorizations (including any prerequisite
Manufacturing approval or authorization related thereto), (c) labeling approval and (d) technical,
medical and scientific licenses.

     1.139 “Regulatory Authority” shall mean any applicable supra-national, federal, national,
regional, state, provincial or local regulatory agencies, departments, bureaus,

*** Confidential Treatment Requested

16

 

commissions, councils or other government entities regulating or otherwise exercising authority
with respect to the Exploitation of the Licensed Compound or the Licensed Product in the Territory.

     1.140 “Regulatory Documentation” shall mean all applications, registrations, licenses,
authorizations and approvals (including all Regulatory Approvals), all correspondence submitted to
or received from Regulatory Authorities (including minutes and official contact reports relating to
any communications with any Regulatory Authority) and all supporting documents and all clinical
studies and tests, relating to the Licensed Product and all data contained in any of the foregoing,
including all INDs, Drug Approval Applications, regulatory drug lists, advertising and promotion
documents, Clinical Data, adverse event files and complaint files (but excluding any Drug Master
File).

     1.141 “Regulatory Exclusivity Period” shall mean any period of data, market or other
regulatory exclusivity, including any such periods listed in the FDA’s Orange Book or periods under
national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 and all international
equivalents.

     1.142 “Regulatory Lead” shall mean, with respect to a country or regulatory region, the Party
that has primary responsibility for preparing, obtaining and maintaining Regulatory Approvals for,
and for conducting communications with the Regulatory Authorities with respect to, the Licensed
Product in such country or region as provided in Section 2.4.

     1.143 “Related Unilateral Activities” shall have the meaning set forth in Section 2.5.6(a).

     1.144 “Royalty Rate Floor” shall have the meaning set forth in Section 7.2.

     1.145 “Royalty Term” shall have the meaning set forth in Section 7.3.

     1.146 “Selected Development Activities” shall mean Development activities for the Licensed
Product consisting of (a) any Exploratory Study or (b) other Development activities in each case
((a) and (b)) provided for in the Development Plan, excluding in each case ((a) and (b)) any
Development activities associated with (i) the SPARC Study, (ii) any other Registrational Study and
(iii) any Unilateral Activities.

     1.147 “SPARC Study” shall have the meaning set forth in Section 2.1.1.

     1.148 “Spectrum Agreement” shall mean that certain Co-Development and License Agreement
between Spectrum Pharmaceuticals, Inc. (f/k/a Neotherapeutics, Inc.) and GPC Biotech AG, dated
September 30, 2002, a redacted copy of which is on file with the United States Securities and
Exchange Commission, as Exhibit 10.1 to GPC Biotech’s Form F-1, dated June 9, 2004.

     1.149 “Spectrum Payments” shall have the meaning set forth in Section 8.4.1(a).

     1.150 “Spectrum Royalty Term” shall have the meaning set forth in Section 7.3.

17

 

     1.151 “Statement Cut-Off Date” shall have the meaning set forth in Section 2.5.6(b).

     1.152 “Sublicensee” shall mean a Person, other than an Affiliate, that is granted a sublicense
by Licensee under the grant in Section 5.1 as provided in Section 5.3.

     1.153 “Supply Agreement” shall mean the agreement for supply of Licensed Product by GPC
Biotech to Licensee executed by the Parties as of the Effective Date.

     1.154 “Supply Price” shall mean one hundred and ten percent (110%) of the Manufacturing Costs.

     1.155 “Territory” shall mean the GPC Biotech Territory and the Licensee Territory.

     1.156 “Third Party” shall mean any Person other than GPC Biotech, Licensee and their respective Affiliates.

     1.157 “Third Party Claims” shall have the meaning set forth in Section 13.1.

     1.158 “Third Party Payment” shall have the meaning set forth in Section 8.4.1(a).

     1.159 “Trademark” shall include any word, name, symbol, color, designation or device or any
combination thereof, including any trademark, trade dress, brand mark, service mark, trade name,
brand name, logo or business symbol, whether or not registered.

     1.160 “Unilateral Activities” shall have the meaning set forth in Section 2.5.2.

     1.161 “Unilateral Activity Cost Statement” shall have the meaning set forth in Section
2.5.6(b).

     1.162 “United States” or “U.S.” shall mean the United States of America, including its
territories and possessions, the District of Columbia and Puerto Rico.

     1.163 “Valid Claim” shall mean, with respect to a particular country, (a) any claim of an
issued and unexpired Patent in such country that (i) has not been held permanently revoked,
unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction,
which decision is unappealable or unappealed within the time allowed for appeal and (ii) has not
been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or
disclaimer or otherwise in such country; or (b) a claim of a pending Patent application, which
claim has not been abandoned or finally disallowed without the possibility of appeal or re-filing
of the application; provided, however, that if a claim of a patent application has been pending for
more than five (5) years, such claim shall not constitute a Valid Claim for the purposes of this
Agreement unless and until a Patent issues with such claim.

     1.164 “VAT” shall have the meaning set forth in Section 7.8.2.

18

 

ARTICLE 2

DEVELOPMENT AND REGULATORY

     2.1 Development of the Licensed Product.

          2.1.1 Ongoing Development. As of the Effective Date, GPC Biotech is conducting a Phase III
Clinical Study for the Initial Indication described more fully in the Development Plan (the “SPARC
Study”) and certain Phase I, Phase I/II and Phase II Clinical Studies for the Licensed Product in
the Territory as listed in the Development Plan. The Parties acknowledge and agree that the SPARC
Study is a pivotal study which is intended to be sufficient for the filing of an MAA for the
Initial Indication in the European Union.

          2.1.2 Diligence.

               (a) In General. Subject to Section 2.1.2(c), each Party shall use Commercially Reasonable
Efforts to perform the responsibilities assigned to it under the Development Plan and this
Agreement expeditiously and efficiently and in accordance with the Development Budget. For
clarity, nothing contained in this Section 2.1.2(a) shall operate to limit any right of the Parties
to amend the Development Plan or Development Budget in accordance with the terms and conditions of
this Agreement.

               (b) By Licensee. Without limitation to Section 2.1.2(a),

                    (i) Licensee shall use Commercially Reasonable Efforts (1) to Develop and obtain Regulatory
Approval for the Licensed Product in all Major Market Countries in the Licensee Territory, and (2)
to Develop and obtain Regulatory Approval for the Licensed Product in each other country in the
Licensee Territory where performing such Development and seeking such Regulatory Approval would be
Commercially Reasonable;

                    (ii) without limitation to Section 2.1.2(b)(i), Licensee shall use Commercially Reasonable
Efforts to Develop and obtain Regulatory Approvals for the Licensed Product in each such country
and with respect to such indications for which Clinical Data obtained from Clinical Studies
performed hereunder is sufficient to support Regulatory Approval for the Licensed Product in such
country; and

                    (iii) Notwithstanding anything contained in this Section 2.1.2, in no event shall Licensee
have any diligence obligations with respect to the conduct of Clinical Studies that are Unilateral
Activities of Licensee, except as otherwise provided in Section 2.6.2(d).

               (c) By GPC Biotech. Notwithstanding anything contained in this Section 2.1.2 or any other
term or condition of this Agreement, (i) provided that GPC Biotech shall use Commercially
Reasonable Efforts to perform the responsibilities assigned to it under the Development Plan with
respect to the SPARC Study, in the event that the SPARC Study is a Non-Approvable Study in the
United States, GPC Biotech shall have no obligation to perform

19

 

any additional Registrational Study or part thereof and (ii) in no event shall GPC Biotech have any
diligence obligations with respect to Unilateral Activities of GPC Biotech.

          2.1.3 Compliance. Each Party shall perform or cause to be performed, any and all of its
Development obligations under this Agreement in good scientific manner, and in compliance with all
Applicable Law, and shall endeavor to achieve the objectives of the Development Plan diligently and
efficiently by allocating sufficient time, effort, equipment and skilled personnel to complete such
Development activities successfully and promptly.

     2.2 Development Plan and Implementation.

          2.2.1 Development Plan.

               (a) As of the Effective Date, the Parties have agreed to the initial Development Plan. The
Joint Development Committee shall review the Development Plan within one hundred and eighty (180)
days after the Effective Date and, thereafter, at least annually, and shall make amendments thereto
with respect to the Development of the Licensed Product in accordance with Section 2.5.1.

               (b) Any amendment to the Development Plan shall continue to provide for the joint Development
by the Parties of the Licensed Product and shall assign responsibility for Development activities
between the Parties by considering (i) the allocation of responsibility set out in the initial
Development Plan, and (ii) the expertise and available resources of the Parties, including the
ability to use the Parties’ respective existing facilities and infrastructure.

          2.2.2 Global Development Plan; Development Leads.

               (a) It is contemplated that from and after the Effective Date, the Clinical Studies and Post
Approval Studies for the Licensed Product, where practicable and without any obligation to amend
the initial Development Plan, shall be structured so as to support the filing of Drug Approval
Applications for the Licensed Product in the United States and European Union.

               (b) Except as otherwise provided in the Development Plan, (i) Licensee shall be the
Development Lead with respect any Clinical Studies, Post Approval Studies and other Development
activities for the Licensed Product that are conducted solely in support of Regulatory Approvals
for the Licensed Product or Commercialization of the Licensed Product in the Licensee Territory,
including any Development activities that constitute Unilateral Activities of Licensee pursuant to
Section 2.5.2 (collectively, the “Licensee Activities”), and (ii) GPC Biotech shall be the
Development Lead with respect to all other Clinical Studies, Post Approval Studies and other
Development activities for the Licensed Product, including any Development activities that
constitute Unilateral Activities of GPC Biotech pursuant to Section 2.5.2 (collectively, “GPC
Biotech Activities”).

          2.2.3 Responsibilities of the Development Lead.

20

 

               (a) Under the direction and supervision of the JDC, and subject to the Development Plan and
Budget, each Party shall have primary responsibility for the day-to-day implementation of the
Clinical Studies and Post Approval Studies for the Licensed Product for which it is the Development
Lead.

               (b) The Party that is not the Development Lead with respect to a Clinical Study or Post
Approval Study for the Licensed Product shall cooperate with the Development Lead in conducting
such Clinical Studies and Post Approval Studies and shall perform such activities with respect
thereto as are assigned to it in the Development Plan under the direction of the Development Lead
and subject to the Development Plan and Budget; provided, however, that in no event (i) shall GPC
Biotech have any obligation to perform any such activities with respect to Licensee Activities
without its consent, and (ii) shall either Party have any obligation (1) to cooperate with the
Development Lead in conducting Unilateral Activities of such Development Lead, unless the Parties
agree in writing to cooperate with respect thereto and the Development Lead agrees to reimburse the
other Party for reasonable costs and expenses associated therewith, or (2) to otherwise perform any
Development activities consisting of or supporting the Unilateral Activities of the other Party.

               (c) Subject to the provisions of Section 2.5.1, each Party shall prepare and propose, for
consideration by the JDC, amendments to the Development Plan and Budget that may be necessary or
desirable to efficiently and expeditiously complete the Development activities, including Clinical
Studies and Post Approval Studies, for which it is the Development Lead. Further, Licensee shall,
subject to the provisions of Section 2.5.1, prepare and propose, for consideration by the JDC,
amendments to the Development Plan and Budget that may be necessary or desirable to efficiently and
expeditiously obtain and maintain Regulatory Approvals and successfully Commercialize the Licensed
Product in each country in the Licensee Territory.

     2.3 Development Budget.

          2.3.1 Amendment of the Development Budget. The Parties have agreed to the initial Development
Budget. The Joint Development Committee shall review the Development Budget within one hundred and
eighty (180) days after the Effective Date and, thereafter, at least annually, and shall make
modifications thereto to reflect any amendments to the Development Plan made pursuant to Sections
2.2.1 and 2.5.1. With respect to any proposed amendments to the Development Plan, each Party
shall, in consultation with the other Party, prepare and submit to the JDC, for its review and
approval, a proposed budget in a format to be agreed by the Parties for the new Clinical Studies,
Post Approval Studies or other Development activities for which it is the Development Lead, which
budget shall include line item estimates of Collaboration Costs broken down on a Calendar Year
basis.

          2.3.2 Cost Overruns.

               (a) In any Calendar Year, each Party shall promptly inform the other Party upon such Party
determining that it is likely to overspend or underspend by more than ten percent (10%) its
respective total Collaboration Costs set forth in the Development Budget for that Calendar Year.

21

 

               (b) If in any such Calendar Year a Party exceeds its budgeted costs and expenses by more than
ten percent (10%), the Party that has so exceeded its budget shall provide to the JDC and to the
JEC (if the matter is escalated to the JEC because it cannot be resolved by the JDC) a full
explanation for exceeding the Development Budget. If and to the extent that any such overspend (i)
was outside the reasonable control of the applicable Party, or (ii) resulted from a reasonable or
necessary acceleration of Development activities within a particular Calendar Year, some or all of
which activities had been expected to occur in a subsequent Calendar Year; then (in each case (i)
and (ii)), provided the applicable Party has promptly notified the other Party of such overspend
and, in the case of overspends covered by clause (i) of this Section 2.3.2(b), used reasonable
efforts to mitigate the size of such overspend, then such overspend shall be included in
Collaboration Costs and shared by the Parties pursuant to Section 6.1.1.

               (c) To the extent that any overspend is not included in Collaboration Costs as provided in
this Section 2.3.2, the Party that has exceeded its budget by more than ten percent (10%) for a
Calendar Year shall be solely responsible for the overspend.

     2.4 Regulatory Matters.

          2.4.1 Regulatory Lead. Licensee shall be the Regulatory Lead with respect to any Drug
Approval Applications and other Regulatory Approvals for the Licensed Product (which, for clarity,
does not include filings of or with respect to INDs and other filings with respect to the
Development of the Licensed Product, which shall be the responsibility of the applicable
Development Lead) in the Licensee Territory. GPC Biotech shall be the Regulatory Lead with respect
to any Drug Approval Applications or Regulatory Approvals for the Licensed Product (which, for
clarity, does not include filings of or with respect to INDs and other filings with respect to the
Development of the Licensed Product, which shall be the responsibility of the applicable
Development Lead) in the GPC Biotech Territory.

          2.4.2 Regulatory Responsibilities With Respect to Licensee Territory; Preparation of
Regulatory Submissions. As promptly as practicable after the Effective Date, under the direction
and supervision of the JDC, Licensee shall assume control of and responsibility for all regulatory
submissions with respect to Regulatory Approvals, including Drug Approval Applications, for the
Licensed Product in the Licensee Territory and Licensee Activities in those countries where such
activities are conducted. Ownership of Regulatory Approvals and related submissions within the
Licensee Territory relating to the Licensed Product shall be governed by Section 8.1.3.

          2.4.3 Clinical and Non-Clinical Data.

                    (a) Subject to Section 2.5.5, each Party shall promptly provide to the other Party copies of
all all clinical and non-clinical data, and other results and analyses with respect to any
Development activities with respect to the Licensed Product, when and as such data, results and
analyses become available; provided, however, in the event that GPC Biotech enters into an
agreement with a GPC Biotech Counter-Party, GPC Biotech shall have no further obligation to provide
Licensee with such data, results or analyses with respect to Unilateral

22

 

Activities or any Development activities in connection with such agreement for which Licensee has
not funded its share as determined hereunder or for which Licensee has Opted-Out.

                    (b) Subject to Section 2.5.5, each Party shall support the other, as may be reasonably
necessary, in obtaining Regulatory Approvals for the Licensed Product, including providing
necessary documents or other materials required by Applicable Law to obtain Regulatory Approvals,
in each case in accordance with the terms and conditions of this Agreement and the Development Plan
and Budget.

               2.4.4 Communications with Regulatory Authorities.

                    (a) Licensee Territory.

                         (i) In General. Licensee shall be responsible for any communications with the Regulatory
Authorities occurring or required in connection with performing its responsibilities set forth in
Section 2.4.2 and shall designate a representative to serve as the designated regulatory
representative with respect to such communications.

                         (ii) Written Communications. Licensee, in consultation with GPC Biotech, shall prepare and
submit to the JDC for its review, all material submissions (including any supplements or
modifications thereto) to the Regulatory Authorities in the Licensee Territory or for which
Licensee is the Development Lead. The JDC shall have the right to expeditiously review and comment
on the content and subject matter of, and strategy for, each Drug Approval Application and other
filing for Regulatory Approval, all correspondence submitted to the Regulatory Authorities related
to the design of Clinical Studies and Post Approval Studies, and all proposed Product Labeling for
the Licensed Product and related communications and decisions with the Regulatory Authorities
(including the final approved Product Labeling for the Licensed Product and any changes thereto);
provided, however, Licensee shall not be required to delay any submission to the applicable
Regulatory Authorities if the JDC does not provide its comments within a reasonable time after
receipt of such proposed material submissions, taking into account any submission deadlines imposed
by the Regulatory Authorities. Without limiting the foregoing, Licensee shall promptly provide GPC
Biotech with (1) copies of all material written or electronic communications received by Licensee,
its Affiliates, Sublicensees or Distributors, from, or forwarded by Licensee or its Affiliates,
Sublicensees or Distributors to, the Regulatory Authorities with respect to obtaining or
maintaining any Regulatory Approvals in the Licensee Territory or any other Licensee Activities,
and (2) copies of all contact reports produced by Licensee, its Affiliates, Sublicensees or
Distributors, in each case ((1) and (2)) within two (2) Business Days of receiving, forwarding or
producing any of the foregoing.

                    (b) GPC Biotech Territory.

                         (i) GPC Biotech shall be solely responsible for any communications with the Regulatory
Authorities occurring or required in connection with obtaining or maintaining any Regulatory
Approvals for the Licensed Product in the GPC Biotech Territory.

23

 

                         (ii) GPC Biotech shall promptly provide Licensee with copies of all written or electronic
correspondence material to the Development or Commercialization of the Licensed Product in the
Licensee Territory received by GPC Biotech or its Affiliates from, or forwarded by GPC Biotech or
its Affiliates to, the Regulatory Authorities with respect to obtaining or maintaining any
Regulatory Approvals in the United States; provided, however, in the event that GPC Biotech enters
into an agreement with a GPC Biotech Counter-Party, GPC Biotech shall have no further obligation to
provide Licensee with such correspondence (to the extent GPC Biotech’s agreement with such GPC
Biotech Counter-Party prohibits providing Licensee with such correspondence), except for any such
correspondence that relates to matters that could reasonably be expected to have a material adverse
effect on the Product Labeling in the Licensee Territory which must be provided to Licensee
notwithstanding the foregoing.

                    (c) Adverse Event Experiences. Without limitation to anything contained in this Section
2.4.4, each Party shall provide to the other Party documentation concerning Adverse Event
Experiences required to be reported to a Regulatory Authority pursuant to Applicable Law in
accordance with Article 9.

               2.4.5 Meetings with Regulatory Authorities. Each Party shall provide the other Party with
prior written notice of any Major Meeting promptly after the Party receives notice of the
scheduling of such Major Meeting, when practicable, within such time period as may be necessary in
order to give the other Party a reasonable opportunity to attend such Major Meeting. GPC Biotech
shall be entitled to have reasonable representation present at, and subject to Section 2.4.6, to
participate in at its expense, all such Major Meetings relating to the Licensed Product in the
Licensee Territory; provided, however, that with respect to Major Meetings relating to Unilateral
Activities of Licensee, GPC Biotech shall be entitled to attend at its expense all such Major
Meetings strictly as a silent observer. Licensee shall be entitled to attend at its expense all
such Major Meetings with the FDA relating to the Licensed Product in the GPC Biotech Territory
strictly as a silent observer unless GPC Biotech otherwise agrees in writing to permit Licensee to
participate actively in any such meeting; provided, however, that GPC Biotech shall have no
obligation under this Section 2.4.5 to permit Licensee to attend any such Major Meeting to the
extent it results from or otherwise relates to Unilateral Activities of GPC Biotech; provided,
further, that in the event that GPC Biotech enters into an agreement with a GPC Biotech
Counter-Party, GPC Biotech shall have no further obligation to permit Licensee to attend Major
Meetings (to the extent GPC Biotech’s agreement with such GPC Biotech Counter-Party prohibits such
attendance), except where the subject of such Major Meeting relates to matters that could
reasonably be expected to have a material adverse effect on the Product Labeling in the Licensee
Territory in which case Licensee shall continue to have the rights specified herein. The Parties,
through the JDC, shall use reasonable efforts to agree in advance on the scheduling of such Major
Meetings and, in the case of Major Meetings with respect to the Licensee Territory, on the
objectives to be accomplished at, GPC Biotech’s active role with respect to, and the agenda for,
such meetings. Each Party shall promptly forward to the other Party copies of all meeting minutes
and summaries of all Major Meetings, as well as any significant written communications received
from representatives of the Regulatory Authorities relating thereto.

               2.4.6 Pricing and Reimbursement Approvals. Licensee shall take the lead in all pricing and
reimbursement approval proceedings relating to the Licensed Product in the

24

 

Licensee Territory; provided that GPC Biotech shall have the right to have one (1) representative
attend all meetings with Regulatory Authorities relating to pricing and reimbursement approvals
strictly as a silent observer, but only if GPC Biotech’s presence is permitted by the relevant
Regulatory Authority and is not otherwise prohibited by Applicable Law. Licensee shall provide GPC
Biotech with reasonable advance notice of all such meetings and advance copies of all related
documents (including documents to be submitted in connection with pricing and reimbursement
approvals) and other relevant information relating to such meetings.

          2.4.7 Regulatory Records. Licensee and GPC Biotech each shall maintain, or cause to be
maintained, records of its respective Development activities with respect to the Licensed Product
in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes,
which shall be complete and accurate and shall fully and properly reflect all work done and results
achieved in the performance of its respective Development activities, and which shall be retained
by such Party for at least three (3) years after the termination of this Agreement, or for such
longer period as may be required by Applicable Law. Each Party shall have the right, during normal
business hours and upon reasonable notice, to inspect and copy any such records, except to the
extent that a Party reasonably determines that such records contain Confidential Information that
is not licensed to the other Party, or to which the other Party does not otherwise have a right
hereunder. Licensee shall provide GPC Biotech with such additional information regarding the
Licensee Activities as GPC Biotech may reasonably request from time to time.

     2.5 Plan Amendments; Unilateral Development.

          2.5.1 Criteria for Amendments to the Development Plan. Either Party, through its
representatives on the JDC, may propose amendments to the Development Plan, including modifications
to a Clinical Study or Post Approval Study already initiated and ongoing under the Development Plan
or the addition of new Clinical Studies for Additional Indications for the Licensed Product
(including for a higher line of therapy for an indication that is already under Development) and
Post Approval Studies for the Licensed Product. Any material amendment proposed by a Party to the
Development Plan with respect to a Clinical Study or Post Approval Study must meet the following
criteria, as applicable:

               (a) Any proposed Exploratory Study, or any material amendment thereto, whether or not
contemplated in the Development Plan as of the Effective Date, shall be designed to comply with all
applicable regulatory guidelines of both the FDA and the EMEA;

               (b) Any proposed Post Approval Study, or any material amendment thereto, whether or not
contemplated in the Development Plan as of the Effective Date, shall be designed to satisfy all
applicable regulatory requirements of both the FDA and the EMEA;

               (c) Any proposed Registrational Study, whether or not contemplated in the Development Plan as
of the Effective Date, shall be: (i) based on a scientific rationale supported by the results of
an Exploratory Study; and (ii) designed to satisfy regulatory requirements of both the FDA and the
EMEA, including, where applicable, conforming to any scientific advice obtained by a Party from
Regulatory Authorities in its portion of the Territory. Any proposed Registrational Study that is
not contemplated in the Development Plan as of the

25

 

Effective Date must, in addition to the criteria in clause (i) and (ii) above, be for an indication
having sufficient commercial potential in both the United States and Europe to justify conduct of
the study taking into consideration the risks of adverse results.

               (d) Any material amendment proposed by a Party with respect to a Registrational Study already
initiated and ongoing under the Development Plan must be either suggested by Regulatory Authorities
or otherwise required or reasonably necessary to obtain Regulatory Approval in the proposing
Party’s portion of the Territory.

     Notwithstanding the foregoing, either Party may propose a material amendment that does not
meet the foregoing criteria if both Parties agree to the proposal. The Party that is proposing any
amendment to the Development Plan pursuant to this Section 2.5.1 shall provide, at the other
Party’s request, reasonable documentation to the JDC demonstrating that such amendment satisfies
the foregoing criteria. Any Dispute in the JDC concerning whether a proposed amendment fails to
meet the applicable criteria shall be referred to the JEC for resolution pursuant to Section 4.4.4,
and, failing resolution by the JEC pursuant to Section 4.4.4 or by the Parties pursuant to Section
15.7.2(a)(iv), to arbitration in accordance with Section 15.7.4(b).

          2.5.2 Unilateral Activities.

               (a) With respect to any Clinical Study or Post Approval Study that satisfies the criteria set
forth in Section 2.5.1, if either Party (the “Opting-Out Party”), pursuant to the terms of Section
2.6, opts-out (each, an “Opt-Out”) of: (a) any modification of a (i) Clinical Study or (ii) a Post
Approval Study, in each case ((i) and (ii)) already initiated and ongoing under the Development
Plan; or (b) initiation of (i) a Clinical Study (including a Registrational Study), or (ii) a Post
Approval Study, in each case ((i) and (ii)) for any part of the Territory, the Party (the
“Developing Party”) desiring to proceed with such activities (“Proposed Unilateral Activities”)
shall prepare and provide to the JDC a proposed development plan and budget with respect thereto.
Such proposed development plan and budget shall in each case be in a format and with such detail
corresponding to the Development Plan in effect at such time. If the JDC determines or it is
otherwise determined that any such Proposed Unilateral Activities comply and are otherwise
consistent with Section 2.5.3, then such activities shall be deemed to be “Unilateral Activities”
hereunder, and the Developing Party shall have the right to proceed with such Unilateral Activities
in accordance with the terms and conditions of this Agreement.

               (b) Notwithstanding the foregoing, either Party may propose to the JDC as a Unilateral
Activity a Clinical Study or Post Approval Study that is scientifically reasonable but does not
satisfy the requirements of Section 2.5.1. In such event, the Parties may agree to incorporate
such Clinical Study in the Development Plan as a joint activity hereunder or the proposing Party
may conduct such Clinical Study or Post Approval Study as a Unilateral Activity. For purposes of
this Agreement, the Party that is conducting such Unilateral Activity shall be deemed the
Developing Party with respect to such Unilateral Activity and the other Party shall be deemed to be
the Opting-Out Party with respect to such Unilateral Activity following confirmation from the other
Party that it did not wish to Opt-In.

26

 

          2.5.3 Limitations on Unilateral Activities. Notwithstanding anything contained in this
Section 2.5, Licensee shall not have the right to conduct any Clinical Study or Post Approval Study
with respect to the Licensed Product for its portion of the Territory where the proposed protocol
of such study creates an unreasonable risk of adverse results that could reasonably be expected to
have a material adverse effect on the Development or Commercialization of Licensed Product in the
GPC Biotech Territory, including with respect to the ability of GPC Biotech to obtain or maintain
Regulatory Approval for the Licensed Product for the Initial Indication or an Additional Indication
in any country in such territory. Any Dispute in the JDC concerning whether such study could
reasonably be expected to have such effect shall be referred to the JEC for resolution pursuant to
Section 4.4.4, and, failing resolution by the JEC pursuant to Section 4.4.4 or by the Parties
pursuant to Section 15.7.2(a)(v), to arbitration in accordance with Section 15.7.4(b).

          2.5.4 Costs of Unilateral Activities. In the case of Unilateral Activities (a) the Developing
Party shall bear the sole cost and expense of such Unilateral Activities, and (b) the Opting-Out
Party shall have no further financial obligation to support or otherwise fund any efforts in
respect of such Unilateral Activities, unless it Opts-In pursuant to Section 2.5.6.

          2.5.5 Limitation on Rights to Clinical Data. With respect to any Unilateral Activities, the
Opting-Out Party, notwithstanding the right of reference granted in Section 5.1.3 or 5.6, as
applicable, shall not have the right to use or reference any Clinical Data or other information
resulting from such Unilateral Activities to support an application for Regulatory Approval for the
Licensed Product unless such Party Opts-In pursuant to Section 2.5.6, provided that if the
inclusion of such Clinical Data or other information is required solely to comply with a
requirement to report worldwide clinical studies to Regulatory Authorities in a filing seeking or
maintaining a Regulatory Approval of the Licensed Product, the Opting-Out Party shall have the
right to use such data and other information solely for such purpose and such use shall not trigger
an Opt-In or other cost-sharing pursuant to Section 2.5.6.

          2.5.6 Opt-In Rights.

               (a) In General. The Opting-Out Party shall have the right to opt-in (“Opt-In”) with respect
to any Unilateral Activities for which such Party Opted-Out at any time within fifty (50) days
after receipt by the Opting-Out Party of a Completion Notice with respect thereto, in each case in
accordance with this Section 2.5.6 (such period, the “Opt-In Exercise Period”); provided, that in
each case the Opting-Out Party shall be required at the time of Opt-In with respect to any
Unilateral Activities relating to a particular indication, to Opt-In with respect to (i) such
Unilateral Activities, and (ii) any other Unilateral Activities with respect to such indication
that are being conducted at such time or that previously were conducted by the Developing Party
(“Related Unilateral Activities”). For clarity, the Opting-Out Party shall be permitted to Opt-In
with respect to Related Unilateral Activities described in clause (ii) of this Section 2.5.6(a),
notwithstanding the fact that the Opt-In Exercise Period with respect to Related Unilateral
Activities may have earlier terminated without the Opting-Out Party’s having exercised an Opt-In
with respect to such Related Unilateral Activities.

               (b) Opt-In Exercise. With respect to any Unilateral Activities conducted by the Developing
Party, promptly after the completion thereof the Developing Party

27

 

shall prepare a report that includes a reasonable summary of the data and top-line results with
respect thereto and provide such report to the Opting-Out Party, together with a notice of
completion of such Unilateral Activities (each a “Completion Notice”). The Completion Notice shall
be accompanied by a written statement of costs and expenses (the “Unilateral Activity Cost
Statement”) incurred by the Developing Party in connection with such Unilateral Activities and any
Related Unilateral Activities through the last day of the Calendar Quarter immediately preceding
the Calendar Quarter in which such notice is provided (such date, the “Statement Cut-Off Date”).
In the event that the Opting-Out Party has an interest in Opting-In with respect to any Unilateral
Activities, it shall provide written notice thereof to the other Party within the Opt-In Exercise
Period (an “Opt-In Exercise Notice”). Thereafter, not later than sixty (60) days after receiving
the Opt-In Exercise Notice, the Developing Party shall provide to the Opting-Out Party a statement
of costs and expenses incurred by the Developing Party in connection with such Unilateral
Activities for the period commencing on the day after the Statement Cut-Off Date and ending on the
date of receipt of the Opt-In Exercise Notice, and the Opting-Out Party shall within sixty (60)
days of the receipt of such statement make a payment to the Developing Party equal to [...***...]
the Opting-Out Party’s funding contribution would have been had the Developing Party’s total costs
and expenses with respect to such activity (and any Related Unilateral Activities) been
Collaboration Costs, up to a maximum of [...***...]of the total costs and expenses of the
Unilateral Activity. From and after the Developing Party’s receipt of the Opt-In Exercise Notice
from the Opting-Out Party, such Unilateral Activities shall cease to be Unilateral Activities and
shall be deemed Development activities under the Development Plan, and the Parties shall share all
such costs and expenses as Collaboration Costs in accordance with Section 6.1.1.

     2.6 Opt-Out Rights.

          2.6.1 Contemplated Exploratory Studies or Post Approval Studies.

               (a) GPC Biotech shall have the right to Opt-Out for any reason with respect to the initiation
of any Exploratory Study or Post Approval Study proposed by Licensee.

               (b) Licensee shall have the right to Opt-Out with respect to the initiation of any Exploratory
Study or Post Approval Study proposed by GPC Biotech only if: (i) the total amount that Licensee
has paid to GPC Biotech pursuant to Section 6.1 with respect to the SPARC Study and any Selected
Development Activities (including such Licensee payments for expenses incurred in connection with
the Development activities under the Development Plan not allocated to a particular Clinical Study
or Post Approval Study), exceeds [...***...] (the “Initial Opt-Out Threshold”); or (ii) there is no
reasonable scientific rationale for such proposed study. For clarity, except as otherwise provided
in Section 2.6.3, if, with respect to any Exploratory Studies or Post Approval Studies, Licensee is
not permitted to Opt-Out pursuant to this Section 2.6.1 prior to the initiation thereof, Licensee
shall not have the right subsequently to Opt-Out of such Exploratory Studies or Post Approval
Studies as a result of the actual amounts paid by Licensee with respect to the SPARC Study and
Selected Development Activities exceeding the Initial Opt-Out Threshold as a result of any overruns
included within Collaboration Costs pursuant to Section 2.3.2.

 

*** Confidential Treatment Requested

28

 

          2.6.2 Contemplated Registrational Studies.

               (a) GPC Biotech shall have the right to Opt-Out for any reason with respect to the initiation
of any Registrational Study proposed by Licensee.

               (b) Licensee shall have the right to Opt-Out with respect to the initiation of any
Registrational Study proposed by GPC Biotech only if: (i) Licensee’s share of the total estimated
costs of such Registrational Study is projected to exceed the Registrational Study Budgeted Funding
Commitment; (ii) in the case of a Registrational Study for an Additional Indication, the available
Clinical Data from Exploratory Studies relating to such Additional Indication does not support the
asserted scientific rationale for such Registrational Study; (iii) the SPARC Study is a
Non-Approvable Study with respect to the European Union and Licensee elects to conduct as a
Unilateral Activity of Licensee an additional Registrational Study for the Initial Indication (a
“Licensee Initial Indication Study”); (iv) GPC Biotech has elected not to pursue any additional
Registrational Studies pursuant to Section 2.1.2(c) and Licensee elects to conduct as a Unilateral
Activity of Licensee an additional Registrational Study for approval of an Additional Indication in
the Licensee Territory; or (v) at such time, the Parties are in agreement as to the initiation of
another Registrational Study other than the SPARC Study under the Development Plan.

               (c) Licensee shall not have the right to Opt-Out, in reliance on Section 2.6.2(b)(i), with
respect to a Registrational Study proposed by GPC Biotech if GPC Biotech agrees in writing to
increase the share of the Collaboration Costs that GPC Biotech otherwise would have an obligation
to bear pursuant to Section 6.1.1 (i.e., sixty-five percent (65%)) with respect to such study and
activities and to decrease the share of the Collaboration Costs that Licensee otherwise would have
an obligation to bear with respect thereto pursuant to Section 6.1.1 (i.e., thirty-five percent
(35%)), in each case by an amount sufficient to ensure that, taking account of such adjusted
shares, the Collaboration Costs projected for the proposed Registrational Study would not result in
Licensee’s funding obligation with respect to such budgeted Collaboration Costs exceeding the
Registrational Study Budgeted Funding Commitment. Any such share adjustment shall apply with
respect to the budgeted Collaboration Costs for such additional Registrational Study, and to the
actual Collaboration Costs specifically identifiable or reasonably allocable to such additional
Registrational Study, and the calculation of any overruns with respect to such Collaboration Costs,
but for no other purpose. In the event of any Dispute between the Parties with respect to whether
the Collaboration Costs projected for the proposed Registrational Study would result in Licensee’s
funding obligation exceeding the Registrational Study Budgeted Funding Commitment, such Dispute
shall be resolved pursuant to Section 15.7.4(b).

               (d) If, in reliance on Section 2.6.2(b)(iii), Licensee Opts-Out of any Registrational Study
proposed by GPC Biotech and Licensee fails to use Commercially Reasonable Efforts to commence,
conduct and complete the Licensee Initial Indication Study within a reasonable time, GPC Biotech
shall have the right, upon thirty (30) days’ written notice to Licensee, to cause Licensee to
Opt-In with respect to the Registrational Study for an Additional Indication with respect to which
Licensee previously Opted-Out and with respect to any Related Unilateral Activities for such
indication. Such Opt-In shall be deemed to be made pursuant to Section 2.5.6(b) (regardless of any
prior termination or expiration of the Opt-In

29

 

Exercise Period with respect to such study) as of the date on which Licensee receives from GPC
Biotech such notice (and a statement of costs and expenses incurred to date by GPC Biotech in
connection with such Registrational Study and any Related Unilateral Activities with respect to
such Additional Indication). Licensee shall make a payment to GPC Biotech in the amount required
pursuant to Section 2.5.6(b) no later than thirty (30) days after receiving from GPC Biotech such
notice (and accompanying statement). In the event of any Dispute between the Parties with respect
to whether Licensee has used Commercially Reasonable Efforts to commence, conduct and complete the
Licensee Initial Indication Study within a reasonable time, such Dispute shall be resolved pursuant
to Section 15.7.4(b).

               2.6.3 Material Modifications to Existing Studies. If a proposed amendment to the Development
Plan and Budget materially modifies any Clinical Study or Post Approval Study being conducted under
the Development Plan, each Party shall have the right to Opt-Out of such Clinical Study or Post
Approval Study on a going forward basis, subject to the provisions of Sections 2.6.1(b) and
2.6.2(b). Upon and following such Opt-Out by a Party, such activity shall be deemed a Unilateral
Activity of the other Party for purposes of Section 2.5.5.

               2.6.4 New Clinical Studies or Post Approval Studies. Each Party shall have the right to
Opt-Out of any proposed new Clinical Study (including a Registrational Study) or Post Approval
Study that is not contemplated in the Development Plan as of the Effective Date, subject to the
provisions of Sections 2.6.1(b) and 2.6.2(b).

               2.6.5 Notice of Opt-Out. The Opting-Out Party shall provide the other Party with written
notice of the Opting-Out Party’s intention to Opt-Out not later than thirty (30) days after the JDC
receives pursuant to Section 2.5.1 a written proposal for a new Clinical Study or Post Approval
Study or a material modification to a Clinical Study or Post Approval Study being conducted under
the Development Plan. In such event, the provisions of Section 2.5.2 shall apply to the conduct of
such study as a Unilateral Activity. With respect to a material modification to a Clinical Study
or Post Approval Study for which a Party has Opted-Out, any Collaboration Costs that have been
incurred prior to the beginning of an Opt-Out Period shall not be reduced or refundable to the
Opting-Out Party.

          2.7 Supply of Licensed Product. Licensee shall purchase its supply of Licensed Product, and
GPC Biotech agrees to supply to Licensee such quantities subject to the terms of the Supply
Agreement.

ARTICLE 3

COMMERCIALIZATION

     3.1 Commercialization of the Licensed Product.

          3.1.1 In General. Except with respect to Joint Commercialization Activities, if any, Licensee
shall have the sole right to Commercialize the Licensed Product in the Licensee Territory at its
sole expense in accordance with the Commercialization Plan and shall do so in

30

 

compliance with this Agreement and all Applicable Law. Joint Commercialization Activities, which
are agreed by the Parties, shall be conducted by the Parties, in accordance with the
Commercialization Plan and Budget and in compliance with Applicable Law.

     3.1.2 Commercialization Obligations. Licensee shall use Commercially Reasonable Efforts: (a)
to Commercialize the Licensed Product in each country in the Licensee Territory where conducting
such activities would be Commercially Reasonable; and (b) without limitation to the foregoing,
within ninety (90) days after obtaining all Regulatory Approvals necessary in such a country in the
Licensee Territory for the Commercialization of the Licensed Product for the Initial Indication or
any Additional Indication that is the subject of a Follow Up Registrational Study, to commence
Commercialization of the Licensed Product in such country. Licensee shall allocate sufficient
time, effort and skilled personnel to achieve the objectives of the Commercialization Plan and each
Country Commercialization Plan.

     3.1.3 Global Strategy.

              (a) Within six (6) months after the Effective Date, the Parties shall jointly develop the
global strategy for Commercializing Licensed Product throughout the Territory which strategy shall
support the goal of maximizing Product revenue and profit in both the Licensee Territory and the
GPC Biotech Territory and (i) shall be consistent with any approved Product Labeling for the
Licensed Product and (ii) take into account, where Commercially Reasonable, any unique market
characteristics of any of the Major Market Countries in Europe and the ANZ Territory (the “Global
Strategy”). Any Dispute regarding the development of the Global Strategy shall be referred to the
JEC for resolution pursuant to Section 4.4.4, and, failing resolution by the JEC pursuant to
Section 4.4.4, shall be subject to resolution under Section 15.7.2(a)(ii).

              (b) Licensee shall use Commercially Reasonable Efforts to ensure, wherever possible in keeping
with its obligation to use Commercially Reasonable Efforts in the Commercialization of the Licensed
Product, that the branding, positioning and messaging for the Licensed Product in the Licensee
Territory is consistent with such Global Strategy for the Licensed Product; provided however, that
Licensee may not act in any manner that is inconsistent with the Global Strategy with respect to
the branding, positioning and messaging for the Licensed Product that could reasonably result in a
material adverse effect on the Commercialization of the Licensed Product in the GPC Biotech
Territory. Any Dispute in the JCC concerning whether the branding, positioning or messaging for
the Licensed Product in the Licensee Territory is consistent with such Global Strategy or whether
any action of the Licensee that is inconsistent with the Global Strategy with respect to the
branding, positioning and messaging for the Licensed Product could reasonably result in a material
adverse effect on the Commercialization of the Licensed Product in the GPC Biotech Territory shall
be referred to the JEC for resolution pursuant to Section 4.4.4, and, failing resolution by the JEC
pursuant to Section 4.4.4, shall be subject to resolution under Section 15.7.2(a)(vi).

     3.1.4 Product Trademarks. Except with respect to the Corporate Names as provided in Section
3.4.2, Licensee and its Affiliates, Sublicensees and Distributors shall Commercialize the Licensed
Product solely under the Product Trademarks designated by the JCC pursuant to Section 3.4.4.

31

 

     3.2 Commercialization Plan and Implementation.

             3.2.1 Commercialization Plan.

     The Commercialization of the Licensed Product in the Licensee Territory and any Joint
Commercialization Activities shall be conducted pursuant to a comprehensive multi-year plan and
budget to be prepared by Licensee pursuant to Section 3.2.2 with respect to the Licensee Territory,
and by the JCC pursuant to Section 4.3.2(d) with respect to any Joint Commercialization Activities,
and approved by the JCC pursuant to Section 4.3.2(c) (the “Commercialization Plan”), which plan and
budget shall be consistent with the Global Strategy and the Parties’ respective obligations set
forth in Section 3.1. The Commercialization Plan shall include: for each Major Market Region and
each Major Market Country in the Licensee Territory (i) general strategies for the promoting,
Detailing, marketing and distribution of the Licensed Product, (ii) pre-launch commercialization
activities and the expected date of launch, (iii) sales force size and allocation throughout the
Licensee Territory, (iv) the expected frequency and position of Details to be carried out, (v) the
nature of promotional activities and Licensed Product sampling activities, if any, (vi) market and
sales forecasts for the Licensed Product, (vii) advertising, public relations and other promotional
programs, including medical education programs such as professional symposia and speaker and
peer-to-peer activity programs to be used in the Commercialization the Licensed Product, (viii)
proposals for any Additional Indications or Post Approval Studies, (ix) projected Net Sales for
Licensed Product, (x) reimbursement and pricing information, and (xi) plans regarding distribution
and supply chain management; and (y) any Joint Commercialization Activities. The Parties agree
that any forecasts provided by Licensee as part of the Commercialization Plan are Licensee’s good
faith estimates based upon conditions then existing and shall not be binding upon Licensee.

             3.2.2 Review and Approval. No later than twelve (12) months prior to the expected date of the
first Regulatory Approval of the Licensed Product, Licensee shall prepare for review and approval
by the JCC a proposed Commercialization Plan for the Licensed Product from the date of launch
through the third anniversary of December 31 of the Calendar Year in which the first Drug Approval
Application for the Licensed Product is expected to be approved in the Licensee Territory. The
Joint Commercialization Committee shall review such proposed plan within sixty (60) days after
receipt thereof and amend such plan to include any Joint Commercialization Activities, as provided
in Section 4.3.2. Thereafter, Licensee shall, on or before September 30 of each Calendar Year,
provide the JCC with proposed amendments to the Commercialization Plan, which, after the first
anniversary of December 31 of the Calendar Year in which the first Drug Approval Application for
the Licensed Product is approved in the Licensee Territory, shall include the Commercialization
Plan for the Calendar Year commencing on the third anniversary of January 1 of the then-current
Calendar Year. The Commercialization Plan may not be amended in any manner that materially reduces
Licensee’s Commercialization efforts to be made in the next two (2) full Calendar Years following
such amendment unless such reduction in efforts is justified by circumstances or events beyond
Licensee’s control that have had or would reasonably be expected to have a material adverse impact
on the market for or the commercial potential of the Licensed Product in the Licensee Territory or
any relevant portion of the Licensee Territory. The JCC, or if there is a dispute in the JCC, the
JEC, shall endeavor to obtain approval for any amendment or addition to the Commercialization Plan
by no later than

32

 

November 30 of the Calendar Year in which it was proposed. Any Disputes resulting from review or
approval of the Commercialization Plan or a Country Commercialization Plan shall be settled in
accordance with Section 4.4.4 below, except with respect to disputes regarding Joint
Commercialization Activities, for which the Parties must reach a mutually acceptable resolution (or
otherwise discontinue such activities). Subject to the foregoing, the JCC may from time to time
amend the Commercialization Plan with respect to the Joint Commercialization Activities. The
Commercialization Plan and any amendment thereto shall be consistent with the Global Strategy.

             3.2.3 Other Country Commercialization Plans. In addition to the Country Commercialization
Plan with respect to the Major Market Countries, Licensee shall provide to the JCC for its review
and comment copies of the commercialization plans prepared by Licensee in the regular course of its
business with respect to any other countries in the Licensee Territory (each such plan a “Country
Commercialization Plan”).

       3.3 [...***...]. [...***...].

       3.4 Promotional Materials and Activities.

             3.4.1 In General. Except with respect to Promotional Materials that are jointly developed by
the Parties pursuant to a Joint Commercialization Activity, Licensee shall be responsible for
preparing all Promotional Materials used to support the Commercialization of the Licensed Product
in the Licensee Territory, in consultation with the JCC. All such Promotional Materials shall be
submitted to the JCC prior to use by Licensee; provided that the content of Promotional Materials,
once submitted, need not be submitted again prior to re-use unless the Product Labeling for the
Licensed Product applicable to such Promotional Materials has been changed since such prior
submission date. All Promotional Materials shall be consistent with the Global Strategy, the
Commercialization Plan, the applicable Country Commercialization Plan(s), Applicable Law and with
the approved Product Labeling for the Licensed Product. Licensee shall be responsible for
obtaining any approvals from the Regulatory Authorities in a country within the Licensee Territory
required for the use of any Promotional Materials and shall submit all applicable Promotional
Materials to the Regulatory Authorities in such country as required by Applicable Law.

             3.4.2 Markings. All Promotional Materials, packaging and Product Labeling for the Licensed
Product used by Licensee, its Affiliates, Sublicensees or Distributors in connection with the
Licensed Product in any country in the Licensee Territory shall (a) comply with the requirements of
Section 8.1(c) of the Spectrum Agreement and (b) contain (i) the Product Trademarks, (ii) Corporate
Names of Licensee and (to the extent permitted by Applicable Law) GPC Biotech where practical with
equal prominence, and (iii) if required by Applicable Law, the logo and corporate name of the
manufacturer (collectively, the

*** Confidential Treatment Requested

33

 

“Markings”). The manner in which the Markings are to be presented on Promotional Materials,
packaging and Product Labeling for the Licensed Product shall be subject to (y) prior review and
approval by the JCC and (z) Sections 5.1.5, 5.5, 5.6 and 8.1.6.

             3.4.3 Audit. Upon request of GPC Biotech at reasonable intervals, Licensee shall provide to
GPC Biotech copies or samples of any Promotional Materials, packaging and Product Labeling for the
Licensed Product that have not been previously reviewed by GPC Biotech.

             3.4.4 Product Trademarks. The JCC shall discuss the Parties’ use of the Product Trademarks
with respect to Commercialization and may, from time to time, recommend and approve additional
Trademarks, packaging designs and other trade dress in connection with the foregoing for use in the
Licensee Territory. The JCC shall have the right to designate additional Product Trademarks as may
be reasonably required to address requirements under Applicable Law or to avoid adverse effects on
the Commercialization of the Licensed Product in a particular country in the Licensee Territory
resulting from local customs, language and other country-specific circumstances. For the avoidance
of doubt, each such Trademark shall be treated as Product Trademark under the terms of this
Agreement.

     3.5 Statements and Compliance with Applicable Law.

             3.5.1 Public Statements Regarding Licensed Product. Licensee shall be responsible for
disseminating accurate information regarding the Licensed Product based on Product Labeling and
Promotional Materials for the Licensed Product (and for causing its Affiliates, Sublicensees and
Distributors to so disseminate such accurate information). In exercising its rights pursuant to
this Article 3, Licensee shall seek to prevent claims or representations in respect of the Licensed
Product or the characteristics of the Licensed Product (e.g., safety or efficacy) being made by or
on behalf of it or its Affiliates, Sublicensees or Distributors (by members of its or their sales
force or otherwise) that do not represent an accurate or fairly balanced summary or explanation of
the Product Labeling for the Licensed Product in the country in question.

             3.5.2 Sales Force Compliance. Licensee shall instruct its sales representatives to and shall
use Commercially Reasonable Efforts to train and monitor its sales representatives so that such
sales representatives, (i) use only Promotional Materials (without any addition, deletion or other
modification) approved for use under Section 3.4.1 for the promotion of the Licensed Product in the
Licensee Territory, (ii) limit claims of efficacy and safety for the Licensed Product to those that
are consistent with Applicable Law and with approved (by the appropriate Regulatory Authority)
promotional claims in Product Labeling and Promotional Materials for the Licensed Product, and not
add, delete or otherwise modify claims of efficacy and safety in the promotion of the Licensed
Product in any respect from those claims of efficacy and safety that are contained in such approved
Product Labeling and Promotional Materials and (iii) Commercialize the Licensed Product in
accordance in all material respects with Applicable Law.

34

 

             3.5.3 Medical and Other Inquiries. The Licensee shall be responsible for responding to all
medical questions or inquiries from customers or others in the Licensee Territory relating to the
Licensed Product sold in Licensee Territory. The Licensee shall keep such records and make such
reports as are reasonably necessary to document such communications in compliance with all
Applicable Law.

             3.5.4 Compliance with Laws. Licensee shall comply with all Applicable Law with respect to the
Commercialization of Licensed Product. Neither Party shall be required to undertake any activity
relating to the Commercialization of the Licensed Product that it believes, in good faith, may
violate Applicable Law. Licensee shall in all material respects conform its practices and
procedures relating to educating the medical community in the Licensee Territory with respect to
the Licensed Product to any applicable industry association regulations, policies and guidelines,
as the same may be amended from time to time and shall comply with Applicable Law with respect
thereto.

     3.6 Use of Distributors. Notwithstanding any other term or condition of this Agreement to the
contrary, Licensee shall not use Distributors to Commercialize the Licensed Product in any country
in the Licensee Territory, except in the countries listed in Exhibit B hereto, which may be amended
from time to time, upon mutual written agreement of the Parties.

     3.7 Sales and Distribution in Licensee Territory. Licensee shall be solely responsible for
invoicing and booking sales, establishing all terms of sale (including pricing and discounts) and
warehousing and distributing the Licensed Product in the Licensee Territory and shall perform all
related services, in each case in a manner consistent with the terms and conditions of this
Agreement. Licensee shall also be solely responsible for handling all returns, recalls or
withdrawals in accordance with Article 10, order processing, invoicing and collection, distribution
and inventory and receivables in the Licensee Territory.

     3.8 Unauthorized Sales. Licensee with respect to the Licensee Territory, and GPC Biotech with
respect to the GPC Biotech Territory (a) shall, and shall cause its Affiliates, sublicensees and
distributors to, distribute, market, promote, offer for sale and sell the Licensed Product only in
its respective part of the Territory, and (b) shall not, and shall not permit its Affiliates,
sublicensees or distributors to, distribute, market, promote, offer for sale or sell the Licensed
Product directly or indirectly (i) to any Person outside its part of the Territory or (ii) to any
Person inside its part of the Territory that (1) is reasonably likely to directly or indirectly
distribute, market, promote, offer for sale or sell the Licensed Product outside its part of the
Territory or assist another Person to do so or (2) has directly or indirectly distributed,
marketed, promoted, offered for sale or sold the Licensed Product outside its part of the Territory
or assisted another Person to do so. If Licensee, its Affiliates or any Sublicensees or
Distributors receives any orders for the Licensed Product for the GPC Biotech Territory, such
Person shall refer such orders to GPC Biotech. If GPC Biotech, its Affiliates or any sublicensees
or distributors receives any orders for the Licensed Product for the Licensee Territory, such
Person shall refer such orders to Licensee. Notwithstanding the foregoing, if any part of the
European Union becomes part of the GPC Biotech Territory during the term of this Agreement, the
foregoing obligations of this Section 3.8 shall not apply in

35

 

relation to such territory and shall be replaced by the following: Licensee shall not actively
solicit orders from customers based in such territory unless the rights to such territory are no
longer held exclusively by GPC Biotech or one of its licensees. For the purposes of the preceding
sentence, “actively solicit” includes, but is not limited to, the use of direct mail, calling on
customers, placing advertisements or making other promotions specifically targeted at customers in
such territory, or establishing warehouses or distribution outlets in such territory.

     3.9 Reporting. Licensee shall prepare and maintain complete and accurate records regarding
Commercialization of the Licensed Product in the Licensee Territory and shall provide to GPC
Biotech and the JCC a detailed report regarding such Commercialization at least twice per Calendar
Year. Such report shall contain sufficient detail to enable GPC Biotech to assess Licensee’s
compliance with the Global Strategy, the Commercialization Plan and the applicable Country
Commercialization Plan(s) including: (i) Licensee’s activities with respect to achieving its
general strategies for the promoting, detailing and marketing of the Licensed Product in such
country(ies); (ii) pre-launch Commercialization activities; (iii) sales force size and allocation;
(iv) the nature of promotional activities and Licensed Product sampling activities conducted, if
any; (v) market and sales reports for the Licensed Product; (vi) an approximate number and position
of Details carried out in the applicable period; (vii) the conduct of advertising, public relations
and other promotional programs, including professional symposia and speaker and peer to peer
activity programs used in the Commercialization of the Licensed Product; (viii) Net Sales of
Licensed Product in the Licensee Territory; and (ix) actual expenditures with respect to the
budgets set forth in the Commercialization Plan and Country Commercialization Plan, including the
Commercialization Budget. Licensee shall provide GPC Biotech with such additional information
regarding the Commercialization of the Licensed Product as GPC Biotech may reasonably request from
time to time.

     3.10 Commercialization Budget. Except for Joint Commercialization Activities, Licensee shall
be responsible for Commercialization in the Licensee Territory at its own cost and expense. The
budget for Joint Commercialization Activities shall be set forth in the Commercialization Plan, as
provided in Section 3.2.1.

             3.10.1 Amendment of the Commercialization Budget. The Joint Commercialization Committee shall
review the Commercialization Budget at least annually, and shall make modifications thereto to
reflect any changes to ongoing Joint Commercialization Activities or any unforeseen events. With
respect to any such changes or unforeseen events, each Party shall, in consultation with the other
Party, prepare and submit to the JCC a proposed budget in a format to be agreed by the Parties for
the new or changed Joint Commercialization Activities, which budget shall include line item
estimates of Collaboration Costs broken down on a Calendar Year basis.

             3.10.2 Cost Overruns.

                        (a) In any Calendar Year, each Party shall promptly inform the other Party upon such Party
determining that it is likely to overspend or underspend by more than ten

36

 

percent (10%) its respective total Collaboration Costs set forth in the Commercialization Budget
for that Calendar Year.

                        (b) If in any such Calendar Year a Party exceeds its budgeted costs and expenses by more than
ten percent (10%), the Party that has so exceeded its budget shall provide to the JCC and to the
JEC (if the matter is escalated to the JEC because it cannot be resolved by the JCC) a full
explanation for exceeding the Commercialization Budget. If and to the extent that any such
overspend (i) was outside the reasonable control of the applicable Party, or (ii) resulted from a
reasonable or necessary acceleration of Joint Commercialization Activities within a particular
Calendar Year, some or all of which activities had been expected to occur in a subsequent Calendar
Year; then (in each case (i) and (ii)), provided the applicable Party has promptly notified the
other Party of such overspend and, in the case of overspends covered by clause (i) of this Section
3.10.2(b), used reasonable efforts to mitigate the size of such overspend, such overspend shall be
included in Collaboration Costs and shared by the Parties pursuant to Section 6.1.1.

                        (c) To the extent that any overspend is not included in Collaboration Costs as provided in
this Section 3.10.2, the Party that has exceeded its budget by more than ten percent (10%) for a
Calendar Year shall be solely responsible for the overspend.

     3.11 GPC Biotech Territory. Licensee acknowledges and agrees that (a) GPC Biotech retains all
rights to Exploit the Licensed Product in the GPC Biotech Territory and to Develop and Manufacture
the Licensed Product in the Territory in connection therewith, and (b) GPC Biotech has and retains
the right to enter into agreements or other arrangements with one or more Third Parties with
respect to such Exploitation, Development and Manufacture, including license agreements,
co-promotion agreements and supply agreements. GPC Biotech shall have the right to delegate one or
more of its obligations with respect to activities conducted pursuant to this Agreement, in whole
or in part, to any such Third Party and Licensee shall cooperate with such Third Party. GPC
Biotech hereby guarantees the performance in accordance with the terms of this Agreement of any
such Third Party to which GPC Biotech delegates obligations under this Agreement, and any such
delegation shall not relieve GPC Biotech of its obligations under this Agreement, except to the
extent they are satisfactorily performed by such Third Party.

ARTICLE 4

COLLABORATION MANAGEMENT

     4.1 Joint Executive Committee (JEC). Within thirty (30) days after the Effective Date, the
Parties shall establish a joint executive committee (the “Joint Executive Committee” or “JEC”),
which shall: (a) oversee the Development of the Licensed Product in the Territory, the
Commercialization of the Licensed Product in the Licensee Territory and the Joint Commercialization
Activities; (b) resolve Disputes that may arise in the JDC or the JCC; (c) coordinate the Parties’
activities under this Agreement, including oversight of the JDC and JCC; (d) review and approve
decisions

37

 

regarding Development and Commercialization of the Licensed Product as set forth in this Agreement,
including Sections 6.1.5, 8.2.5, 8.4.1 and 11.6; (e) create such other committees with such
responsibilities as the Parties may mutually agree to from time to time, such as, by way of
example, a joint patent committee or joint manufacturing committee; and (f) perform such other
functions as are set forth herein with respect to the JEC, or as the Parties may mutually agree in
writing. The JEC shall have the membership and shall operate by the procedures set forth in
Section 4.4.1. Each Party shall designate its initial members of the JEC within thirty (30) days
after the Effective Date by written notice to the other Party.

     4.2 Joint Development Committee (JDC).

             4.2.1 Formation and Purpose. Within thirty (30) days after the Effective Date, the Parties
shall form a joint development committee (the “Joint Development Committee” or “JDC”) to oversee,
coordinate and expedite the Development of, and the filing of Drug Approval Applications and other
regulatory filings for, the Licensed Product in the Territory in order to obtain and maintain
Regulatory Approvals in the Licensee Territory. The JDC shall also facilitate the flow of
information with respect to Development activities being conducted for the Licensed Product and
direct and supervise all Clinical Studies and Post Approval Studies for the Licensed Product
conducted under the Development Plan. The JDC shall have the membership and shall operate by the
procedures set forth in Section 4.4.1. Each Party shall designate its initial members of the JDC
within thirty (30) days after the Effective Date by written notice to the other Party.

             4.2.2 Specific Responsibilities of the JDC. In support of its responsibility for overseeing,
coordinating and expediting the Development of, and regulatory filings for, the Licensed Product,
the JDC shall: (a) review and, if necessary, amend the Development Plan and Development Budget
from time to time, but no less frequently than once per Calendar Year; (b) establish a worldwide
strategy for the Development and Regulatory Approval of the Licensed Product, consistent with the
applicable Development Plan and Budget; (c) direct and supervise the implementation of the
Development Plan for the Licensed Product; (d) review and approve the statistical analysis plans
and protocols for all Clinical Studies for the Licensed Product conducted under the Development
Plan and, in consultation with the JCC, Post Approval Studies for the Licensed Product conducted
under the Development Plan, and any revisions thereto (in each case other than with respect to
Unilateral Activities); (e) review and discuss the development plan for and execution of any
Unilateral Activities; (f) review all proposed Product Labeling; (g) review all proposed Drug
Approval Applications and other filings with the Regulatory Authorities with respect to Regulatory
Approvals in the Licensee Territory; (h) monitor the progress of all Clinical Studies and Post
Approval Studies for the Licensed Product, including reviewing costs and activities against the
Development Plan and Budget; (i) facilitate the exchange of all information and data relating to
all Clinical Studies, Post Approval Studies and other Development activities for the Licensed
Product; (j) consult and coordinate with the JCC to assure a smooth transition from Development to
Commercialization of the Licensed Product for each indication and with respect to Post Approval
Studies or the proposed Development of Additional Indications and lines of therapy for the Licensed
Product; (k) consult with the JCC with respect to such other matters as may have an effect on the
Commercialization of the Licensed Product; (l) provide updates on JDC’s activities and achievements
to the JEC no

38

 

less often than each Calendar Quarter during the term of this Agreement; and (m) perform such other
functions as are set forth herein or as the Parties may mutually agree in writing, except where in
conflict with any provision of this Agreement.

     4.3 Joint Commercialization Committee (JCC).

             4.3.1 Formation and Purpose. GPC Biotech and Licensee shall establish a joint
commercialization committee (the “Joint Commercialization Committee” or “JCC”) and hold the initial
meeting of the JCC, as provided in Section 4.4.2, within ninety (90) days after the Effective Date,
which Committee shall coordinate and oversee the Commercialization of the Licensed Product in the
Licensee Territory to ensure consistent branding, messaging and positioning of the Licensed Product
on a worldwide basis in accordance with the Global Strategy and direct any Joint Commercialization
Activities undertaken by the Parties in accordance with Article 3. The JCC shall have the
membership and shall operate by the procedures set forth in Section 4.4.1. Each Party shall
designate its initial members of the JCC within thirty (30) days after the Effective Date by
written notice to the other Party.

             4.3.2 Specific Responsibilities of the JCC. In support of its responsibility for coordinating
and overseeing the Commercialization of the Licensed Product in the Licensee Territory and
directing any Joint Commercialization Activities, the JCC shall: (a) review and provide a forum
for the Parties to discuss the Global Strategy; (b) oversee the implementation of the Global
Strategy by Licensee in the Licensee Territory; (c) review and approve the Commercialization Plan
and Budget and determine conformance of the foregoing with the Global Strategy; (d) identify any
activities that will be jointly performed by mutual written agreement of the Parties in support of
Commercialization of the Licensed Product in the Territory (the “Joint Commercialization
Activities”) and prepare and approve such portions of the Commercialization Plan and Budget with
respect thereto; (e) review advertising materials and strategies and Promotional Materials to be
used in the Licensee Territory, and Markings and Trademark usage with respect to the Licensed
Product in the Licensee Territory and determine conformance with the Global Strategy; (f)
facilitate the flow of information with respect to the Commercialization of the Licensed Product
between the Parties; (g) review the periodic reports provided by Licensee pursuant to Section 3.9
and otherwise monitor Licensee’s activities under, and compliance with, the Commercialization Plan
and Budget and each Country Commercialization Plan; (h) consult with the JDC with respect to all
proposed Product Labeling for the Licensed Product; (i) consult with the JDC with respect to
Commercialization issues that may arise with respect to the Development of the Licensed Product;
(j) review all (i) Drug Approval Applications and other filings with the Regulatory Authorities
with respect to Regulatory Approvals for the Licensed Product in the Licensee Territory, (ii) Post
Approval Studies for the Licensed Product and Additional Indications and lines of therapy with
respect to the Licensed Product and (iii) otherwise work to assure a smooth transition from
Development to Commercialization of the Licensed Product for each indication; (k) provide updates
on the JCC’s activities and achievements to the JEC no less frequently than each Calendar Quarter
during the term of this Agreement; and (l) perform such other functions as are set forth herein or
as the Parties may mutually agree in writing.

39

 

     4.4 General Provisions Governing Committees. The following general provisions shall govern
the conduct of the JEC, JDC, JCC and such other committees as the JEC may establish from time to
time under this Agreement (each, a “Committee”), except as otherwise expressly provided elsewhere
in this Agreement or as agreed to by the Parties in writing:

             4.4.1 Membership. Each Committee shall include an equal number of representatives from each
of the Parties, each with the requisite experience and seniority to enable them to make decisions
on behalf of the Parties with respect to the issues falling within the jurisdiction of such
Committee. From time to time, each Party may substitute one or more of its representatives to a
Committee on written notice to the other Party. GPC Biotech shall designate one of its
representatives on the JEC and JDC to serve as chairperson of such Committees and Licensee shall
designate one of its representatives to serve as chairperson of the JCC, which designation such
Party may change from time to time by written notice to the other Party. GPC Biotech shall have
the right to designate as its representatives on a Committee one or more representatives of
Spectrum Pharmaceuticals, Inc. or any GPC Biotech Counter-Party.

             4.4.2 Meetings and Minutes. Each Committee shall meet quarterly, or as otherwise agreed to by
the Parties, with the location of such meetings alternating between locations designated by GPC
Biotech and locations designated by Licensee, provided that each Committee may meet by
teleconference if in-person meetings are not feasible. The chairperson of the Committee shall be
responsible for calling meetings, provided that the chairperson shall call a meeting of the
Committee promptly upon the reasonable request of Licensee, in the case of the JEC or JDC, or GPC
Biotech, in the case of the JCC. The Parties shall provide to the other Party proposed agenda
items along with appropriate information at least ten (10) Business Days in advance of each meeting
of the applicable Committee; provided that under exigent circumstances requiring Committee input, a
Party may provide its agenda items to the other Party within a shorter period of time in advance of
the meeting, or may propose that there not be a specific agenda for a particular meeting, so long
as such other Party consents to such later addition of such agenda items or the absence of a
specific agenda for such Committee meeting, such consent not to be unreasonably withheld or
delayed. The Party that designates the location of a meeting shall prepare and circulate for
review and approval of the Parties minutes of such meeting within ten (10) Business Days after such
meeting. The Parties shall agree on the minutes of each meeting promptly, but in no event later
than the next meeting of the applicable Committee.

             4.4.3 Procedural Rules. A Committee shall have the right to adopt such standing rules as
shall be necessary for its work to the extent that such rules are not inconsistent with this
Agreement. A quorum of a Committee shall exist whenever there is present at a meeting at least one
representative appointed by each Party. Members of a Committee may attend a meeting either in
person or by telephone, video conference or similar means in which each participant can hear what
is said by, and be heard by, the other participants. Representation by proxy shall be allowed. A
Committee shall take action by consensus of the members present at a meeting at which a quorum
exists, with each Party having a single vote irrespective of the number of representatives of such
Party in attendance or by a written resolution signed by a representative of each of the members of
the Committee. Employees or consultants of either Party that are not members of a Committee may
attend any meeting of such Committee;

40

 

provided, however, that such attendees (a) shall not vote or otherwise participate in the
decision-making process of such Committee and (b) are bound by obligations of confidentiality and
non-disclosure equivalent to those set forth in Article 11.

             4.4.4 Dispute Resolution. If a Committee (other than the JEC) cannot, or does not, reach
consensus on an issue, then the dispute shall be referred to the JEC for resolution and a special
meeting of the JEC may be called for such purpose. If the JEC cannot, or does not, reach consensus
on an issue, including any dispute arising in another Committee, then the dispute resolution
provisions set forth in Section 15.7 shall apply.

             4.4.5 Limitations on Authority. Each Party shall retain the rights, powers and discretion
granted to it under this Agreement and no such rights, powers, or discretion shall be delegated to
or vested in a Committee unless such delegation or vesting of rights is expressly provided for in
this Agreement or the Parties expressly so agree in writing. No committee shall have the power to
amend, modify or waive compliance with this Agreement, which may only be amended or modified as
provided in Section 15.9 or compliance with which may only be waived as provided in Section 15.12.

             4.4.6 Interactions Between Committees and Internal Teams. The Parties recognize that each
Party possesses an internal structure (including various committees, teams and review boards) that
will be involved in administering such Party’s activities under this Agreement. Each Committee
shall establish procedures to facilitate communications between such Committee and the relevant
internal committee, team or board of each of the Parties in order to maximize the efficiency of the
Committees and the performance of the Parties of their obligations under this Agreement, including
by requiring appropriate members of such Committee to be available at reasonable times and places
and upon reasonable prior notice for making appropriate oral reports to, and responding to
reasonable inquiries from, the relevant internal committee, team or board.

             4.4.7 Alliance Managers.

                        (a) Appointment. Within thirty (30) days of the Effective Date, each Party shall appoint a
single individual to act as a single point of contact between the Parties to assure a successful
collaboration (each, an “Alliance Manager”). Each Party may change its designated Alliance Manager
from time to time upon written notice to the other Party. Any Alliance Manager may designate a
substitute to temporarily perform the functions of that Alliance Manager by written notice to the
other Party.

                        (b) Responsibilities. The Alliance Managers shall attend all Committee meetings and support
the representatives of each Committee in the discharge of their responsibilities. Alliance
Managers shall be nonvoting participants in such Committee meetings, unless they are also appointed
members of such Committee pursuant to Section 4.4.1; provided, however, that an Alliance Manager
may bring any matter to the attention of any Committee if such Alliance Manager reasonably believes
that such matter warrants such attention. Each Alliance Manager shall be charged with creating and
maintaining a collaborative work environment within and among the Committees. In addition, each
Alliance Manager: (i) shall be the point of first referral in all matters of conflict resolution;
(ii) shall coordinate the relevant

41

 

functional representatives of the Parties in developing and executing strategies and plans for the
Licensed Product in an effort to ensure consistency and efficiency throughout the Territory; (iii)
shall provide a single point of communication for seeking consensus both internally within the
respective Parties’ organizations and between the Parties regarding key strategy and plan issues;
(iv) shall identify and bring disputes to the attention of the appropriate Committee in a timely
manner; (v) shall plan and coordinate cooperative efforts and internal and external communications;
and (vi) shall take responsibility for ensuring that governance activities, such as the conduct of
required Committee meetings and production of meeting minutes occur as set forth in this Agreement,
and that relevant action items resulting from such meetings are appropriately carried out or
otherwise addressed.

ARTICLE 5

GRANT OF RIGHTS

     5.1 Grants to Licensee. Subject to the terms and conditions of this Agreement and the
applicable terms and conditions of the Spectrum Agreement, GPC Biotech (on behalf of itself and its
Affiliates) hereby grants to Licensee:

             5.1.1 an exclusive (including with regard to GPC Biotech and its Affiliates), royalty-bearing
license, with the right to grant sublicenses in accordance with Section 5.3, under the GPC Biotech
Patents, the GPC Biotech Know-How, the Joint Patents (to the extent Controlled by GPC Biotech) and
the Joint Know-How (to the extent Controlled by GPC Biotech) to obtain, maintain and hold
Regulatory Approvals for and to Commercialize the Licensed Product in the Field in the Licensee
Territory;

             5.1.2 a royalty bearing, non-exclusive license, with the right to grant sublicenses in
accordance with Section 5.3, under the GPC Biotech Patents, the GPC Biotech Know-How, the Joint
Patents (to the extent Controlled by GPC Biotech) and the Joint Know-How (to the extent Controlled
by GPC Biotech) to Develop (but not to Manufacture) the Licensed Product in the Field in the
Territory as set forth in the Development Plan, and, subject to the provisions of Section 2.5 with
respect to Unilateral Activities, solely for purposes of exercising its rights under Section 5.1.1;

             5.1.3 subject to Section 2.5.5, an exclusive royalty-bearing license and right of reference in
the Licensee Territory, with the right to grant further sublicenses and rights of reference to
Sublicensees in accordance with Section 5.3, under GPC Biotech’s right, title and interest in and
to any Regulatory Approvals, Drug Master File and all Regulatory Documentation that GPC Biotech may
Control with respect to the Licensed Product as necessary to exercise its rights under the grants
in Sections 5.1.1 and 5.1.2;

             5.1.4 subject to Section 5.5, a royalty-bearing license, exclusive in the Licensee Territory,
with the right to grant sublicenses in accordance with Section 5.3, to use the Product Trademarks
as necessary to exercise its rights under the grants in Sections 5.1.1 and 5.1.2; and

42

 

             5.1.5 subject to Sections 5.5 and 8.1.6, a non-exclusive, non-transferable (except to
Affiliates or as the Parties may agree by mutual written consent, such consent not to be
unreasonably withheld or delayed) license, without the right to grant sublicenses, except in
connection with the grant of sublicenses pursuant to Section 5.3, to use certain of GPC Biotech’s
Corporate Names as necessary to exercise its rights under the grants set forth in Sections 5.1.1
and 5.1.2, as specifically designated by GPC Biotech with respect to a country or as required by
Applicable Law to identify GPC Biotech as having Developed, Manufactured or Commercialized the
Licensed Product sold in such country, and for no other purpose.

Licensee acknowledges that (a) the GPC Biotech Know-How and the information included in the Drug
Master Files and the Regulatory Documentation are secret and substantial and that without GPC
Biotech Know-How, the Drug Master Files and the Regulatory Documentation Licensee would not be able
to obtain and maintain Regulatory Approvals, (b) such Regulatory Approvals will allow Licensee to
obtain and maintain Regulatory Exclusivity Periods with respect to the Licensed Product, (c) access
to GPC Biotech Know-How, the rights with respect to the Drug Master Files and the Regulatory
Documentation and such Regulatory Approvals and the license to the Product Trademark will provide
Licensee with a competitive advantage in the marketplace beyond the exclusivity afforded by the GPC
Biotech Patents and the Regulatory Exclusivity Period and (d) the milestone payments and royalties
set forth in Sections 7.1.2 and 7.2 are, in part, intended to compensate GPC Biotech for such
exclusivity and such competitive advantage. The Parties agree that the royalty rates set forth in
Section 7.2 reflect a reasonable allocation of the values provided by GPC Biotech to Licensee.

     5.2 Retention of Rights. Notwithstanding anything to the contrary in this Agreement, GPC
Biotech retains all right, title and interest in and to the GPC Biotech Patents, the GPC Biotech
Know-How, the Joint Patents (to the extent Controlled by GPC Biotech) and the Joint Know-How (to
the extent Controlled by GPC Biotech), the GPC Biotech Corporate Name, the Drug Master Files, the
Regulatory Documentation and the Product Trademarks as may be necessary or useful (a) to obtain,
maintain and hold Regulatory Approvals for, and to market, sell, have sold and otherwise
Commercialize, the Licensed Product in the GPC Biotech Territory, (b) to Develop and Exploit the
Licensed Product in the Territory to exercise its rights and perform its obligations hereunder and
to market, sell and have sold and otherwise Commercialize the Licensed Product in the GPC Biotech
Territory, (c) to use and Exploit the Drug Master Files, Regulatory Documentation, Product
Trademarks and GPC Biotech Corporate Name for any and all purposes, subject only GPC Biotech’s
obligations expressly set forth hereunder with respect thereto, and (d) to Manufacture and have
Manufactured the Licensed Compound and the Licensed Product in the Territory. Except as expressly
provided herein, GPC Biotech grants no other right or license, including any rights or licenses to
the GPC Biotech Patents, the GPC Biotech Know-How, Drug Master Files, the Regulatory Data, the
Product Trademarks, the GPC Biotech Corporate Name, the Licensed Compound, any other Patent or
Intellectual Property Rights or any Improvements to any of the foregoing not otherwise expressly
granted herein.

     5.3 Sublicenses. The rights and licenses granted to Licensee under Section 5.1 shall include
the right to grant sublicenses (or further rights of reference to Sublicensees) in the Field in the
Licensee Territory, only with GPC Biotech’s prior written consent (such consent not to be
unreasonably withheld or delayed) and the consent of any

43

 

applicable Third Party licensor to the extent required under any license agreement with such Third
Party; provided, however, that: (a) Licensee undertakes to use all commercially reasonable efforts
to procure the performance by any Sublicensee of the terms of each such sublicense and (b) any
Sublicensee shall comply with the applicable terms and conditions of this Agreement and of the
Spectrum Agreement. Licensee hereby guarantees the performance of its Affiliates, Distributors and
permitted Sublicensees that are sublicensed as permitted herein, and the grant of any such
sublicense shall not relieve the Licensee of its obligations under this Agreement, except to the
extent they are satisfactorily performed by such Sublicensee. Any such permitted sublicenses shall
be consistent with and subject to the terms and conditions of this Agreement. A copy of any
sublicense agreement executed by Licensee (with financial terms redacted) shall be provided to the
GPC Biotech within fourteen (14) days of its execution.

     5.4 Right of First Negotiation. In the event that GPC Biotech Controls any Derivative
Compound during the term of this Agreement for which there is clinical data demonstrating efficacy,
GPC Biotech shall provide to Licensee written notice thereof (each, a “Compound Option Notice”),
and Licensee shall have an exclusive option and right of first negotiation to obtain rights to
Commercialize such Derivative Compound in the Licensee Territory in the Field by giving written
notice to GPC Biotech within thirty (30) days after Licensee’s receipt of such Compound Option
Notice. If Licensee fails to provide timely written notice of its desire to Commercialize such
Derivative Compound, or notifies GPC Biotech in writing that Licensee does not desire to acquire
such rights and obligations, then GPC Biotech shall have the right to enter into an agreement with
a Third Party to Commercialize and otherwise Exploit such Derivative Compound, without any further
obligation to negotiate with Licensee, or provide to Licensee a right of negotiation, with respect
thereto. If Licensee provides timely written notice of interest, then the Parties shall negotiate
in good faith with respect to the foregoing, but neither Party shall have any obligation to enter
into any agreement unless they are able to agree on mutually acceptable terms and conditions at
such time. In the event the Parties are unable to conclude such an agreement within [...***...]
after receipt by GPC Biotech of Licensee’s written notice of interest, Licensee shall provide to
GPC Biotech a detailed written summary of the terms on which Licensee would have been prepared to
conclude such agreement. If Licensee indicates in writing at such time to GPC Biotech that
Licensee desires to continue negotiations with GPC Biotech, the Parties shall continue to negotiate
in good faith, provided that GPC Biotech shall be free from and after the end of such [...***...]
negotiation period to negotiate and enter into agreements with Third Parties; provided, further
that, for a period of [...***...] after the end of such [...***...] negotiation period, GPC Biotech
shall not enter into any such agreement on any terms less favorable to GPC Biotech, when taken as a
whole, than those set forth in Licensee’s written offer to GPC Biotech.

     5.5 Use of Trademarks and Corporate Names.

             5.5.1 GPC Biotech shall have the sole right to own and, subject to Section 3.4.4 with respect
to the Licensee Territory, determine the Product Trademarks to be used with respect to the
Exploitation of the Licensed Product on a worldwide basis. Licensee shall not, and shall not
permit its Sublicensees, Distributors or Affiliates to use in their respective businesses, any
Trademark that is confusingly similar to, misleading or deceptive with respect to or that dilutes

 

*** Confidential Treatment Requested

44

 

any (or any part) of the Product Trademarks. Licensee shall, and shall cause its Sublicensees,
Distributors and Affiliates to, (y) conform to the customary industry standards for the protection
of Trademarks for pharmaceutical products and such guidelines of GPC Biotech (as provided in
writing by GPC Biotech) with respect to manner of use of the Product Trademarks and (z) maintain
the quality standards of GPC Biotech with respect to the goods sold and services provided in
connection with such Product Trademarks. Licensee shall, and shall cause its Affiliates,
Sublicensees and Distributors to, use commercially reasonable efforts not to do any act which
endangers, destroys or similarly affects, in any material respect, the value of the goodwill
pertaining to the Product Trademarks. Licensee shall not, and shall not permit its Sublicensees,
Distributors or Affiliates to, attack, dispute or contest the validity of or ownership of such
Product Trademark anywhere in the Territory or any registrations issued or issuing with respect
thereto. Licensee acknowledges and agrees that no ownership rights are vested or created in such
Product Trademark anywhere in the Territory by the licenses and other rights granted in Section 5.1
and that all use of such Product Trademark by Licensee, its Sublicensees, Distributors and
Affiliates, whether in combination with or apart from Licensee Corporate Names, including any
goodwill generated in connection therewith, inures to the benefit of GPC Biotech, and GPC Biotech
may call for a confirmatory assignment thereof.

             5.5.2 With respect to any Corporate Names licensed to a Party under Sections 5.1.5 or 5.6.2,
such Party agrees to conform to the customary guidelines of the granting Party with respect to
manner of use (as provided in writing by the owner of the Corporate Name), and to maintain the
quality standards of such granting Party with respect to the goods sold and services provided in
connection with such Party’s Corporate Names. Each Party shall use commercially reasonable efforts
not to do any act which endangers, destroys or similarly affects the value of the goodwill
pertaining to the other Party’s Corporate Names. Each Party shall execute any documents required
in the reasonable opinion of the other Party to be entered as a “registered user” or recorded
licensee of the other Party’s Corporate Names or to be removed as registered user or licensee
thereof.

     5.6 Grants to GPC Biotech. Subject to the terms and conditions of this Agreement, Licensee
(on behalf of itself and its Affiliates) hereby grants to GPC Biotech:

             5.6.1 a perpetual, irrevocable royalty-free license, with the right to sublicense through
multiple tiers of sublicensees, under the Licensee Patents, Licensee Know-How, the Joint Patents
(to the extent Controlled by Licensee) and Joint Know-How (to the extent Controlled by Licensee):

                        (a) to Develop the Licensed Product in the Field in the Territory in accordance with the
Development Plan or as otherwise provided in Article 2, which license shall be co-exclusive with
Licensee (except as otherwise provided in Section 14.8.2 below);

                        (b) to obtain, maintain and hold Regulatory Approvals for the Licensed Product in the Field in
the GPC Biotech Territory, which license shall be exclusive (except as otherwise provided in
Section 14.8.2 below);

45

 

               (c) to Exploit the Licensed Compound and the Licensed Product in the Field in the Territory as
necessary or useful to exercise its rights and perform its obligations hereunder, and the right to
otherwise Exploit the Licensed Compound and the Licensed Product in the GPC Biotech Territory,
which license shall be exclusive in the GPC Biotech Territory (except as otherwise provided in
Section 14.8.2 below); and

               (d) to Manufacture and have Manufactured the Licensed Compound and the Licensed Product in the
Territory, which grant shall be exclusive (except as otherwise provided in Section 14.8.2 below).

Further, subject to Section 2.5.5, Licensee (on behalf of itself and its Affiliates and
Sublicensees) grants to GPC Biotech a royalty free license and right of reference, with the right
to grant further rights of reference, under Licensee’s right, title and interest in and to the
Regulatory Approvals and any Regulatory Documentation with respect thereto that Licensee may
Control with respect to the Licensed Product as necessary to conduct Manufacturing and Development
throughout the Territory in accordance with the terms hereof and as necessary to Exploit the
Licensed Product in the Field in the GPC Territory, which license and right shall be exclusive in
the GPC Biotech Territory; and

          5.6.2 subject to Sections 5.5 and 8.1.6, a non-exclusive,
non-transferable (except to Affiliates or as the Parties may agree by mutual written consent, such
consent not to be unreasonably withheld or delayed) license, without the right to grant
sublicenses, to use certain of Licensee’s Corporate Names to exercise GPC Biotech’s rights under
the grants set forth in this Section 5.6, as specifically designated by Licensee with respect to a
country as necessary or as required by Applicable Law to identify Licensee as having Developed,
Commercialized or performed other activities with respect to the Licensed Product sold in such
country, and for no other purpose.

     5.7 No Implied Rights. For the avoidance of doubt, Licensee and its Affiliates, Sublicensees
and Distributors shall have no right, express or implied, with respect to the GPC Biotech Patents,
the GPC Biotech Know-How, the Regulatory Documentation, the Drug Master Files, the Product
Trademarks and the GPC Biotech Corporate Names, and GPC Biotech and its Affiliates and sublicensees
shall have no right, express or implied, with respect to the Licensee Patents, the Licensee
Know-How, the Regulatory Documentation and the Licensee Corporate Names, except, in each case, as
expressly provided in Sections 5.1 and 5.6.

ARTICLE 6

COLLABORATION COSTS

     6.1 General.

          6.1.1 Responsibility for Collaboration Costs. The Parties shall share all Collaboration Costs
in the following proportions: GPC Biotech shall bear sixty-five percent

46

 

(65%) of all Collaboration Costs and Licensee shall bear thirty-five percent (35%) of all
Collaboration Costs.

          6.1.2 Initial Collaboration Costs. On or before January 3, 2006, Licensee shall make a
payment to GPC Biotech in the amount of Nineteen Million One Hundred Thousand U.S. Dollars
($19,100,000), representing its thirty-five percent (35%) share of (a) the Collaboration Costs
incurred by GPC Biotech after October 1, 2005 and prior to the Effective Date and (b) those
payments on Collaboration Costs identified in Section 6.1.6(a).

          6.1.3 FTE Costs. Each Party shall record and account for its FTE Costs and its out-of-pocket
costs for the Development of the Licensed Product and the Joint Commercialization Activities and
shall report such costs to the JDC on a quarterly basis, in each case in a manner that allocates
costs to the extent possible to a specific activity in the Development Plan and Budget or
Commercialization Plan and Budget. FTEs allocable to the Development Plan shall be charged to
Collaboration Costs. Out-of-pocket costs allocable to Collaboration Costs, but otherwise included
within FTE Costs, shall not be charged separately as Collaboration Costs.

          6.1.4 Adjustment of FTE Costs. The FTE Costs shall be adjusted annually, with each annual
adjustment effective as of January 1 of each Calendar Year, the first such annual adjustment to be
made as of January 1, 2007, based on the percentage change in the U.S. Department of Labor Consumer
Price Index for All Urban Consumers for the prior Calendar Year or as otherwise mutually agreed
upon by the Parties.

          6.1.5 Reports. Each Party shall report to the other Party within forty five (45) days after
the end of each Calendar Quarter the Collaboration Costs incurred by such Party during such
Calendar Quarter for the Licensed Product. Such report shall specify in reasonable detail all
amounts included in such Collaboration Costs with respect to the Licensed Product during such
Calendar Quarter (broken down by activity) and shall be accompanied by invoices or other
appropriate supporting documentation for any payments made by such Party to Third Parties that
individually exceed Fifty Thousand U.S. Dollars ($50,000) or Fifty
Thousand Euros (€50,000), as
applicable, or as may be determined by the JEC. Each such report shall enable the receiving Party
to compare the reported costs against the Development Plan and Budget and Commercialization Plan
and Budget, on both a quarterly basis and a cumulative basis for each activity. The Parties shall
seek to resolve any questions related to such accounting statements within thirty (30) days
following receipt by each Party of the other Party’s report hereunder.

          6.1.6 Payments.

               (a) Payment of Collaboration Costs. The up-front payment of Collaboration Costs made by
Licensee pursuant to Section 6.1.2 shall consist of the following payments of Collaboration Costs
to be incurred in accordance with the Development Budget: (i) [...***...] for the SPARC Study
(including reimbursement of Collaboration Costs incurred by GPC Biotech after October 1, 2005 and
prior to the Effective Date); (ii) [...***...] for Exploratory Studies and Post Approval Studies;
and (iii) [...***...] for other expenses incurred in connection with the

 

*** Confidential Treatment Requested

47

 

Development activities not allocated to a particular Clinical Study or Post Approval Study,
including, for example, Manufacturing Costs, as itemized in the Development Budget. With respect
to payments for a further Registrational Study to be conducted by the Parties in accordance with
the Development Plan and Budget, Licensee shall make payments in accordance with the following
schedule:

                    (x) Forty Percent (40%) of Licensee’s share of the total Collaboration Costs budgeted for such
Registrational Study at the time the first patient is accrued in such study;

                    (y) Thirty Percent (30%) of Licensee’s share of the total Collaboration Costs budgeted for
such Registrational Study upon reaching fifty percent (50%) of the target accrual for patients
specified in the approved protocol for the study; and

                    (z) Thirty Percent (30%) of Licensee’s share of the total Collaboration Costs budgeted for
such Registrational Study at the time such study is fully accrued.

          (b) Ongoing Collaboration Costs. The Parties agree that the above payments made by Licensee
shall be credited toward Licensee’s share of Collaboration Costs (including associated FTE Costs)
incurred by GPC Biotech for a given Development activity specified in the Development Plan and
Budget or for the categories specified in Section 6.1.6(a) (as offset by GPC Biotech’s share
(sixty-five percent (65%)) of the Collaboration Costs incurred by Licensee for such activities).
Within forty five (45) days after the end of each Calendar Quarter during the term of this
Agreement, each Party will provide to the other Party a reasonably complete and accurate report of
its Collaboration Costs (including associated FTE Costs) itemized per category. Once Licensee’s
share of the Collaboration Costs incurred exceed the payments made for any category pursuant to
Section 6.1.6(a), each Party’s share of Collaboration Costs in such category shall be paid as
follows:

                    (i) Within thirty (30) days after the date of each Party’s quarterly report on Collaboration
Costs, Licensee shall pay to GPC Biotech its share of the Collaboration Costs in such category or
categories incurred during such Calendar Quarter, as offset by GPC Biotech’s (sixty-five percent
(65%)) share of the Collaboration Costs incurred by Licensee during such quarter as noted in
Licensee’s report thereon and taking account of any overruns included within such Collaboration
Costs pursuant to Section 2.3.2 or 3.10.2.

                    (ii) With respect to Collaboration Costs associated with any further Registrational Studies
(as specified in Section 6.1.6(a)(x-z) above), within sixty (60) days of the last day of the
Calendar Quarter in which such study is completed, including any early termination of such study,
the Party that has paid less than its share of the actual total Collaboration Costs incurred in
connection with such study, taking account of any overruns included within such Collaboration Costs
pursuant to Section 2.3.2 and any payments previously made by Licensee pursuant to pursuant to
Section 6.1.6(a)(x-z), shall make a reconciling payment to the other Party to achieve the
appropriate allocation of the Collaboration Costs with respect thereto.

48

 

     6.2 Accounting Procedures. For purposes of determining Collaboration Costs, any expense
allocated by either Party to a particular category under Collaboration Costs for the Licensed
Product shall not also be allocated to another category under Collaboration Costs for the Licensed
Product. Each Party shall determine Collaboration Costs with respect to the Licensed Product using
its standard accounting procedures in accordance with GAAP, consistently applied, to the maximum
extent practical as if the Licensed Product were a solely-owned product of the Party (provided that
the application of such procedures results, on balance, in outcomes that are fair and equitable to
both Parties taking into consideration the interests of both Parties as reflected in this
Agreement). Each Party shall have the right to audit the other Party’s records to confirm the
accuracy of the other Party’s costs and reports as provided in Section 7.11. If the Parties fail to agree on the accuracy of such costs and reports, such Dispute shall
be resolved in accordance with Section 15.7.4(b).

ARTICLE 7

CONSIDERATION

     7.1 Payments to GPC Biotech. In partial consideration of the licenses and other rights
granted herein, Licensee shall make the following payments to GPC Biotech:

          7.1.1 Reimbursement of Past Development Costs. Licensee shall make a non-refundable,
non-creditable payment of Eighteen Million U.S. Dollars ($18,000,000) on or before January 3, 2006
to reimburse GPC Biotech for Licensee’s thirty-five percent (35%) share of a proportion of the
total costs related to Development of the Licensed Product incurred prior to October 1, 2005.

          7.1.2 Milestone Payments. Licensee shall make the milestone payments provided below within
ten (10) days following achievement, after the Effective Date, of the corresponding milestone
event:

Clinical and Regulatory Milestones & Payments

	 	 	 
	(a) Upon the first to occur of the
filing with the EMEA of the first
MAA for (i) the Initial Indication
or (ii) any of the Additional
Indications listed in clause (d)
below

	 	Eight Million U.S. Dollars
($8,000,000)
	 
	 	 
	(b) Upon the first to occur of
obtaining the first Regulatory
Approval in a country in Europe for
(i) the Initial Indication or (ii)
any of the Additional Indications
listed in clause (d) below

	 	Twenty Million U.S. Dollars
($20,000,000)
	 
	 	 
	(c) Upon the first to occur of
obtaining the first Regulatory
Approval in a country in the ANZ
Territory for (i) the Initial
Indication or (ii) any of

	 	Two Million Five Hundred Thousand

49

 

	 	 	 
	the Additional Indications listed in clause (d) below

	 	U.S. Dollars ($2,500,000)
	 
	 	 
	(d) Upon obtaining the first Regulatory Approval in
a country in Europe for each of the following
Additional Indications for which a milestone payment
has not been made under clause (b) hereof: non-small
cell lung cancer, breast cancer, ovarian cancer,
gastric cancer, head and neck cancer, bladder
cancer, esophageal cancer, cervical/uterine cancer,
for use as a radiation therapy adjuvant, or
first-line treatment of prostate cancer

	 	Fifteen Million U.S.
Dollars ($15,000,000),
per such additional
Regulatory Approval,
with a maximum of five
(5) such additional
Regulatory Approvals

Commercial Milestones & Payments

	 	 	 
	(e) One Hundred and Fifty Million U.S. Dollars
($150,000,000) in aggregate Net Sales in the
Licensee Territory in any Calendar Year

	 	Ten Million U.S. Dollars
($10,000,000)
	 
	 	 
	(f) Two Hundred and Fifty Million U.S. Dollars
($250,000,000) in aggregate Net Sales in the
Licensee Territory in any Calendar Year

	 	Fifteen Million U.S.
Dollars ($15,000,000)
	 
	 	 
	(g) Five Hundred Million U.S. Dollars ($500,000,000)
in aggregate Net Sales in the Licensee Territory in
any Calendar Year

	 	Thirty Million U.S.
Dollars ($30,000,000)
	 
	 	 
	(h) One Billion U.S. Dollars ($1,000,000,000) in
aggregate Net Sales in the Licensee Territory in any
Calendar Year

	 	Fifty Million U.S.
Dollars ($50,000,000)

For clarification, except with respect to the milestone set forth in Section 7.1.2(d) above, each
milestone payment shall be payable only once irrespective of the number of times the milestone
events set forth in this Section 7.1.2 have been achieved and the milestone set forth in Section
7.1.2(d) shall be payable each time one of the applicable milestones is achieved. Licensee shall
notify GPC Biotech promptly of any determination, filing or approval that would trigger a payment
by Licensee to GPC Biotech under this Section 7.1.2 and the amount of the payment required and
shall pay such amount as provided herein.

     7.2 Royalties. Subject to Sections 7.3 and 7.4, Licensee shall pay to GPC Biotech, for each full or partial Calendar Year,
royalties based on aggregate Net Sales of the Licensed Product in the Licensee Territory during
such Calendar Year as set forth in Sections 7.2.1, 7.2.2 and 7.2.3 below, provided that, except as otherwise expressly provided in
Sections 7.4.1, 7.4.2 and 8.4.1(b), in no event shall the royalty rate
on Net Sales fall below [...***...] (the “Royalty Rate Floor”):

          7.2.1 for that portion of aggregate Net Sales of the Licensed Product in the Licensee
Territory in such Calendar Year that is less than One Hundred Fifty Million U.S. Dollars
($150,000,000), the royalty rate shall be Twenty-Six and One Quarter Percent (26.25%);

 
 

*** Confidential Treatment Requested

50

 

          7.2.2 for that portion of aggregate Net Sales of the Licensed Product in
the Licensee Territory in such Calendar Year that equals or exceeds One Hundred
and Fifty Million U.S. Dollars ($150,000,000) but is less than Five Hundred
Million U.S. Dollars ($500,000,000), the royalty rate shall be Thirty Percent
(30%); and

          7.2.3 for that portion of aggregate Net Sales of the Licensed Product in
the Licensee Territory in such Calendar Year that equals or exceeds Five Hundred
Million U.S. Dollars ($500,000,000), the royalty rate shall be Thirty-Four
Percent (34%).

     7.3 Royalty Term. Licensee’s obligations to pay royalties under this Article 7 shall
terminate, on a country-by-country basis, with respect to the Licensed Product, on the
last to occur of: (a) the date that the sales of Generic Product(s) by one or more
Third Parties in such country in any six (6)-month period exceed (on a per unit basis)
[...***...] of the entire market for the Licensed Product and such Generic Product(s) in
such country; (b) the last day of the Royalty Term, as defined in the Spectrum Agreement (such term, the “Spectrum Royalty Term”), (c) the expiration date in such
country of the last to expire of any GPC Biotech Patent or Joint Patent that includes at
least one Valid Claim that would, in the absence of the licenses granted hereunder, be
infringed by the sale of the Licensed Product (or, in the case of a Valid Claim of a
Patent application, would be infringed if a Patent were to issue from such Patent
application) and (d) the expiration of all Regulatory Exclusivity Periods with respect
to the Licensed Product in such country (such period when royalties are due hereunder
with respect to a country, the “Royalty Term”).

     7.4 Royalty Adjustments.

          7.4.1 Expiration of Royalty Obligation Under Spectrum Agreement. On a
country-by-country basis during the applicable Royalty Term, (a) the royalty
rates set forth in Sections 7.2.1, 7.2.2 and 7.2.3 and (b) the applicable Royalty
Rate Floor, shall be reduced by [...***...] with respect to Net Sales in such
country that occur after the first date on which the Spectrum Royalty Term has
expired; provided, however, that such reductions shall not apply with respect to
any Net Sales that are subject to a royalty reduction pursuant to Section 7.4.2.

          7.4.2 Step-Down Period. On a country-by-country basis during the
applicable Royalty Term, (a) the royalty rates set forth in Sections 7.2.1, 7.2.2
and 7.2.3, and (b) the applicable Royalty Rate Floor, shall be reduced by
[...***...] with respect to Net Sales in such country that occur after the first
date on which (i) the Spectrum Royalty Term has expired, and (ii) the last to
expire of any GPC Biotech Patent or Joint Patent that includes at least one Valid
Claim (that would, in the absence of the licenses granted hereunder, be infringed
by the sale of the Licensed Product or, in the case of a Valid Claim of a Patent
application, would be infringed if a Patent were to issue from such Patent
application) has expired in such country, and (iii) all Regulatory Exclusivity
Periods have expired in such country.

          7.4.3 Supply Price Adjustment. In the event that the Supply Price for
the Licensed Product, expressed as a percentage of Net Sales of Licensed Product
for which such Supply Price applies, exceeds [...***...], Licensee may deduct the
excess amount from royalties owed pursuant to Section 7.2 for those Net Sales for
which

 

*** Confidential Treatment Requested

51

 

such Supply Price applies; provided that, in no event shall the royalty rate on Net Sales payable
to GPC Biotech fall below the applicable Royalty Rate Floor.

     7.5 Royalty Payments. Running royalties shall be payable on a quarterly basis,
within sixty (60) days after the end of each Calendar Quarter, based upon the Net Sales
during such Calendar Quarter. Royalties shall be calculated in accordance with GAAP and
with the terms of this Article 7. Only one royalty payment shall be due on Net Sales
even though the sale or use of the Licensed Product may be covered by more than one
Patent or Know-How in a country.

     7.6 Royalty Statements. Each royalty payment hereunder shall be accompanied by a
statement showing, at a minimum (a) Invoiced Sales and Net Sales, (b) the number of
units of Licensed Product sold on a country-by-country basis during the applicable
Calendar Quarter, (c) a detailed breakdown of any deductions from the Invoiced Sales
that were taken to calculate Net Sales, and (d) the amount of royalties due on such Net
Sales.

     7.7 Mode of Payment. All payments to GPC Biotech or Licensee under this Agreement
shall be made by deposit of (a) Euros, in the case of any royalty payments, and (b)
United States Dollars, in the case of all other payments, in each case ((a) and (b)) in
the requisite amount to such bank account as the receiving Party may from time to time
designate by notice to the paying Party. With respect to sales outside the European
Union, payments shall be calculated based on currency exchange rates for the Calendar
Quarter for which remittance is made for royalties. For each month and each currency,
such exchange rate shall equal the arithmetic average of the daily exchange rates
(obtained as described below) during such Calendar Quarter; each daily exchange rate
shall be obtained from the Reuters Daily Rate Report or The Wall Street Journal, Eastern
Edition or, if not so available, as otherwise agreed by the Parties. Notwithstanding
the foregoing, for purposes of calculating the Net Sales thresholds and ceilings set
forth in Sections 7.2.1, 7.2.2 and 7.2.3, the aggregate Net Sales with respect to each
Calendar Quarter within a Calendar Year shall be calculated based on the currency
exchange rates for the Calendar Quarter in which such Net Sales occurred, in a manner
consistent with the exchange rate procedures set forth in the immediately preceding
sentence.

     7.8 Taxes.

          7.8.1 General. The royalties, milestones and other amounts payable by
Licensee to GPC Biotech pursuant to this Agreement (“Payments”) shall not be
reduced on account of any taxes unless required by Applicable Law. GPC Biotech
alone shall be responsible for paying any and all taxes (other than withholding
taxes required by Applicable Law to be paid by Licensee) levied on account of, or
measured in whole or in part by reference to, any Payments it receives. Licensee
shall deduct or withhold from the Payments any taxes that it is required by
Applicable Law to deduct or withhold. Notwithstanding the foregoing, if GPC
Biotech is entitled under any applicable tax treaty to a reduction of rate of, or
the elimination of, applicable withholding tax, it may deliver to Licensee or the
appropriate governmental authority (with the assistance of Licensee to the extent
that this is reasonably required and is expressly requested in writing) the
prescribed forms necessary to reduce the applicable rate of withholding or to
relieve Licensee of its obligation to withhold tax, and Licensee shall apply the
reduced rate

52

 

of withholding, or dispense with withholding, as the case may be, provided that Licensee has
received evidence, in a form reasonably satisfactory to Licensee, of GPC Biotech’s delivery of all
applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at
least fifteen (15) days prior to the time that the Payments are due. If, in accordance with the
foregoing, Licensee withholds any amount, it shall pay to GPC Biotech the balance when due, make
timely payment to the proper taxing authority of the withheld amount and send to GPC Biotech proof
of such payment within sixty (60) days following that payment. Licensee shall be responsible for
any sales tax that GPC Biotech may be required to collect with respect to the Payments.

          7.8.2 Value Added Tax. Notwithstanding anything contained in Section 7.8.1, this Section
7.8.2 shall apply with respect to value added tax (“VAT”). All Payments are exclusive of VAT. If
any VAT is chargeable in respect of any Payments, Licensee shall pay VAT at the applicable rate in
respect of any such Payments following the receipt of a VAT invoice in the appropriate form issued
by GPC Biotech in respect of those Payments, such VAT to be payable on the later of the due date of
the payment of the Payments to which such VAT relates and sixty (60) days after the receipt by
Licensee of the applicable invoice relating to that VAT payment.

     7.9 Interest on Late Payment. If any payment due to either Party under this Agreement is
overdue (and is not subject to a good faith dispute), then such paying Party shall pay interest
thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily
basis) of the lesser of four percent (4%) above the prime rate as reported in The Wall Street
Journal, Eastern Edition, and the maximum rate permitted by Applicable Law, such interest to run
from the date upon which payment of such sum became due until payment thereof in full together with
such interest.

     7.10 Financial Records. Licensee shall, and shall cause its Affiliates, Sublicensees and
Distributors to, keep reasonably complete and accurate books and records pertaining to the
Commercialization, sale, delivery and use of the Licensed Product, including books and records of
the Invoiced Sales (including any deductions therefrom) and Net Sales of Licensed Product, in
sufficient detail to calculate the royalties payable under this Agreement. Both Parties shall, and
shall cause their respective Affiliates and, with respect to Licensee, its Sublicensees to, keep
reasonably complete and accurate books and records pertaining to Collaboration Costs. Such books
and records shall be retained by both Parties and their Affiliates and with respect to Licensee,
its Sublicensees and Distributors, until the later of (a) three (3) years after the end of the
period to which such books and records pertain and (b) the expiration of the applicable tax statute
of limitations (or any extensions thereof), or for such longer period as may be required by
Applicable Law.

     7.11 Audit. At the request of either Party, the other Party shall, and shall cause its
Affiliates and, with respect to Licensee, its Sublicensees and Distributors, to, permit the
requesting Party and its representatives, at reasonable times and upon reasonable notice, to
examine the books and records maintained pursuant to Section 7.10. Such examinations may not (a)
be conducted for any Calendar Quarter more than three (3) years after the end of such quarter, (b)
be conducted more than once in any twelve (12) month period or (c) be repeated for any Calendar
Quarter. Except as provided below, the cost of this examination

53

 

shall be borne by the Party that requested the examination, unless the audit reveals a variance of
more than five percent (5%) from the reported amounts, in which case the audited Party shall bear
the cost of the audit. Unless disputed pursuant to Section 7.12 below, if such audit concludes
that additional payments were owed or that excess payments were made during such period, the paying
Party shall pay the additional royalties or the receiving Party shall reimburse such excess
payments, with interest from the date originally due as provided in Section 7.9, within sixty (60)
days after the date on which a written report of such audit is delivered to the Parties.

     7.12 Audit Dispute. In the event of a Dispute regarding such books and records, including the
amount of royalties owed to GPC Biotech under this Article 7 or the calculation or allocation of
Collaboration Costs pursuant to Article 6, GPC Biotech and Licensee shall work in good faith to
resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of
any such Dispute within thirty (30) days, the dispute shall be submitted for arbitration to a
certified public accounting firm selected by each Party’s certified public accountants or to such
other Person as the Parties shall mutually agree (the “Arbitrator”). The decision of the
Arbitrator shall be final and the costs of such arbitration as well as the initial audit shall be
borne between the Parties in such manner as the Arbitrator shall determine. Not later than ten
(10) days after such decision, (a) with respect to such decisions regarding royalties, Licensee
shall pay to GPC Biotech any additional royalties owed to GPC Biotech, in accordance with such
decision and (b) with respect to such decisions regarding Collaboration Costs and in accordance
with such decision, the paying Party shall pay the additional payments or the receiving Party shall
reimburse such excess payments, as applicable. For clarity, notwithstanding anything contained in
Section 15.7, any Dispute subject to arbitration pursuant to this Section 7.12 shall not be subject
to the terms and conditions of Section 15.7.

     7.13 Confidentiality. The receiving Party shall treat all information subject to review under
this Article 7 in accordance with the confidentiality provisions of Article 11 and the Parties
shall cause any auditor or the Arbitrator to enter into a reasonably acceptable confidentiality
agreement with the audited Party obligating such firm to retain all such financial information in
confidence pursuant to such confidentiality agreement.

ARTICLE 8

INTELLECTUAL PROPERTY

     8.1 Ownership of Intellectual Property.

          8.1.1 Ownership of Technology. Subject to Sections 8.1.2, 8.1.3, 8.1.4, 8.1.5 and 8.1.6 and
the licenses and rights of reference granted under Sections 5.1 and 5.6, as between the Parties,
each Party shall own and retain all right, title and interest in and to any and all: (a)
Information that is conceived, discovered, developed or otherwise made, as necessary to

54

 

establish authorship, inventorship or ownership under applicable United States law, by or on behalf
of such Party under or in connection with this Agreement (or its Affiliates or its licensees or
Sublicensees), whether or not patented or patentable, and any and all Patents and Intellectual
Property Rights with respect thereto, except to the extent that any such Information, or any
Patents or Intellectual Property Rights with respect thereto, is Joint Know-How or Joint Patents,
and (b) other Information or other inventions and Patents and Intellectual Property Rights that are
owned or otherwise Controlled (other than pursuant to the license grants set forth in Sections 5.1
and 5.6) by such Party, its Affiliates or its licensees or Sublicensees.

          8.1.2 Ownership of Product Trademarks, GPC Biotech Patents and GPC Biotech Know-How. Subject
to the licenses and rights of reference granted under Sections 5.1 and 5.6, as between the Parties,
GPC Biotech shall own and retain all right, title and interest in and to all Product Trademarks,
GPC Biotech Patents and GPC Biotech Know-How.

          8.1.3 Ownership of Regulatory Documentation and the Drug Master File. Subject to the licenses
and rights of reference granted to GPC Biotech under Section 5.6, as between the Parties, Licensee
shall own all right, title and interest in and to all Regulatory Approvals (other than the Drug
Master Files) with respect to the Licensed Product in the Licensee Territory and the Regulatory
Documentation (other than Clinical Data except as otherwise provided in Section 8.1.4) with respect
thereto. Subject to the right of reference granted to Licensee under Section 5.1.3, GPC Biotech
shall own and retain all right, title and interest in and to all other Regulatory Approvals, all
Regulatory Documentation and all Drug Master Files with respect to the Licensed Compound or the
Licensed Product. Licensee shall promptly disclose to GPC Biotech in writing, and shall cause its
Affiliates, Sublicensees and Distributors to so disclose, the development, making, conception or
reduction to practice of any such Regulatory Approvals, Regulatory Documentation and Clinical Data
(except for Clinical Data referred to in Section 8.1.4), and shall, and does hereby, assign, and
shall cause its Affiliates, Sublicensees and Distributors to so assign, to GPC Biotech, without
additional compensation, such right, title and interest in and to any such Regulatory Approvals,
Regulatory Documentation and Clinical Data (except for Clinical Data referred to in Section 8.1.4)
as well as any Patents and other Intellectual Property Rights with respect thereto, as is necessary
to fully vest sole ownership in GPC Biotech as provided for in foregoing sentence.

          8.1.4 Clinical Data. Subject to the right of reference granted to GPC Biotech in Section 5.6,
Licensee shall own and retain all right, title and interest in and to all Clinical Data generated
by or on behalf of Licensee in connection with the Unilateral Activities of Licensee. Subject to
the right of reference granted to Licensee under Section 5.1.3, GPC Biotech shall own and retain
all right, title and interest in and to all other Clinical Data. For each Unilateral Activity of
Licensee for which GPC Biotech Opts-In pursuant to Section 2.5.6, Licensee hereby assigns to GPC
Biotech all of Licensee’s right, title and interest in and to the Clinical Data generated by or on
behalf of Licensee in connection with the Unilateral Activity of Licensee for which GPC Biotech
elects to Opt-In pursuant to Section 2.5.6.

          8.1.5 Ownership of Joint Patents and Joint Know-How. Except as expressly set forth in Section
8.1.3 and 8.1.4, as between the Parties, the Parties shall each own an equal, undivided interest in
any and all (a) Information and Improvements that are conceived, discovered, developed or otherwise
made, as necessary to establish authorship, inventorship or

55

 

ownership under applicable United States law, jointly by or on behalf of GPC Biotech (or its
Affiliates), on the one hand, and Licensee (or its Affiliates or its Sublicensees), on the other
hand, in connection with the work conducted under or in connection with this Agreement, whether or
not patented or patentable (to the extent such Information or Improvements are not generally known
and not covered or claimed by published Joint Patents, the “Joint Know-How”) and (b) Patents and
Intellectual Property Rights with respect to such Information and Improvements (the “Joint
Patents”). Together, such Information, Improvements, Patents and Intellectual Property Rights as
described in clause (a) and clause (b) of this Section 8.1.5 shall be referred to herein as the
“Joint Intellectual Property Rights.” Each Party shall promptly disclose to the other Party in
writing, and shall cause its Affiliates, licensees and Sublicensees to so disclose, the
development, making, conception or reduction to practice of any Joint Know-How or Joint Patents.
Each Party shall have the right to Exploit the Joint Intellectual Property Rights outside the scope
of this Agreement in any manner that is not inconsistent with the rights and obligations of the
Parties under this Agreement in its sole discretion, in each case, without the consent of the other
Party, and provided, that neither Party shall assign, pledge, encumber or otherwise transfer any of
its rights in any Joint Intellectual Property Rights without the other Party’s prior written
consent, such consent not to be unreasonably withheld or delayed.

          8.1.6 Ownership of Corporate Names. As between the Parties, each Party shall retain all
right, title and interest in and to its Corporate Names and agrees that it shall not attack,
dispute or contest the validity of or ownership of such other Party’s Corporate Names or any
registrations issued or issuing with respect thereto. Each Party expressly acknowledges and agrees
that no ownership rights are vested or created by the limited rights of use granted pursuant to
Section 5.1.5 or 5.6 and that all use of the Corporate Names in accordance therewith, including any
goodwill generated in connection therewith, inures to the benefit of the respective owner of the
Corporate Names and the owner of such Corporate Names may call for a confirmatory assignment
thereof.

     8.2 Maintenance and Prosecution of Patents and Trademarks.

          8.2.1 GPC Biotech Patents and Product Trademarks. Subject to Section 8.2.4 and the Spectrum
Agreement, GPC Biotech, through patent attorneys or agents of its choice, shall be responsible for
obtaining, prosecuting and maintaining throughout the Territory the GPC Biotech Patents and the
Product Trademarks. In this regard, GPC Biotech shall have the first right to (a) file, prosecute
and maintain Patent applications to seek Patent rights for the Licensed Compound and the Licensed
Product and any patentable GPC Biotech Know-How in the Major Market Countries and such other
countries as determined by GPC Biotech (after taking into account in good faith Licensee’s comments
with respect thereto) or as mutually agreed by GPC Biotech and Licensee and (b) control the
registration, prosecution and maintenance of the Product Trademarks in the Territory. Reasonable
and verifiable expenses incurred by GPC Biotech in the preparation, registration, filing,
prosecution and maintenance (as applicable) of the GPC Biotech Patents and Product Trademarks (i)
in the GPC Biotech Territory shall be borne by GPC Biotech and (ii) in the Licensee Territory after
October 1, 2005 shall be borne by Licensee, subject to the provisions hereof; provided that with
respect to any such expenses incurred in connection with activities in support of the preparation,
registration, filing, prosecution or maintenance of the GPC Biotech Patents or Product Trademarks
filed or intended

56

 

for filing in both the Licensee Territory and the GPC Biotech Territory, Licensee shall bear
thirty-five percent (35%) of such expenses and GPC Biotech shall bear sixty-five (65%) percent of
such expenses. With respect to the Licensee Territory, GPC Biotech shall not abandon or cease the
prosecution of any such application for a Patent or Trademark or permit any Patent or Trademark
registration issuing therefrom to lapse without first notifying Licensee and permitting Licensee to
continue the prosecution of such applications or registrations or pay any required fees in the name
of GPC Biotech, at Licensee’s expense and through patent attorneys of its choice. Licensee shall
not become an assignee of any Patent or application for Patent or Trademark as a result of its
continuing the prosecution or registration of an application for Patent or Trademark or paying any
fees according to this Section 8.2.1.

          8.2.2 Licensee Patents. Subject to Section 8.2.4, Licensee, through patent attorneys or
agents of its choice and at its sole cost and expense, shall be responsible for obtaining,
prosecuting and maintaining throughout the Territory the Licensee Patents. In this regard,
Licensee shall have the first right to prepare, file, prosecute and maintain Patent applications to
seek Patent rights for the Licensed Compound and Licensed Product and any patentable Licensee
Know-How in the GPC Biotech Territory and Major Market Countries and such other countries as
determined by Licensee or as mutually agreed by GPC Biotech and Licensee. With respect to any
Licensee Patent, Licensee shall not abandon or cease the prosecution of any such application for a
Patent (or preparation thereof) or permit any Patent issuing therefrom to lapse without first
notifying GPC Biotech and permitting GPC Biotech to continue the preparation, filing, prosecution
and maintenance of such applications or pay any required fees in the name of Licensee, at GPC
Biotech’s expense and through patent attorneys or agents of its choice. GPC Biotech shall not
become an assignee of any application for Patent or Patent as a result of its continuing the
prosecution of an application for Patent or paying any fees according to this Section 8.2.2.

          8.2.3 Joint Patents. Subject to Section 8.2.4 and the Spectrum Agreement, GPC Biotech,
through patent attorneys or agents of its choice, shall have the first right, but not obligation,
to prepare and file Patent applications claiming the Joint Know-How and to obtain, prosecute and
maintain Joint Patents throughout the Territory. GPC Biotech shall not abandon or cease the
prosecution of any such application for a Patent or permit any Patent issuing therefrom to lapse
without first notifying Licensee and permitting Licensee to continue the prosecution of such
applications, or pay any required fees in connection therewith, through patent attorneys or agents
of its choice. Reasonable and verifiable expenses incurred by the Party that prepares, files,
obtains, prosecutes and maintains the Joint Patents (a) in the GPC Biotech Territory shall be borne
by GPC Biotech and (b) in the Licensee Territory shall be borne by Licensee; provided that Licensee
shall bear thirty-five percent (35%) and GPC Biotech shall bear sixty-five percent (65%) of any
such expenses incurred in connection with the preparation and filing of PCT patent applications for
the Joint Patents that are to be filed in both the Licensee Territory and the GPC Biotech
Territory. In the event that either Party provides the other Party written notice that such
notifying Party no longer wishes to fund such prosecution or maintenance of one or more Joint
Patents, such notifying party shall assign and agrees to assign such Patent to the other Party.
Any such Joint Patents assigned by GPC Biotech shall become Licensee Patents hereunder and any such
Joint Patents assigned by Licensee shall become GPC Biotech Patents hereunder.

57

 

          8.2.4 Cooperation. Each Party shall assist and cooperate with the other Party as such other
Party may reasonably request from time to time in connection with its activities set forth in
Section 8.2.1, 8.2.2 and 8.2.3. Each Party shall (a) keep the other Party currently informed of
the status of and all steps to be taken in the preparation and prosecution of all applications
filed by it according to this Section 8.2, (b) furnish the other Party with copies of such
applications for Patents, amendments thereto and other related material correspondence to and from
patent offices, and (c) to the extent reasonably practicable, permit the other Party an opportunity
to offer its comments thereon and give such comments good faith consideration before making a
submission to a patent office which could materially affect the scope or validity of the Patent
coverage that may result. Such other Party shall offer its comments, if any, promptly.

          8.2.5 Patent Term Extensions. The JEC shall be responsible for making decisions regarding
patent term extensions, including supplementary protection certificates and any other extensions
that are now or become available in the future, wherever applicable, for GPC Biotech Patents,
Licensee Patents and Joint Patents in any country in the Licensee Territory, provided that (a) any
Dispute with respect thereto shall be resolved by GPC Biotech and (b) any applications or filings
with respect thereto shall be made by GPC Biotech. Each Party shall reasonably cooperate, as
requested by the other Party, to promptly and timely implement or effect such decisions.
Notwithstanding the foregoing, the Parties shall coordinate their activities with respect to any
patent term extension with respect to all Patents in order to secure the optimal protection for the
Licensed Product available under Applicable Law.

     8.3 Enforcement of Patents and Trademarks.

          8.3.1 Rights and Procedures. In the event that either Party reasonably believes that a Third
Party may be infringing any of the GPC Biotech Patents, the Licensee Patents, the Joint Patents or
the Product Trademarks, such Party shall promptly notify the other Party in writing, identifying
the alleged infringer and the alleged infringement complained of and furnishing the information
upon which such determination is based. With respect to the GPC Biotech Patents, the Joint Patents
and the Product Trademarks, GPC Biotech shall, subject to the Spectrum Agreement, have the first
right, but not the obligation, through counsel of its choosing, to take any measures it deems
appropriate to stop such infringing activities by such Third Party in any part of the Territory or,
to the extent not in conflict with the terms of this Agreement, to grant the infringing Third Party
adequate rights and licenses necessary for continuing such activities. With respect to the
Licensee Patents, Licensee shall have the first right, but not the obligation, through counsel of
its choosing, to take any measures it deems appropriate to stop such infringing activities by such
Third Party in any part of the Territory or, to the extent not in conflict with the terms of this
Agreement, to grant the infringing Third Party adequate rights and licenses necessary for
continuing such activities. Upon reasonable request by the enforcing Party, the other Party shall
give the enforcing Party all reasonable information and assistance, including allowing the
enforcing Party access to the other Party’s files and documents and to the other Party’s personnel
who may have possession of relevant information and, if necessary for the enforcing Party to
prosecute any legal action, joining in the legal action as a party at its own expense. In the
event the enforcing Party fails within ninety (90) days following notice of such infringement, as
provided in the first sentence of this Section 8.3.1, or earlier notifies the other

58

 

Party in writing of its intent not to take commercially appropriate steps to stop any infringement
of any (a) GPC Biotech Patent, Joint Patent or Product Trademark in the Licensee Territory, in the
case of GPC Biotech, or (b) Licensee Patent in the Territory, in the case of Licensee, that is
likely or could reasonably be expected to have a material adverse effect on the sale of the
Licensed Product in the Territory and the enforcing Party has not granted the infringing Third
Party rights and licenses to continue its otherwise infringing activities, then, unless the
enforcing Party provides the other Party with a commercially reasonable basis in writing for not
taking such steps, the other Party shall have the right, but not the obligation, to do so at the
other Party’s sole cost and expense; provided, however, that if the enforcing Party has commenced
negotiations with an alleged infringer for discontinuance of such infringement within such ninety
(90) day period, the enforcing Party shall have an additional ninety (90) days to conclude its
negotiations before the other Party may bring suit for such infringement. Upon reasonable request
by the other Party, the enforcing Party shall give the other Party all reasonable information and
assistance in connection with such suit for infringement.

          8.3.2 Generic Competition. Notwithstanding the foregoing, if either Party (a) reasonably
believes that a Third Party may be filing or preparing or seeking to file a generic or abridged
Drug Approval Application that refers to or relies on Regulatory Documentation submitted by either
Party to any Regulatory Authority whether or not such a filing may be in violation of any
Regulatory Exclusivity Period or infringe the GPC Biotech Patents, the Licensee Patents or the
Joint Patents or (b) receives any notice of certification regarding the GPC Biotech Patents, Joint
Patents or Licensee Patents pursuant to the U.S. “Drug Price Competition and Patent Term
Restoration Act” of 1984 (21 United States Code §355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV)) (“ANDA
Act”) claiming that any such Patents are invalid or unenforceable or claiming that the any such
Patents will not be infringed by the Manufacture, use, marketing or sale of a product for which an
application under the ANDA Act is filed or (c) receives any equivalent or similar certification or
notice in any other jurisdiction, it shall notify the other Party in writing, identifying the
alleged applicant or potential applicant and furnishing the information upon which such
determination is based, and provide the other Party a copy of any such notice of certification
within ten (10) days of receipt and the Parties’ rights and obligations with respect to any legal
action as a result of such certification shall be as set forth in Section 8.3.1; provided, however,
that if the enforcing Party elects not to bring suit against the Third Party providing notice of
such certification within thirty (30) days of receipt of such notice with respect to any (y) GPC
Biotech Patent or Joint Patent in the Licensee Territory or (z) Licensee Patent in the Territory,
then the other Party shall have the right, but shall not the obligation, to bring suit against such
Third Party and to join the enforcing Party as a Party plaintiff if necessary to bring such a suit,
in which event the other Party shall hold the enforcing Party harmless from and against any and all
costs and expenses of such litigation, including reasonable attorney’s fees and expenses.

          8.3.3 Costs and Expenses. Each Party shall bear its own costs and expenses relating to any
enforcement action pursuant to Section 8.3.1 or 8.3.2. Any damages or other amounts collected
shall be used to reimburse the Parties for their costs and expenses in making such recovery (which
amounts shall be allocated pro rata if insufficient to cover the totality of such expenses), with
any remainder being retained by the Party that pursued such enforcement action; provided, however,
with respect to any amount received by the enforcing Party that

59

 

relates to infringement of a Patent in the Licensee Territory, such remainder shall be shared
equally by the Parties.

     8.4 Potential Third Party Rights

          8.4.1 Third Party Licenses. If the Exploitation of the Licensed Product in accordance with
the terms and conditions of this Agreement, by Licensee, its Affiliates or any of its Sublicensees
or Distributors infringes or misappropriates any Patent or any Intellectual Property Right of a
Third Party in any country, such that Licensee or any of its Affiliates, Sublicensees or
Distributors cannot, in the reasonable opinion of Licensee as advised by competent patent counsel,
Develop or Commercialize the Licensed Product in such country without infringing the Patent or
Intellectual Property Right of such Third Party, then, subject to the Spectrum Agreement, (x) if
such Patent or other Intellectual Property Right is pending, issued or registered only in the
Licensee Territory, Licensee shall have the first right to take the lead on negotiating the terms
of each such license with such Third Party and (y) otherwise GPC Biotech shall have the first right
to take the lead on negotiating the terms of each such license, and in each case ((x) and (y)), if
such Party does not take such lead, then the other Party may do so; provided that Licensee may seek
or obtain any such license solely with respect to one or more countries in the Licensee Territory;
and provided, further, in either case: the terms of any such license shall permit the Party
obtaining such license to grant to the other Party a sublicense thereunder; the Parties shall
cooperate in negotiating the terms of such license with such Third Party; and the Party obtaining
such license shall consult with the other Party prior to making any proposal regarding, or
otherwise agreeing to, the terms of any such license. The determination of whether to seek and the
terms of any such license shall be approved by the JEC. If one or both Parties enter into such a
Third Party license agreement for the Licensee Territory, then:

               (a) Each Party shall be solely responsible for all license fees, milestones, royalties or
other such payments due to such any Third Party (“Third Party Payments”) (irrespective of the Party
that has entered into an agreement with, or first made a payment to, such Third Party) consisting
of payments with respect to the Commercialization of such Licensed Product in each Party’s portion
of the Territory. Any Third Party Payments (irrespective of the Party that has entered into an
agreement with, or first made a payment to, such Third Party) consisting of license fees,
milestones or other payments with respect to Development shall be shared by the Parties such that
Licensee shall bear thirty-five percent (35%) of such Third Party Payments and GPC Biotech shall
bear sixty-five (65%) percent of such Third Party Payments; provided that GPC Biotech shall be
solely responsible for all license fees, milestones and royalties due to Spectrum pursuant to the
Spectrum Agreement (the “Spectrum Payments”) and any Third Party Payments under any agreements
entered into pursuant to clause (y) of Section 8.4.1 to the extent such agreement relates solely to
the GPC Biotech Territory; and, provided, further, that Licensee shall be solely responsible for
Third Party Payments under any agreement entered into pursuant to clause (x) of Section 8.4.1. In
the event that either Party has entered into such Third Party license agreement pursuant to this
Section and has the obligation pursuant to such agreement to pay to such Third Party such Third
Party Payments, such amounts shall be paid by the other Party to such contracting Party as early as
may be necessary to ensure that such contracting Party has received from the other Party the
required payment at least five (5) Business Days prior to the date on which such contracting

60

 

Party owes the corresponding payment to the Third Party. For clarity, no amount paid by Licensee
to a Third Party as a Third Party Payment for the Licensee Territory in accordance with this
Section shall be included in the Collaboration Costs; and

               (b) Licensee shall have the right to deduct up to [...***...] of any Third Party Payments paid
by Licensee with respect to the Licensee Territory from royalty payments set forth in Section 7.2
hereunder, provided that the royalty rate payable to GPC Biotech under Section 7.2 shall not be
reduced by more than [...***...] in any Calendar Quarter. In the event that any reduction permitted
under this Section is so limited, Licensee may carry the unused portion of such Third Party
Payments, comprised solely of upfront license fee payments, forward to subsequent Calendar
Quarters, subject to the application of the limitations set forth in this Section.

          8.4.2 Invalidity or Unenforceability Defenses or Actions.

               (a) In the event that a Third Party or Sublicensee asserts, as a defense or as a counterclaim
in any infringement action under Section 8.3.1, that any Product Trademark, GPC Biotech Patent,
Licensee Patent or Joint Patent is invalid or unenforceable, then the Party pursuing such
infringement action shall promptly give written notice to the other Party. With respect to the
Product Trademarks, GPC Biotech Patents and the Joint Patents, subject to the Spectrum Agreement,
GPC Biotech shall have the first right, but not the obligation, through counsel of its choosing, to
respond to such defense or defend against such counterclaim (as applicable) and, if Licensee is
pursuing the applicable infringement action under Section 8.3.1, Licensee shall allow GPC Biotech
to control such response or defense (as applicable). With respect to the Licensee Patents Licensee
shall have the first right, but not the obligation, through counsel of its choosing, to respond to
such defense or defend against such counterclaim (as applicable) and, if GPC Biotech is pursuing
the applicable infringement action under Section 8.3.1, GPC Biotech shall allow Licensee to control
such response or defense (as applicable). Any costs and expenses with respect to such response or
defense against such counterclaim shall be borne by the Party controlling such response or defense.
If either Party determines not to respond to such defense or defend against such counterclaim (as
applicable), the other Party shall, at its sole cost and expense, have the right to respond to such
defense or defend against such counterclaim (as applicable); provided, however, that such other
Party shall obtain the written consent of GPC Biotech, with respect to the GPC Biotech Patents and
the Joint Patents, or Licensee, with respect to the Licensee Patents, prior to ceasing to defend,
settling or otherwise compromising such defense or counterclaim, such consent not to be
unreasonably withheld or delayed.

               (b) Similarly, if a Third Party or Sublicensee asserts, in a declaratory judgment action or
similar action or claim filed by such Third Party, that any Product Trademark, GPC Biotech Patent,
Licensee Patent or Joint Patent is invalid or unenforceable, then the Party first becoming aware of
such action or claim shall promptly give written notice to the other Party. With respect to the
Product Trademarks, GPC Biotech Patents and Joint Patents, subject to the Spectrum Agreement, GPC
Biotech shall have the first right, but not the obligation, through counsel of its choosing, to
defend against such action or claim. With respect to the Licensee Patents Licensee shall have the
first right, but not the obligation, through counsel of its choosing, to defend against such action
or claim. Any costs and expenses with respect to such

 

*** Confidential Treatment Requested

61

 

defense shall be borne by the Party defending against such action or claim. If either Party
determines not to assume such defense with respect to (y) the Product Trademarks, GPC Biotech
Patents and Joint Patents in the Licensee Territory or (z) the Licensee Patents in the Territory,
then other Party shall, at its sole cost and expense, have the right to defend against such action
or claim; provided, however, that the other Party shall obtain the written consent of GPC Biotech,
with respect to the GPC Biotech Patents and the Joint Patents, or Licensee, with respect to the
Licensee Patents, prior to ceasing to defend, settling or otherwise compromising any such action or
claim, such consent not to be unreasonably withheld or delayed.

               (c) Each Party shall provide to the other Party all reasonable assistance requested by the
other Party in connection with any action, claim or suit under this Section 8.4.2, including
allowing such other Party access to the assisting Party’s files and documents and to the assisting
Party’s personnel who may have possession of relevant information. In particular, the assisting
Party shall promptly make available to the other Party, free of charge, all information in its
possession or control that it is aware will be reasonably necessary to assist the other Party in
responding to any such action, claim or suit.

          8.4.3 Third Party Litigation. In the event of any actual or threatened suit against Licensee
or its Affiliates, Sublicensees, Distributors or customers alleging that the Development or
Commercialization of the Licensed Product in the Licensee Territory infringes the Patents or
Intellectual Property Rights of any Third Party, Licensee shall, subject to the Spectrum Agreement,
assume direction and control of the defense of claims arising therefrom (including the right to
settle such claims at its sole discretion); provided, however, that Licensee shall obtain the
written consent of GPC Biotech prior to ceasing to defend, settling or otherwise compromising such
claims where such settlement or compromise would have an adverse affect on the validity or
enforceability of any Patents and Intellectual Property Rights of GPC Biotech (including the Joint
Intellectual Property Rights) or where such consent would otherwise be required pursuant to Section
13.5.2, such consent not to be unreasonably withheld or delayed. Each Party shall provide the
other Party with copies of any notices it receives from Third Parties relating to any patent
nullity actions, declaratory judgment actions and any alleged infringement or misappropriation of
the Intellectual Property Rights of a Third Party by the Development, Manufacture or
Commercialization of the Licensed Product in any country of the Territory. Such notices shall be
provided promptly, but in no event more than ten (10) days following receipt thereof or, with
respect to notices received prior to the Effective Date, on or prior to the Effective Date.

          8.4.4 Retained Rights. Nothing in this Section 8.4 shall prevent Licensee, at its own
expense, from obtaining any license or other rights from Third Parties it deems appropriate in
order to permit the full and unhindered exercise of its rights under this Agreement.

          8.4.5 Cooperation. In the event that a Third Party [...***...] institutes a Patent, trade
secret or other infringement suit against GPC Biotech, Licensee or their respective Affiliates or,
in the case of Licensee, Sublicensees or Distributors, during the term of this Agreement with
respect to the Licensed Products, each Party shall, at its own cost and expense, use all reasonable
efforts to assist and cooperate with the other Party in connection with the defense of such suit.

 

*** Confidential Treatment Requested

62

 

ARTICLE 9

ADVERSE EVENT REPORTING

     9.1 Complaints. Each Party shall maintain a record of any and all Complaints it receives with
respect to the Licensed Product. Each Party shall notify the other Party in reasonable detail of
any Complaint received by it within five (5) days after the event, and in any event in sufficient
time to allow such Party to comply with all Applicable Law in any country or with respect to any
activity for which it is the Regulatory Lead or the Development Lead, as applicable. For purposes
of this Section 9.1, a “Complaint” means any oral or written communication of dissatisfaction
regarding the identity, quality, durability, reliability or performance of the Licensed Product.
Examples include appearance, low fills, foreign materials, foreign product, defective packaging or
defective labeling.

     9.2 Adverse Event Reporting. Each Party shall provide the other Party with all information
necessary or desirable for such other Party to comply with its pharmacovigilance responsibilities
in the Territory, including any Adverse Event Experiences from pre-clinical or clinical laboratory,
animal toxicology and pharmacology studies, clinical trials and commercial experiences with the
Licensed Product. “Adverse Event Experience” shall mean (a) any finding from tests in laboratory
animals or in vitro that suggests a significant risk for human subjects including reports of
mutagenicity, teratogenicity or carcinogenicity and (b) any undesirable, untoward or noxious event
or experience associated with the clinical, commercial or other use or occurring following
administration, of the Licensed Product in humans, occurring at any dose, whether expected or
unexpected and whether or not considered related to or caused by the Licensed Product, including
such an event or experience as occurs in the course of the use of the Licensed Product in
professional practice, in a clinical trial, from overdose, whether accidental or intentional, from
abuse, from withdrawal or from a failure of expected pharmacological or biological therapeutic
action of the Licensed Product, and including those events or experiences that are required to be
reported to the FDA under 21 C.F.R. sections 312.32 or 314.80 or to foreign Regulatory Authorities
under corresponding Applicable Law outside the United States.

     9.3 Pharmacovigilance. Subject to the terms of this Agreement, within three (3) months of the
Effective Date, GPC Biotech and Licensee shall discuss and develop mutually acceptable guidelines
and procedures for the investigation, exchange, receipt, recordation, communication (as between the
Parties) and exchange of Adverse Event Experience information and all other information regarding
matters covered in this Article 9. Until such guidelines and procedures are set forth in an
agreement between the Parties (the “Pharmacovigilance Agreement”), the terms of Sections 9.1 and
9.2 shall apply. Following the execution of the Pharmacovigilance Agreement, such Sections shall
continue to apply unless expressly amended by the Parties, provided that in the event of any
conflict between the terms of Sections 9.1 and 9.2 and the terms of the Pharmacovigilance
Agreement, the terms of the Pharmacovigilance Agreement shall control. It is anticipated that such
Pharmacovigilance Agreement shall include provisions for the exchange between the Parties of
Adverse Event Experience reports, the creation and maintenance by GPC Biotech of

63

 

an electronic database comprised of all adverse events reported on a worldwide basis with respect
to the Licensed Product and the establishment of appropriate mechanisms by which Licensee can, in a
timely manner, access such database on a read only basis to comply with Applicable Law and to
perform its responsibilities and exercise its rights under this Agreement. Each Party shall be
responsible for its own costs incurred in connection with receiving, recording, reviewing,
communicating, reporting and responding to adverse events.

ARTICLE 10

LICENSED PRODUCT RECALL

     10.1 Notification and Recall. In the event that any Regulatory Authority issues or requests a
recall or takes similar action in connection with the Licensed Product or in the event either Party
determines that an event, incident or circumstance has occurred that may result in the need for a
recall or market withdrawal, the Party notified of or desiring such recall or similar action shall,
within twenty-four (24) hours, advise the other Party thereof by telephone (and confirm by email or
facsimile), email or facsimile. Following notification of a recall in the Licensee Territory, the
JEC shall meet to discuss such notification or recall and Licensee shall decide whether to conduct
a recall (except in the case of a government-mandated recall) and the manner in which any such
recall shall be conducted. Following notification or a recall in the GPC Biotech Territory, the
JEC shall meet to discuss such notification or recall and GPC Biotech shall decide whether to
conduct a recall (except in the case of a government-mandated recall) and the manner in which any
such recall shall be conducted.

     10.2 Recall Expenses. Licensee shall bear the expenses of any recall of the Licensed Product
in the Licensee Territory; provided, however, that GPC Biotech shall bear the expense of a recall
to the extent that such recall resulted from GPC Biotech’s breach of its obligations hereunder or
under the Supply Agreement or its gross negligence or willful misconduct. GPC Biotech shall bear
the expenses of any recall of the Licensed Product in the GPC Biotech Territory.

ARTICLE 11

CONFIDENTIALITY AND NON-DISCLOSURE

     11.1 Confidentiality Obligations. At all times during the term of this Agreement and for a
period of ten (10) years following termination or expiration hereof, each Party shall, and shall
cause its officers, directors, employees and agents to, keep completely confidential and not
publish or otherwise disclose and not use, directly or indirectly, for any purpose, any
Confidential Information furnished or otherwise made known to it, directly or indirectly, by the
other Party, except to the extent such disclosure or use is expressly permitted by the terms of
this Agreement or is reasonably

64

 

necessary for the performance of this Agreement. “Confidential Information” means any information
provided by one Party to another relating to the terms of this Agreement, the Licensed Compound or
the Licensed Product (including the Regulatory Documentation, Regulatory Approvals and Drug Master
Files any information or data contained therein), any Development or Commercialization of the
Licensed Compound or the Licensed Product or the scientific, regulatory or business affairs or
other activities of either Party. All Clinical Data shall be the Confidential Information of the
Party that owns such data, regardless of which Party furnished such data. Such Confidential
Information may be used by the receiving Party only for the purposes of carrying out obligations or
exercising its rights set forth in this Agreement. Notwithstanding the foregoing, Confidential
Information shall not include any information that:

          11.1.1 is or hereafter becomes part of the public domain by public use, publication, general
knowledge or the like through no wrongful act, fault or negligence on the part of receiving Party;

          11.1.2 can be demonstrated by documentation or other competent proof to have been in the
receiving Party’s possession prior to disclosure by the disclosing Party without any obligation of
confidentiality with respect to said information;

          11.1.3 is subsequently received by the receiving Party from a Third Party who is not bound by
any obligation of confidentiality with respect to said information;

          11.1.4 has been published by a Third Party or otherwise enters the public domain through no
fault of the receiving Party in breach of this Agreement; or

          11.1.5 can be demonstrated by documentation or other competent evidence to have been
independently developed by or for the receiving Party without reference to the disclosing Party’s
Confidential Information.

Specific aspects or details of Confidential Information shall not be deemed to be within the public
domain or in the possession of the receiving Party merely because the Confidential Information is
embraced by more general information in the public domain or in the possession of the receiving
Party. Further, any combination of Confidential Information shall not be considered in the public
domain or in the possession of the receiving Party merely because individual elements of such
Confidential Information are in the public domain or in the possession of the receiving Party
unless the combination and its principles are in the public domain or in the possession of the
receiving Party.

     11.2 Permitted Disclosures. Each Party may disclose Confidential Information to the extent
that such disclosure is:

          11.2.1 Made in response to a valid order of a court of competent jurisdiction or other
supra-national, federal, national, regional, state, provincial and local governmental or regulatory
body of competent jurisdiction or, if in the reasonable opinion of the receiving Party’s legal
counsel, such disclosure is otherwise required by law; provided, however, that the receiving Party
shall first have given notice to the disclosing Party and given the disclosing Party a reasonable
opportunity to quash such order and to obtain a protective order requiring that the

65

 

Confidential Information and documents that are the subject of such order be held in confidence by
such court or agency or, if disclosed, be used only for the purposes for which the order was
issued; and provided further that if a disclosure order is not quashed or a protective order is not
obtained, the Confidential Information disclosed in response to such court or governmental order
shall be limited to that information which is legally required to be disclosed in response to such
court or governmental order;

          11.2.2 Made by the receiving Party to the Regulatory Authorities as required in connection
with any filing, application or request for Regulatory Approval; provided, however, that reasonable
measures, to the extent available, shall be taken to assure confidential treatment of such
information; or

          11.2.3 Made by either Party or its Affiliates or sublicensees to Third Parties as may be
necessary or useful in connection with the Manufacture or Exploitation of the Licensed Compound,
the Licensed Product, (to the extent permitted or contemplated hereunder) Improvements thereto or
otherwise in connection with the performance of its obligations or exercise of its rights
(including, with respect to GPC Biotech, its rights under Sections 5.2 and 5.6 or disclosures to
Spectrum or GPC Biotech Counter-Parties) as contemplated by this Agreement, including
subcontracting and sublicensing transactions in connection therewith; provided, however, that such
persons shall be subject to obligations of confidentiality and non-use with respect to such
Confidential Information comparable to the obligations of confidentiality and non-use of the
receiving Party pursuant to this Article 11.

     11.3 Use of Name. Except as expressly set forth in Sections 5.1.5 and 5.6.2, neither Party
shall mention or otherwise use the name, insignia, symbol, Trademark, trade name or logotype of the
other Party (or any abbreviation or adaptation thereof) in any publication, press release,
promotional material or other form of publicity without the prior written approval of such other
Party in each instance. The restrictions imposed by this Section shall not prohibit either Party
from making any disclosure identifying the other Party that is required by Applicable Law.

     11.4 Press Releases. Press releases or other similar public communication by either Party
relating to this Agreement shall be approved in advance by the other Party, which approval shall
not be unreasonably withheld or delayed, except for those communications required by Applicable
Law, disclosures of information for which consent has previously been obtained, information that
has been previously disclosed publicly or as otherwise set forth in this Agreement; provided that
the other Party is given a reasonable opportunity to review and comment on any such press release
or public communication in advance thereof.

     11.5 Patient Information. The Parties agree to abide (and to cause their respective
Affiliates, Sublicensees and Distributors to abide) and to take (and to cause their respective
Affiliates, Sublicensees and Distributors to take) all reasonable and appropriate actions to ensure
that all Third Parties conducting or assisting with any clinical development activities hereunder
in accordance with, and subject to the terms of, this Agreement, shall abide, to the extent
applicable, by all Applicable Law concerning the confidentiality or protection of patient
identifiable information and/or patient’s protected health

66

 

information, including the regulations at 45 C.F.R. Parts 160 and 164 and where relevant, the
applicable national laws implementing the European Union Directive 95/46/EC on the protection of
individuals with regard to the processing of personal data and on the free movement of such data of
24 October 1995 and any other Applicable Law, in the course of their performance under this
Agreement.

     11.6 Publications. The JEC (or its appropriate designees) shall determine the strategy for,
and coordinate, the publication and presentation of results of studies of the Licensed Product or
other data generated under this Agreement. Each Party recognizes that the publication of papers
regarding results of and other information regarding activities under this Agreement, including
oral presentations and abstracts, may be beneficial to both Parties, provided such publications are
subject to reasonable controls to protect Confidential Information. In particular, it is the
intent of the Parties to maintain the confidentiality of any Confidential Information included in
any Patent application until such Patent application has been filed. Accordingly, each Party shall
have the right to review and approve any paper proposed for publication by the other Party,
including any oral presentation or abstract, which pertains to results of Clinical Studies, Post
Approval Studies or other studies with respect to the Licensed Product or includes other data
generated under this Agreement or which includes Confidential Information of the other Party.
Before any such paper is submitted for publication or an oral presentation is made, the publishing
or presenting Party shall deliver a complete copy of the paper or materials for oral presentation
to the other Party at least thirty (30) days prior to submitting the paper to a publisher or making
the presentation. The other Party shall review any such paper and give its comments to the
publishing Party within fifteen (15) days of the delivery of such paper to the other Party. With
respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts
to expedite review of such materials and abstracts, and shall return such items as soon as
practicable to the publishing or presenting Party with appropriate comments, if any, but in no
event later than fifteen (15) days from the date of delivery to the other Party. Failure to
respond within such fifteen (15) days shall be deemed approval to publish or present. If approval
is not given or deemed given, either Party may refer the matter to the JEC for resolution together
with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or
presenting Party shall comply with the other Party’s request to delete references to such other
Party’s Confidential Information in any such paper and shall withhold publication of any such paper
or any presentation of same for an additional sixty (60) days in order to permit the Parties to
obtain patent protection if either Party deems it necessary. Any publication shall include
recognition of the contributions of the other Party according to standard practice for assigning
scientific credit, either through authorship or acknowledgement, as may be appropriate. Each Party
shall use commercially reasonable efforts to cause investigators and institutions participating in
Clinical Studies and Post Approval Studies for the Licensed Product with which it contracts to
agree to terms substantially similar to those set forth in this Section, which efforts shall
satisfy such Party’s obligations under this Section with respect to such investigators and
institutions.

     11.7 Return of Confidential Information. Upon the effective date of the termination of this
Agreement for any reason, either Party may request in writing, and the other Party shall either,
with respect to Confidential Information to which such other Party does not retain rights
hereunder: (i) promptly destroy all copies of such Confidential Information in the possession of
the other Party and

67

 

confirm such destruction in writing to the requesting Party; or (ii) promptly deliver to the
requesting Party, at the other Party’s expense, all copies of such Confidential Information in the
possession of the other Party; provided, however, the other Party shall be permitted to retain one
(1) copy of such Confidential Information for the sole purpose of performing any continuing
obligations hereunder or for archival purposes. Notwithstanding the foregoing, such other Party
also shall be permitted to retain such additional copies of or any computer records or files
containing such Confidential Information that have been created solely by such Party’s automatic
archiving and back-up procedures, to the extent created and retained in a manner consistent with
such other Party’s standard archiving and back-up procedures, but not for any other use or purpose.
All Confidential Information shall continue to be subject to the terms of this Agreement for the
period set forth in Section 11.1.

ARTICLE 12

REPRESENTATIONS AND WARRANTIES

     12.1 Representations, Warranties and Covenants. Each Party hereby represents, warrants and
covenants to the other Party that, as of the Effective Date:

          12.1.1 Corporate Authority. Such Party (a) has the power and authority and the legal right to
enter into this Agreement and perform its obligations hereunder and (b) has taken all necessary
action on its part required to authorize the execution and delivery of this Agreement and the
performance of its obligations hereunder. This Agreement has been duly executed and delivered on
behalf of such Party and constitutes a legal, valid and binding obligation of such Party and is
enforceable against it in accordance with its terms subject to the effects of bankruptcy,
insolvency or other laws of general application affecting the enforcement of creditor rights and
judicial principles affecting the availability of specific performance and general principles of
equity, whether enforceability is considered a proceeding at law or equity.

          12.1.2 Litigation. Such Party is not aware of any pending or threatened litigation (and has
not received any communication) that alleges that such Party’s activities related to this Agreement
have violated or that by conducting the activities as contemplated herein such Party would violate,
any of the Patent or Intellectual Property Rights of any other Person.

          12.1.3 Consents and Approvals. All necessary consents, approvals and authorizations of all
regulatory and governmental authorities and other Persons required to be obtained by such Party in
connection with the execution and delivery of this Agreement and the performance of its obligations
hereunder have been obtained.

          12.1.4 Conflicts. The execution and delivery of this Agreement and the performance of such
Party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable law
or regulation or any provision of the articles of association or limited partnership agreement or
any similar instrument of such Party, as applicable, in any

68

 

material way, and (b) do not conflict with, violate or breach or constitute a default or require
any consent under, any contractual obligation or court or administrative order by which such Party
is bound.

     12.2 Additional Representations, Warranties and Covenants of Licensee. Licensee represents,
warrants and covenants to GPC Biotech that, as of the Effective Date:

          12.2.1 Licensee (a) is a corporation duly organized and in good standing under the laws of
Switzerland and (b) has full power and authority and the legal right to own and operate its
property and assets and to carry on its business as it is now being conducted and as it is
contemplated to be conducted by this Agreement.

          12.2.2 Neither Licensee nor any of its Affiliates has been debarred or is subject to debarment
and neither Licensee nor any of its Affiliates will use in any capacity, in connection with the
services to be performed under this Agreement, any Person who has been debarred pursuant to Section
306 of the FFDCA or who is the subject of a conviction described in such section. Licensee shall
inform GPC Biotech in writing immediately if it or any Person who is performing services hereunder
is debarred or is the subject of a conviction described in Section 306 or if any action, suit,
claim, investigation or legal or administrative proceeding is pending or, to the best of Licensee’s
Knowledge, is threatened, relating to the debarment or conviction of Licensee or any Person
performing services hereunder.

     12.3 Additional Representations, Warranties and Covenants of GPC Biotech. GPC Biotech
represents, warrants and covenants to Licensee that, as of the Effective Date:

          12.3.1 GPC Biotech is a corporation duly organized under the laws of Germany and has full
power and authority and the legal right to own and operate its property and assets and to carry on
its business as it is now being conducted and as is contemplated to be conducted by this Agreement.

          12.3.2 Neither GPC Biotech nor any of its Affiliates has been debarred or is subject to
debarment and neither GPC Biotech nor any of its Affiliates will use in any capacity, in connection
with the services to be performed under this Agreement, any Person who has been debarred pursuant
to Section 306 of the FFDCA or who is the subject of a conviction described in such section. GPC
Biotech shall inform Licensee in writing immediately if it or any Person who is performing services
hereunder is debarred or is the subject of a conviction described in Section 306 or if any action,
suit, claim, investigation or legal or administrative proceeding is pending or, to the best of GPC
Biotech’s Knowledge, is threatened, relating to the debarment or conviction of Licensee or any
Person performing services hereunder.

          12.3.3 GPC Biotech Controls the Patents listed on Exhibit A and the GPC Biotech Know-How, and
is entitled to grant the licenses specified herein. Except for any obligation of GPC Biotech or
any of its Affiliates under the German act on employees’ inventions (Gesetz über
Arbeitnehmererfindungen) or corresponding laws in other jurisdictions, the requirements of which,
to GPC Biotech’s Knowledge, have been satisfied, GPC Biotech has

69

 

not caused any GPC Biotech Patent to be subject to any liens or encumbrances and GPC Biotech has
not granted to any Third Party any rights or licenses under any of the GPC Biotech Know-How or GPC
Biotech Patents that would conflict with the licenses granted to Licensee hereunder. To GPC
Biotech’s Knowledge, neither the Development nor Commercialization of the Licensed Product in the
Field as currently conducted by GPC Biotech or as contemplated by this Agreement does or would
infringe or result in the misappropriation of any Patent or other Intellectual Property Rights of
any Third Party.

          12.3.4 To GPC Biotech’s Knowledge, the GPC Biotech Patents have been procured or are being
procured from the respective Patent Offices in accordance with Applicable Law.

          12.3.5 GPC Biotech has no Knowledge of any actual infringement or threatened infringement of
the GPC Biotech Patents or GPC Biotech Know-How by any Person.

          12.3.6 GPC Biotech has no Knowledge of any claim or litigation that has been brought or
threatened in writing by any Person alleging that (a) the GPC Biotech Patents or the GPC Biotech
Know-How are invalid or unenforceable or (b) the Development and Commercialization of the Licensed
Product in the Field as contemplated by this Agreement infringes any Patent or other Intellectual
Property Right Controlled by any Third Party.

          12.3.7 GPC Biotech has not, up through and including the Effective Date, Knowingly withheld
(except as previously stated by GPC Biotech to Licensee) any material information, including
reports of Adverse Event Experiences and warning letters from Regulatory Authorities, in GPC
Biotech’s possession from Licensee in response to Licensee’s reasonable inquiries in connection
with its due diligence relating to the Licensed Compound, Licensed Product, this Agreement and the
underlying transaction. To GPC Biotech’s Knowledge, the clinical data related to Licensed Product
in the Field that GPC Biotech has provided to Licensee prior to the Effective Date was, when access
was provided to Licensee, up-to-date and accurate in all material respects and GPC Biotech has
provided Licensee with any material updates to such clinical data that have occurred since the time
such access was provided to Licensee.

          12.3.8 GPC Biotech has provided Licensee with a complete and correct (except as may be
redacted by Spectrum or its licensor) copy of the Spectrum Agreement existing as of the Effective
Date. To GPC Biotech’s Knowledge, the Spectrum Agreement remains in full force and effect as of
the Effective Date and, except for any rights of GPC Biotech under the German act on employees’
inventions (Gesetz über Arbeitnehmererfindungen) or corresponding laws in other jurisdictions, is
the only agreement with a Third Party (a) pursuant to which GPC Biotech has acquired any rights to
the Licensed Compound or the Licensed Products in the Field, and (b) that imposes an obligation on
GPC Biotech to pay royalties to a Third Party based upon Commercialization of the Licensed Product
in the Field. GPC Biotech represents and warrants to Licensee that to GPC Biotech’s Knowledge, as
of the Effective Date, GPC Biotech is in compliance in all material respects with the terms of the
Spectrum Agreement and that the performance of GPC Biotech’s obligations and the exploitation of
any rights granted to Licensee hereunder in accordance with the terms and conditions of this
Agreement will not violate, breach, or constitute a default or require any consent under, the terms
of the Spectrum

70

 

Agreement. GPC Biotech covenants to Licensee and agrees that it shall use all commercially
reasonable efforts not to take any action or omit to take any action that would constitute a breach
of the Spectrum Agreement or enter into any amendment to the Spectrum Agreement, which amendment
would be reasonably likely to have a material adverse effect on the Development or
Commercialization of the Licensed Product in the Licensee Territory. GPC Biotech shall provide
Licensee promptly with notice of the occurrence of any such breach or any notice alleging that GPC
Biotech has committed any such breach. Licensee acknowledges that pursuant to Section 5 of the
Spectrum Agreement, Spectrum Pharmaceuticals has a right to negotiate for co-promotion rights to
Licensed Products in the United States. Notwithstanding the foregoing, in this event, the operation
of the limitations in Sections 2.4.3, 2.4.4 and 2.4.5 by virtue of Spectrum Pharmaceuticals
becoming a GPC Biotech Counter Party through such provisions shall not be deemed a material adverse
effect.

     12.4 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS ARTICLE 12,
NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN
FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY
OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF
QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE
VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD
PARTIES.

ARTICLE 13

INDEMNITY

     13.1 Indemnification of GPC Biotech. Licensee shall indemnify GPC Biotech, its Affiliates and
their respective directors, officers, employees, licensors and agents, and defend and save each of
them harmless, from and against any and all losses, damages, liabilities, costs and expenses
(including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in connection with any
and all suits, investigations, claims or demands of Third Parties (collectively, “Third Party
Claims”) arising from or occurring as a result of: (a) the breach by Licensee or its Affiliates,
Sublicensees or Distributors of any term of this Agreement; (b) the negligence or willful
misconduct on the part of Licensee or its Affiliates or any Sublicensees or Distributors in
performing their obligations under this Agreement; or (c) the Unilateral Activities by Licensee or
its Affiliates or any Sublicensees in the Territory; or (d) subject to Section 13.3, the
Commercialization by Licensee or its Affiliates or any Sublicensees or Distributors of the Licensed
Product in the Licensee Territory, except for those Losses which GPC Biotech has an obligation to
indemnify Licensee pursuant to Section 13.2 hereof, as to which Losses each Party shall indemnify
the other to the extent of their respective liability; provided, however, that Licensee shall not
be obligated to indemnify GPC Biotech for any Losses to the extent that such Losses arise as a

71

 

result of gross negligence or willful misconduct on the part of GPC Biotech or any of its
Affiliates.

     13.2 Indemnification of Licensee. GPC Biotech shall indemnify Licensee, its Affiliates and
their respective directors, officers, employees and agents, and defend and save each of them
harmless, from and against any and all Losses in connection with any and all Third Party Claims
arising from or occurring as a result of: (a) the breach by GPC Biotech or any GPC Biotech
Counter-Party of this Agreement; (b) the negligence or willful misconduct on the part of GPC
Biotech or any GPC Biotech Counter-Party in performing its obligations under this Agreement; or (c)
the Unilateral Activities by GPC Biotech or any GPC Biotech Counter-Party in the Territory; or (d)
subject to Section 13.3, Commercialization by GPC Biotech of the Licensed Compound or Licensed
Product in the GPC Biotech Territory, except for those Losses for which Licensee has an obligation
to indemnify GPC Biotech and its Affiliates pursuant to Section 13.1 hereof, as to which Losses
each Party shall indemnify the other to the extent of their respective liability for the Losses;
provided, however, that GPC Biotech shall not be obligated to indemnify Licensee for any Losses to
the extent that such Losses arise as a result of gross negligence or willful misconduct on the part
of Licensee or any of its Affiliates, Sublicensees or Distributors.

     13.3 Certain Losses. Any Losses for personal injury or death or damage or destruction of
property, other than those Losses for which indemnification is provided in Section 13.1(a) or (b)
or Section 13.2(a) or (b), in connection with any claim brought against either Party by a Third
Party resulting directly or indirectly from the conduct of Clinical Studies of the Licensed Product
by either Party (or its Affiliates, employees or agents) in accordance with the Development Plan or
the Joint Commercialization Activities in accordance with the Commercialization Plan, shall be
included as a Collaboration Cost only to the extent such Losses are not covered by insurance
policies of such Party. In no event shall Losses from claims of infringement of Third Party Patent
rights in connection with the Development of the Licensed Product be included as a Collaboration
Cost. The Parties shall confer through the JEC with respect to how to respond to the claim and how
to handle the claim in an efficient manner. In the absence of such an agreement, each Party shall
have the right to take such action as it deems appropriate.

     13.4 Notice of Claim. All indemnification claims in respect of a Party, its Affiliates or
their respective directors, officers, employees and agents shall be made solely by such Party to
this Agreement (the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party
prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon
which such indemnified Party intends to base a request for indemnification under Section 13.1 or
13.2, but in no event shall the indemnifying Party be liable for any Losses that result from any
delay in providing such notice. Each Indemnification Claim Notice must contain a description of
the claim and the nature and amount of such Loss (to the extent that the nature and amount of such
Loss is known at such time). The Indemnified Party shall furnish promptly to the indemnifying
Party copies of all papers and official documents received in respect of any Losses and Third Party
Claims.

     13.5 Control of Defense. At its option, the indemnifying Party may assume the defense of any
Third Party Claim by giving

72

 

written notice to the Indemnified Party within thirty (30) days after the indemnifying Party’s
receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim
by the indemnifying Party shall not be construed as an acknowledgment that the indemnifying Party
is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor shall it
constitute a waiver by the indemnifying Party of any defenses it may assert against the Indemnified
Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the
indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal
counsel selected by the indemnifying Party. In the event the indemnifying Party assumes the
defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the indemnifying
Party all original notices and documents (including court papers) received by the Indemnified Party
in connection with the Third Party Claim. Should the indemnifying Party assume the defense of a
Third Party Claim, except as provided in Section 13.5.1, the indemnifying Party shall not be liable
to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in
connection with the analysis, defense or settlement of the Third Party Claim. In the event that it
is ultimately determined that the indemnifying Party is not obligated to indemnify, defend or hold
harmless the Indemnified Party from and against the Third Party Claim, the Indemnified Party shall
reimburse the indemnifying Party for any and all costs and expenses (including attorneys’ fees and
costs of suit) and any Third Party Claims incurred by the indemnifying Party in its defense of the
Third Party Claim.

          13.5.1 Right to Participate in Defense. Without limiting Section 13.5 above, any Indemnified
Party shall be entitled to participate in, but not control, the defense of such Third Party Claim
and to employ counsel of its choice for such purpose; provided, however, that such employment shall
be at the Indemnified Party’s own expense unless, subject to the consent of an insurer, if
applicable, (a) the employment thereof has been specifically authorized by the indemnifying Party
in writing, (b) the indemnifying Party has failed to assume the defense and employ counsel in
accordance with Section 13.5 (in which case the Indemnified Party shall control the defense) or (c)
the interests of the indemnitee and the indemnifying Party with respect to such Third Party Claim
are sufficiently adverse to prohibit the representation by the same counsel of both parties under
Applicable Law, ethical rules or equitable principles.

          13.5.2 Settlement. With respect to any Third Party Claims relating solely to the payment of
money damages in connection with a Third Party Claim and that shall not result in the Indemnified
Party’s becoming subject to injunctive or other relief or otherwise adversely affecting the
business of the Indemnified Party in any manner, and as to which the indemnifying Party shall have
acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the
indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into
any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its
sole discretion, shall deem appropriate. With respect to all other Losses in connection with Third
Party Claims, where the indemnifying Party has assumed the defense of the Third Party Claim in
accordance with Section 13.5.1, the indemnifying Party shall have authority to consent to the entry
of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains
the prior written consent of the Indemnified Party (which consent shall not be unreasonably
withheld or delayed). The indemnifying Party shall not be liable for any settlement or other
disposition of a Loss by an Indemnified Party that is reached without the written consent of the
indemnifying Party. Regardless of whether the

73

 

indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnified Party shall
admit any liability with respect to or settle, compromise or discharge, any Third Party Claim
without the prior written consent of the indemnifying Party, such consent not to be unreasonably
withheld or delayed.

          13.5.3 Cooperation. Regardless of whether the indemnifying Party chooses to defend or
prosecute any Third Party Claim, the Indemnified Party shall, and shall cause each Indemnified
Party to, cooperate in the defense or prosecution thereof and shall furnish such records,
information and testimony, provide such witnesses and attend such conferences, discovery
proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith.
Such cooperation shall include access during normal business hours afforded to indemnifying Party
to, and reasonable retention by the Indemnified Party of, records and information that are
reasonably relevant to such Third Party Claim, and making indemnified Parties and other employees
and agents available on a mutually convenient basis to provide additional information and
explanation of any material provided hereunder, and the indemnifying Party shall reimburse the
Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith.

          13.5.4 Expenses. Except as provided above, the costs and expenses, including fees and
disbursements of counsel, incurred by the Indemnified Party in connection with any claim shall be
reimbursed on a Calendar Quarter basis by the indemnifying Party, without prejudice to the
indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject
to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify
the Indemnified Party.

     13.6 Limitation on Damages and Liability. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR
INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES (OR WITH RESPECT TO LICENSEE, ITS SUBLICENSEES
OR DISTRIBUTORS), OR WITH RESPECT TO LOSSES ARISING FROM THIRD PARTY CLAIMS UNDER SECTION 13.1 OR
13.2, NO PARTY OR ANY OF THEIR RESPECTIVE AFFILIATES SHALL BE LIABLE FOR SPECIAL, INDIRECT,
INCIDENTAL OR CONSEQUENTIAL DAMAGES, OR FOR LOST PROFITS, MILESTONES OR ROYALTIES, WHETHER IN
CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF (a) THE
DEVELOPMENT, MANUFACTURE, USE OR SALE OF THE LICENSED PRODUCT OR LICENSED COMPOUND UNDER THIS
AGREEMENT, (b) THE USE OF OR REFERENCE TO ANY PATENTS, KNOW-HOW, REGULATORY DOCUMENTATION OR DRUG
MASTER FILE, OR (c) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT.

     13.7 Insurance. Each Party shall have and maintain such type and amounts of liability
insurance covering the Manufacture, Development, use and sale of the Licensed Product as is normal
and customary in the pharmaceutical industry generally for parties similarly situated, and shall
upon request provide the other Party with a copy of its policies of insurance in that regard, along
with any amendments and revisions thereto. Each Party shall provide the other Party thirty (30)
days’ advance written notice of the termination of coverage in its insurance program.

74

 

          13.7.1 Without limiting the generality of the foregoing, at a minimum, Licensee shall maintain
during any period in which Licensee has indemnification obligations to GPC Biotech, (a) commercial
general liability insurance with a combined single limit for bodily injury and property damage of
not less than Five Million U.S. Dollars ($5,000,000) per occurrence and Ten Million U.S. Dollars
($10,000,000) in the aggregate, (b) products liability/completed operations coverage with a minimum
indemnity limit of Ten Million U.S. Dollars ($10,000,000) per claim and in the aggregate and (c) a
global cargo insurance policy with a minimum indemnity limit of One Million Five Hundred Thousand
U.S. Dollars ($1,500,000) per occurrence and insurance on product inventory at processor locations
of Five Million U.S. Dollars ($5,000,000) per occurrence. Such policies shall (x) be provided by
insurance carrier(s) reasonably acceptable to GPC Biotech, and (y) show GPC Biotech as additional
insured and loss payee, as its interests may appear. Such policies shall remain in effect
throughout the term of this Agreement and shall not be cancelled or subject to a reduction of
coverage without the prior written authorization of GPC Biotech. Should Licensee at any time or
for any reason fail to obtain the insurance required herein, or should such insurance be cancelled
or reduced below the above limits, GPC Biotech shall have the right to procure the same at
Licensee’s expense. GPC Biotech shall have the right to offset any such expense that is owed by
Licensee but not paid against any payments owed by GPC Biotech, if any, under this Agreement.

          13.7.2 Without limiting the generality of the foregoing, at a minimum, GPC Biotech shall
maintain during any period in which GPC Biotech has indemnification obligations to Licensee, (a)
commercial general liability insurance with a combined single limit for bodily injury and property
damage of not less than Five Million Euros (€5,000,000) in the aggregate and Two Million U.S.
Dollars ($2,000,000) in the aggregate and One Million U.S. Dollars ($1,000,000) per occurrence in
the United States, (b) products liability/completed operations coverage with a minimum indemnity
limit of Ten Million U.S. Dollars ($10,000,000) per occurrence, (c) a global cargo insurance policy
with a minimum indemnity limit of Seven Hundred Fifty Thousand U.S. Dollars ($750,000) per
occurrence, and (d) an all-risks insurance policy covering its United States facilities with a
minimum indemnity limit of Eight Million U.S. Dollars ($8,000,000) per occurrence and in the
aggregate. Such policies shall (x) be provided by insurance carrier(s) reasonably acceptable to
Licensee, and (y) show Licensee as additional insured and loss payee, as its interests may appear.
Such policies shall remain in effect throughout the term of this Agreement and shall not be
cancelled or subject to a reduction of coverage without the prior written authorization of
Licensee. Should GPC Biotech at any time or for any reason fail to obtain the insurance required
herein, or should such insurance be cancelled or reduced below the above limits reduced, Licensee
shall have the right to procure the same at GPC Biotech’s expense. Licensee shall have the right
to offset any such expense that is owed by GPC Biotech but not paid against any payments owed by
Licensee under this Agreement.

ARTICLE 14

TERM AND TERMINATION

     14.1 Term. This Agreement shall commence upon the Effective Date and shall continue in each
country in the Licensee Territory until such time as

75

 

Licensee no longer owes any royalty payments under this Agreement with respect to such country,
unless earlier terminated in accordance with this Article 14. Unless earlier terminated in
accordance with this Article 14, and subject to the applicable terms and conditions of the Spectrum
Agreement, upon expiration of this Agreement on a country-by-country basis, Licensee shall retain a
non-exclusive, fully-paid, royalty-free license to the GPC Biotech Know-How and, subject to Section
5.5, the Product Trademarks, in each case, for the purpose of continuing to Commercialize the
Licensed Product in the Field in such country.

     14.2 Termination of this Agreement in its Entirety for Material Breach. In the event that
either Party (the “Breaching Party”) shall be in material default in the performance of any of its
material obligations under this Agreement, in addition to any other right and remedy the other
Party (the “Complaining Party”) may have, the Complaining Party may terminate this Agreement in its
entirety by sixty (60) days’ prior written notice (the “Notice Period”) to the Breaching Party,
specifying the breach and its claim of right to terminate, provided always that the termination
shall not become effective at the end of the Notice Period if the Breaching Party cures the breach
complained about during the Notice Period (or, if such default cannot be cured within such sixty
(60)-day period, if the Breaching Party commences actions to cure such default within the Notice
Period and thereafter diligently continues such actions, provided that such default is cured within
one hundred eight (180) days after the receipt of such notice), except in the case of a payment
default of amounts not subject to a good faith Dispute, as to which the Breaching Party shall have
only a ten (10)-day cure period. For the avoidance of doubt, in the event of a Dispute between the
Parties with respect to whether Licensee has failed to utilize Commercially Reasonable Efforts with
respect to the Development or Commercialization of Licensed Product, or as to whether a payment is
owed hereunder, then such Dispute shall be resolved in accordance with Section 15.7.1 and the
applicable cure period shall be tolled during the pendency of such resolution.

     14.3 Termination of this Agreement in a Country or Major Market Region for Material Breach.
In the event that Licensee shall be in material default in the performance of any of its material
obligations under this Agreement with respect to a country, in addition to any other right and
remedy GPC Biotech may have, GPC Biotech may without limiting its right to terminate this Agreement
in its entirety pursuant to Section 14.2 (with respect to any such default that constitutes a
material default within the meaning of Section 14.2 with respect to the Agreement as a whole),
terminate this Agreement, at its election, either (a) in such country or (b) if such country is a
Major Market Country, in all or any part of the Major Market Region in which such Major Market
Country is located, by sixty (60) days’ prior written notice to Licensee, specifying such alleged
breach, identifying the countries at issue and specific detailed reasons of such allegation and its
claim of right to terminate, provided always that the termination shall not become effective at the
end of the Notice Period if Licensee cures such breach during the Notice Period (or, if such
default cannot be cured within such sixty (60)-day period, if Licensee commences actions to cure
such default within the Notice Period and thereafter diligently continues such actions, provided
that such default is cured within one hundred and eighty (180) days after the receipt of such
notice), except in the case of a payment default of amounts not subject to good faith Dispute by
Licensee as to which Licensee shall have a ten (10)-day cure period. For the avoidance of doubt,
in the event of a Dispute between the

76

 

Parties with respect to whether Licensee has failed to utilize Commercially Reasonable Efforts with
respect to the Development or Commercialization of Licensed Product in a country, or as to whether
a payment is owed hereunder, then such Dispute shall be resolved in accordance with Section 15.7.1
and the applicable cure period shall be tolled during the pendency of such resolution.

     14.4 Termination by Licensee. If Licensee reasonably determines that it is not feasible for
Licensee to pursue the Development or Commercialization of the Licensed Product in a country within
the Licensee Territory or Europe, in the case of a country within Europe, due to a scientific,
technical, regulatory or commercial reasons, including (a) safety or efficacy concerns, including
adverse events of the Licensed Product, (b) concerns relating to the present or future
marketability or profitability of the Licensed Product, (c) reasons related to patent coverage or
(d) existing and anticipated competition, which renders the Commercialization of the Licensed
Product no longer commercially practicable for Licensee, then Licensee shall promptly notify GPC
Biotech in writing of such determination and provide GPC Biotech with the pertinent information
with respect thereto. Promptly following the receipt of such notice from Licensee, the Parties
shall meet and discuss any amendments to this Agreement to address Licensee’s concerns. If the
Parties are not able to agree on such amendments within ninety (90) days and if Licensee still
reasonably believes that it is not feasible for Licensee to pursue the Development, launch or sale
of the Licensed Product in a country, Licensee may terminate this Agreement with respect to such
country or countries or Europe, in the case of any country within Europe, in the Licensee Territory
upon ninety (90) days’ prior written notice to GPC Biotech; provided that if (i) Licensee
terminates this Agreement with respect to a country that is a Major Market Country, GPC Biotech
shall have the right to terminate the Agreement with respect to all or any part of the Major Market
Region in which such Major Market Country is located upon written notice to Licensee, or (ii)
Licensee terminates this Agreement with respect to any Major Market Country in Europe, GPC Biotech
shall have the right to terminate this Agreement in its entirety upon written notice to Licensee.

     14.5 Termination by GPC Biotech.

          14.5.1 In the event that Licensee or any of its Affiliates, Sublicensees or Distributors,
anywhere in the Territory, institutes, prosecutes or otherwise participates in (or in any way aids
any Third Party in instituting, prosecuting or participating in), at law or in equity or before any
administrative or regulatory body, including the U.S. Patent and Trademark Office or its foreign
counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any
other remedy or for an enjoinment, injunction or any other equitable remedy, including any
interference, re-examination, opposition or any similar proceeding, (a) alleging that any claim in
a GPC Biotech Patent is invalid, unenforceable or otherwise not patentable or would not be
infringed by activities of Licensee, its Affiliates, Sublicensees, or Distributors absent the
rights and licenses granted hereunder or (b) that attacks, disputes or contests the validity of or
ownership of a Product Trademark or any registrations issuing with respect thereto, GPC Biotech
shall have the right to immediately terminate this Agreement, including the rights of any
Sublicensees or Distributors, on written notice to Licensee; provided, however, that the foregoing
shall not apply to any defense asserted by Licensee or any of its Affililates,

77

 

Sublicensees or Distributors to any claim or action brought by [...***...] for infringement of any
of the GPC Biotech Patents by Licensee or any of its Affililates, Sublicensees or Distributors.

          14.5.2 If Licensee or its ultimate parent corporation proposes or is the subject of a Change
of Control, after the Effective Date and during the term of this Agreement, upon any public
announcement of such proposed Change of Control, Licensee shall provide GPC Biotech with prompt
written notice of the proposed Change of Control in reasonable detail (the “Licensee Change of
Control Notice”). If the Change of Control that is described in the Licensee Change of Control
Notice involves a Third Party that has a Competitive Program, then, unless the Parties agree
otherwise in writing, Licensee shall, within thirty (30) days after the date of the Change of
Control, notify GPC Biotech whether Licensee intends to: (x) cease, or cause its relevant Affiliate
to cease, the Competitive Program; (y) divest with respect to the Licensee Territory, or cause its
relevant Affiliate to so divest, whether by license or otherwise, the Competitive Program; or (z)
terminate this Agreement pursuant to Section 14.4, to the extent applicable. Without limitation to
any other term or condition of this Agreement, in the case of any Change of Control transaction,
whether or not consummated, Licensee may not, between the date of the Licensee Change of Control
Notice and the consummation of such Change of Control or the termination of the proposed
transaction, reduce the resources applied to Commercialization of the Licensed Product in the
Licensee Territory during the applicable time period in terms of sales force size, Detail frequency
or promotional efforts below what is specified in the then-current Commercialization Plan, or
modify the sales force commission structure in any manner that is prejudicial to the Licensed
Products, unless such reduction or modification is justified by circumstances or events beyond the
Licensee’s control that have had or would reasonably be expected to have a material adverse impact
on the market for or the commercial potential of the Licensed Product in the Licensee Territory or
any relevant portion of the Licensee Territory.

               (a) If Licensee notifies GPC Biotech in writing within such thirty (30)-day period that it
intends to cease or cause its relevant Affiliate to cease the Competitive Program, Licensee or, if
applicable, its Affiliates shall (i) promptly cease the Competitive Program as quickly as possible
with due regard for patient safety and the rights of any subjects that are participants in any
clinical studies or post-approval studies relating to the Competitive Program and Applicable Law;
and (ii) keep GPC Biotech reasonably informed of its efforts and progress in effecting such
cessation of activities and shall provide a written summary of such efforts to GPC Biotech each
Calendar Quarter until completed.

               (b) If Licensee notifies GPC Biotech in writing within such thirty (30)-day period that it
intends to divest such Competitive Program in the Licensee Territory, Licensee or its Affiliate
shall use all reasonable efforts to effect such divestiture as quickly as possible and shall keep
GPC Biotech reasonably informed of its efforts and progress in effecting such divestiture and shall
provide a written summary of such efforts each Calendar Quarter until completed. If Licensee or
its Affiliate effects such divestiture by way of one or more sublicenses, the licensor shall be
entitled to receive license fees, milestones and royalties on sales of any products developed
pursuant to the Competitive Program so divested, [...***...]. If, notwithstanding such reasonable
efforts, Licensee is not

 

*** Confidential Treatment Requested

78

 

able to effect such a divestiture, it shall have the right to cease such Competitive Program as
provided in Section 14.5.2(a).

               (c) If Licensee fails to provide such notice within such thirty (30)-day period, or having
provided such notice, fails to carry out the designated actions, then, unless the Parties agree
otherwise, GPC Biotech shall have the right to terminate this Agreement effective immediately upon
GPC Biotech’s providing written notice thereof to Licensee.

          14.5.3 During the term of the Agreement, in the event that Licensee or its ultimate parent
corporation undergoes a Change of Control transaction, Licensee (or its successor) or acquirer, as
the case may be, (the “Merger Party”) shall be bound by the obligations of this Agreement,
including any Development Plans and Budgets or Commercialization Plans and Budgets existing at the
time of the consummation of the Change of Control and all diligence obligations with respect
thereto. In the event of any such Change of Control, a Merger Party, in satisfying its obligations
to use Commercially Reasonable Efforts to Commercialize Licensed Products hereunder, may not
thereafter reduce the resources applied to Commercialization of the Licensed Product in the
Licensee Territory during the applicable time period in terms of sales force size, Detail frequency
or promotional efforts below what is specified in the then-current Commercialization Plan, or
modify the sales force commission structure in any manner that is prejudicial to the Licensed
Products, unless such reduction or modification is justified by circumstances or events beyond the
Merger Party’s control that have had or would reasonably be expected to have a material adverse
impact on the market for or the commercial potential of the Licensed Product in the Licensee
Territory or any relevant portion of the Licensee Territory. In the event that a
Commercialization Plan has not been approved by the JCC prior to the consummation of the Change of
Control transaction, such Merger Party shall provide a proposed Commercialization Plan as provided
in Section 3.2.1 within ninety (90) days thereof, which plan shall be subject to written approval
by GPC Biotech, such approval not to be unreasonably withheld or delayed. Any Disputes regarding
Commercialization Plans proposed pursuant to this Section shall be resolved in accordance with
Section 15.7.1 and any Arbitration Matters resulting therefrom shall be resolved pursuant to
Section 15.7.4(c).

     14.6 Termination Upon Insolvency. Either Party may terminate this Agreement if, at any time,
the other Party or its ultimate parent corporation shall file in any court or agency pursuant to
any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or
insolvency or for reorganization or for an arrangement or for the appointment of a receiver or
trustee of that Party or of its assets, or if the other Party or its ultimate parent corporation
shall be served with an involuntary petition against it, filed in any insolvency proceeding, and
such petition shall not be dismissed within sixty (60) days after the filing thereof, or if the
other Party or its ultimate parent corporation shall propose or be a party to any dissolution or
liquidation, or if the other Party or its ultimate parent corporation shall make an assignment for
the benefit of its creditors.

     14.7 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this
Agreement by Licensee or GPC Biotech are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined
under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of
such rights under this

79

 

Agreement, shall retain and may fully exercise all of their rights and elections under the U.S.
Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy
proceeding by or against either Party under the U.S. Bankruptcy Code, the Party hereto that is not
a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as
appropriate) any such intellectual property and all embodiments of such intellectual property,
which, if not already in the non-subject Party’s possession, shall be promptly delivered to it (a)
upon any such commencement of a bankruptcy proceeding upon the non-subject Party’s written request
therefor, unless the Party subject to such proceeding elects to continue to perform all of its
obligations under this Agreement or (b) if not delivered under (a) above, following the rejection
of this Agreement by or on behalf of the Party subject to such proceeding upon written request
therefor by the non-subject Party.

     14.8 Consequences of Termination.

          14.8.1 Upon Termination in its Entirety for Licensee Breach or by Licensee for Convenience.
Upon any termination of this Agreement in its entirety by GPC Biotech under Section 14.2, 14.5 or
14.6 or by either Party under Section 14.4:

               (a) All licenses and sublicenses granted to Licensee by GPC Biotech under this Agreement shall
terminate, and, subject to Section 14.8.9, Licensee, its Affiliates, Sublicensees and Distributors
shall have no further right in or to the GPC Biotech Patents or to use the GPC Biotech Know-How,
Product Trademarks or the GPC Biotech Corporate Name.

               (b) Licensee shall and does hereby automatically and without any further consideration
relinquish its rights hereunder and assign and cause its Affiliates, Sublicensees and Distributors
to assign to GPC Biotech without further compensation therefor, all right, title and interest, if
any, in and to the Product Trademarks, Regulatory Approvals, Regulatory Documentation (including
any Clinical Data generated from Unilateral Activities of Licensee) and any Drug Master Files, and
shall grant to GPC Biotech with effect from the effective date of termination a perpetual,
irrevocable and exclusive (including with regard to Licensee and its Affiliates, Sublicensees and
Distributors), worldwide, royalty-free license, with the right to grant sublicenses (through
multiple tiers of sublicensees), under the Joint Patents (to the extent Controlled by Licensee),
Joint Know-How (to the extent Controlled by Licensee), Licensee Know-How and Licensee Patents,
solely to Exploit the Licensed Compound and the Licensed Product. Further, Section 2.5 shall
terminate and have no further effect with respect to the obligations and restrictions imposed under
such Section on GPC Biotech.

               (c) Any payments under Section 7.1 shall be retained by GPC Biotech.

               (d) In the event that GPC Biotech terminates this Agreement pursuant to Sections 14.2, 14.5.1
or 14.5.2(c) hereof, Licensee shall have an obligation to continue funding its share of
Collaboration Costs in accordance with the provisions of Section 6.1.6 hereof that are incurred in
connection with the Development Budget in existence prior to the effective date of termination, and
subject to all other applicable provisions of this Agreement, for [...***...] after termination of
the Agreement or, if earlier, until such time as (i) Licensee’s share of the Collaboration Costs
paid hereunder totals [...***...],

 

*** Confidential Treatment Requested

80

 

or (ii) GPC Biotech enters into an agreement with a Third Party which includes the European Union
as a territory under which such Third Party assumes an obligation to fund a share of costs and
expenses that would be considered Collaboration Costs equal to or greater than Licensee’s share of
Collaboration Costs under this Agreement. In the event that GPC Biotech enters into an agreement
with a Third Party which includes the European Union and under which such Third Party assumes an
obligation to fund a share of costs and expenses that would be considered Collaboration Costs less
than Licensee’s share hereunder, Licensee’s obligation to fund Collaboration Costs incurred
thereafter shall be proportionately reduced until Licensee has otherwise satisfied the obligations
of this Section.

               (e) In event that Licensee terminates this Agreement pursuant to Section 14.4 hereof, Licensee
shall have an obligation to continue funding its share of Collaboration Costs in accordance with
the provisions of Section 6.1.6 hereof that are incurred in connection with the Development Budget
in existence prior to the effective date of termination, and subject to all other applicable
provisions of this Agreement, until such time as (i) Licensee’s share of the Collaboration Costs
paid hereunder totals [...***...], or (ii) GPC Biotech enters into an agreement with a Third Party
which includes the European Union as a territory under which such Third Party assumes an obligation
to fund a share of costs and expenses that would be considered Collaboration Costs equal to or
greater than Licensee’s share of Collaboration Costs under this Agreement. In the event that GPC
Biotech enters into an agreement with a Third Party which includes the European Union as a
territory under which such Third Party assumes an obligation to fund a share of costs and expenses
that would be considered Collaboration Costs less than Licensee’s share hereunder, Licensee’s
obligation to fund Collaboration Costs incurred thereafter shall be proportionately reduced until
Licensee has otherwise satisfied the obligations of this Section.

          14.8.2 Upon Termination in its Entirety for GPC Biotech Breach. Upon any termination of this
Agreement in its entirety by Licensee under Section 14.2 or 14.6:

               (a) All licenses and sublicenses granted to Licensee by GPC Biotech under this Agreement shall
terminate, and, subject to Section 14.8.9, Licensee, its Affiliates, Sublicensees and Distributors
shall have no further right in or to the GPC Biotech Patents or to use the GPC Biotech Know-How,
Product Trademarks or the GPC Biotech Corporate Names. Licensee shall and does hereby
automatically and without any further consideration relinquish its rights hereunder and assign and
cause its Affiliates, Sublicensees and Distributors to assign to GPC Biotech without further
compensation therefor, all right, title and interest, if any, in and to the Product Trademarks,
Regulatory Approvals, Regulatory Documentation (excluding any Clinical Data generated in connection
with Unilateral Activities of Licensee) and any Drug Master Files; provided that Licensee shall
have a period of up to one hundred eighty (180) days to continue to Commercialize the Licensed
Products in the Licensee Territory prior to the transition of Commercialization to GPC Biotech.

               (b) The licenses granted to GPC Biotech pursuant to Section 5.6.1 shall survive termination of
this Agreement on a perpetual and irrevocable, non-exclusive, royalty-free, world-wide basis;
provided that at GPC Biotech’s option, such licenses shall be made exclusive and royalty-bearing,
subject to an agreement by the Parties on an applicable royalty rate and other related terms and
conditions to be negotiated in good faith.

 

*** Confidential Treatment Requested

81

 

               (c) Section 2.5.5 shall survive with respect to any obligations and restrictions imposed under
such Section on either Party, provided that, in the event of such termination, GPC Biotech shall
have the right to Opt-In with respect to any Unilateral Activities conducted by Licensee prior to
the effective date of such termination (and the Clinical Data and other information resulting
therefrom), with such Opt-In conducted as contemplated under Section 2.5.6, except that (i) such
Opt-In right shall not be impacted by any earlier expiration of the applicable Opt-In Exercise
Period, and (ii) any request for information concerning such Unilateral Activities provided by GPC
Biotech pursuant to this Section 14.8.2 shall be treated as the Opt-In Information Request under
Section 2.5.6;

               (d) Any payments under Section 7.1 shall be retained by GPC Biotech.

               (e) Any amounts paid by Licensee to GPC Biotech pursuant to Section 6.1.2 or Section 6.1.6,
that have not been expended by GPC Biotech with respect to Development activities as of the
effective date of such termination in accordance with the Development Budget in existence prior to
the date of Licensee’s notice of termination shall be refunded to Licensee within thirty (30) days
of the effective date of termination.

          14.8.3 Upon Partial Termination. Upon any termination of a portion of this Agreement by GPC
Biotech under Section 14.3 or by either Party under Section 14.4:

               (a) all licenses and sublicenses granted to Licensee by GPC Biotech under this Agreement shall
terminate for such portion of the Licensee Territory terminated pursuant to Section 14.3 or 14.4,
as applicable, and, subject to Section 14.8.9, Licensee, its Affiliates, Sublicensees and
Distributors shall have no further right in or to the GPC Biotech Patents or to use the GPC Biotech
Know-How, Product Trademarks or GPC Biotech Corporate Names in the terminated portion of the
Licensee Territory;

               (b) Licensee shall and does hereby automatically and without any further consideration
relinquish its rights hereunder and assign and cause its Affiliates, Sublicensees and Distributors
to assign to GPC Biotech without further compensation therefor, all right, title and interest, if
any, in and to the Product Trademarks, Regulatory Approvals, Regulatory Documentation (including
any Clinical Data generated in connection with Unilateral Activities of Licensee) and any Drug
Master Files held by Licensee, its Affiliates, Sublicensees or Distributors in that portion of the
Licensee Territory terminated pursuant to Section 14.3 or 14.4, as applicable, and shall grant to
GPC Biotech with effect from the effective date of termination a perpetual, irrevocable and
exclusive (including with regard to Licensee and its Affiliates, Sublicensees and Distributors),
royalty-free license, with the right to grant sublicenses (through multiple tiers of sublicensees),
under the Joint Patents (to the extent Controlled by Licensee), Joint Know-How (to the extent
Controlled by Licensee), Licensee Know-How and Licensee Patents, solely to Exploit the Licensed
Compound and the Licensed Product, in such portion of the Licensee Territory terminated pursuant to
Section 14.3 or 14.4, as applicable;

               (c) Section 2.5.5 shall survive with respect to any obligations and restrictions imposed under
such Section on either Party only with respect to the non-terminated portion of the Licensee
Territory; and

82

 

               (d) any payments under Section 7.1 shall be retained by GPC Biotech.

          14.8.4 Ceasing Exploitation of Licensed Product. Subject to Section 14.8.6 and 14.8.9, upon
termination of this Agreement, however caused or arising, Licensee shall, and shall cause its
Affiliates, Sublicensees and Distributors to, promptly, cease all Exploitation of the Licensed
Product in the Territory or such terminated countries, as applicable, and, within thirty (30) days
of the effective date of such termination, at GPC Biotech’s election, either destroy or return to
GPC Biotech, at Licensee’s expense, any and all unsold quantities of Licensed Product.

          14.8.5 Transfer of Materials. Without limitation to Section 11.7, except as provided in
Section 14.8.6, Licensee shall cooperate with GPC Biotech in transferring to GPC Biotech or a Third
Party, as GPC Biotech may direct, within sixty (60) days of the termination hereof, all data, files
and other materials in the possession or under the control of Licensee or its Affiliates,
Sublicensees (subject to Section 14.8.9) or Distributors that are Controlled by GPC Biotech or
licensed to GPC Biotech pursuant to this Section 14.8 upon such termination, except that Licensee
may retain one (1) copy of such data, files or materials Controlled by GPC Biotech for the sole
purpose of performing any continuing obligations hereunder or for archival purposes.
Notwithstanding the foregoing, Licensee also shall be permitted to retain such additional copies of
or any computer records or files containing such data or files that have been created solely by
Licensee’s automatic archiving and back-up procedures, to the extent created and retained in a
manner consistent with Licensee’s standard archiving and back-up procedures, but not for any other
use or purpose.

          14.8.6 Sale of Inventory. Upon termination of this Agreement by Licensee under Sections 14.2,
14.4 or 14.6 or by GPC Biotech under Sections 14.5 or 14.6 and provided that Licensee is not in
material breach of any obligation under this Agreement at the time of such termination, Licensee
shall have the right for six (6) months after the effective date of such termination to dispose of
all Licensed Product then in its inventory, as though this Agreement had not terminated. For the
avoidance of doubt, Licensee shall continue to make payments thereon as provided in Article 7.

          14.8.7 Assignments. In connection with any and all assignments contemplated by this Section
14.8, Licensee shall execute and deliver, and shall cause its Affiliates and Sublicensees to
execute and deliver such instruments and take such actions as may be necessary or desirable to
effect such transfer.

          14.8.8 Remedies. Except as otherwise expressly provided herein, termination of this Agreement
in accordance with the provisions hereof shall not limit remedies which may otherwise be available
in law or equity.

          14.8.9 Effect of Termination on Sublicenses. Termination of this Agreement shall not
terminate any sublicense granted by Licensee pursuant to Sections 5.1 and 5.3 with respect to a
Sublicensee, provided that (a) such Sublicensee is not in breach of any provision of this Agreement
or the applicable sublicense agreement, (b) such Sublicensee shall perform all obligations of
Licensee under this Agreement and (c) GPC Biotech shall have all rights with respect to any and all
Sublicensees as it had hereunder with respect to Licensee prior to termination of this Agreement
with respect to Licensee. Licensee shall include in any sublicense

83

 

a provision in which said Sublicensee acknowledges its obligations to GPC Biotech hereunder and the
rights of GPC Biotech to terminate this Agreement with respect to any Sublicensee for material
breaches of this Agreement by such Sublicensee that are within the scope of Sections 14.2 and 14.3
hereof. The failure of Licensee to include in a sublicense the provision referenced in the
immediately preceding sentence shall render the affected sublicense void ab initio.

          14.8.10 Assistance. In the event of any termination pursuant to this Article 14, Licensee
shall, and shall cause its Affiliates, Sublicensees and Distributors to, at the request of GPC
Biotech, provide GPC Biotech with such assistance as is reasonably necessary to effectuate a smooth
and orderly transition of any Development and Commercialization of the Licensed Product, including
any ongoing Clinical Studies or Post Approval Studies, to GPC Biotech or its designee so as to
minimize any disruption of such activities, including the assignment of any such contracts (to the
extent such contracts permit assignment) and the transfer of any such materials related to the
Licensed Product, in each case that is the subject of such obligation, to the extent not prohibited
under the terms of such contracts. In performing its obligations under this Section 14.8.10,
Licensee shall, and shall cause its Affiliates, Sublicensees and Distributors to, cooperate with
GPC Biotech (at Licensee’s reasonable expense) to effect such transfers and assignments in an
orderly fashion and shall provide to GPC Biotech or its designee any copies of relevant documents
and rights of reference or access necessary to allow GPC Biotech to Exploit the Licensed Compound
and Licensed Product and any Improvements thereto in the GPC Biotech Territory or, in the event the
Agreement is terminated in its entirety, in the Territory. GPC Biotech shall promptly compensate
Licensee for all of its direct and indirect costs (including its FTE Costs) associated with the
performance of any of it obligations under this Section 14.8.10 with respect to any termination of
this Agreement by Licensee under Section 14.2 or 14.6.

     14.9 Accrued Rights; Surviving Obligations.

          14.9.1 Accrued Rights. Termination or expiration of this Agreement for any reason shall be
without prejudice to any rights that shall have accrued to the benefit of a Party prior to such
termination or expiration. Such termination or expiration shall not relieve a Party from
obligations that are expressly indicated to survive the termination or expiration of this
Agreement.

          14.9.2 Survival. Without limiting the foregoing, Sections 2.4.7, 5.2, 5.6, 5.7, 7.10, 7.11,
7.12, 7.13, 12.4, 14.7, 14.8, this Section 14.9, Sections 15.3, 15.6, 15.7, 15.8, 15.11, 15.12,
15.14, 15.15, 15.17 and 15.18 and Articles 8 (with respect to provisions which by their nature must
survive termination), 9, 10, 11, and 13 of this Agreement shall survive the termination or
expiration of this Agreement for any reason and Sections 2.5.5 and 2.5.6 shall survive termination
of this Agreement as provided in Section 14.8.2(c) or 14.8.3(c), as applicable.

     14.10 Termination of Spectrum Agreement. Upon any termination of the Spectrum Agreement and
as provided in the Spectrum Agreement, the portions of this Agreement applicable to the rights that
are sublicensed to Licensee in accordance with the Spectrum Agreement shall be automatically

84

 

assigned to Spectrum Pharmaceuticals, Inc. (f/k/a Neotherapeutics, Inc.) in accordance with the
Spectrum Agreement.

ARTICLE 15

MISCELLANEOUS

     15.1 Force Majeure. Neither Party shall be held liable or responsible to the other Party or
be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or
performing any term of this Agreement when such failure or delay is caused by or results from
events beyond the reasonable control of the non-performing Party, including fires, floods,
earthquakes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be
declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts or other
labor disturbances (whether involving the workforce of the non-performing Party or of any other
Person), acts of God or acts, omissions or delays in acting by any governmental authority. The
non-performing Party shall notify the other Party of such force majeure within thirty (30) days
after such occurrence by giving written notice to the other Party stating the nature of the event,
its anticipated duration, and any action being taken to avoid or minimize its effect. The
suspension of performance shall be of no greater scope and no longer duration than is necessary and
the non-performing Party shall use commercially reasonable efforts to remedy its inability to
perform. In the event that such force majeure event lasts for more than ninety (90) days, such
other Party shall have the right to terminate this Agreement upon sixty (60) days written notice to
the non-performing Party.

     15.2 Export Control. This Agreement is made subject to any restrictions concerning the export
of products or technical information from the United States or other countries that may be imposed
on related to the Parties from time to time. Each Party agrees that it shall not export, directly
or indirectly, any technical information acquired from the other Party under this Agreement or any
products using such technical information to a location or in a manner that at the time of export
requires an export license or other governmental approval, without first obtaining the written
consent to do so from the appropriate agency or other governmental entity in accordance with
Applicable Law.

     15.3 Non-Solicitation. During the term of this Agreement and for a period of one (1) year
thereafter, neither Party shall actively recruit or solicit any employee of the other Party or its
Affiliates. For the avoidance of doubt, nothing shall limit a Party from engaging in general
recruitment efforts through advertisements or recruiting through “head-hunters” so long as the
employees of the other Party and its Affiliates are not specifically targeted in such recruitment
effort.

     15.4 Assignment. Without the prior written consent of the other Party hereto, neither Party
shall sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily,
involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties
hereunder; provided, however, that (a) GPC Biotech may, without such consent, assign this Agreement
and its rights and obligations hereunder to an

85

 

Affiliate, to the purchaser of the GPC Biotech Patents or GPC Biotech Know-How or to its successor
entity or acquirer in the event of a merger, consolidation or change in control of GPC Biotech and
(b) subject to Sections 14.5.2 and 14.5.3, Licensee may, without such consent, assign this
Agreement and its rights and obligations hereunder to an Affiliate or to its successor entity or
acquirer in the event of a merger, consolidation or Change of Control of Licensee; provided further
that in either case ((a) or (b)), with respect to an assignment to an Affiliate, such assigning
Party shall remain responsible for the performance by such Affiliate of the rights and obligations
hereunder. Any attempted assignment or delegation in violation of the preceding sentence shall be
void and of no effect. All validly assigned and delegated rights and obligations of the Parties
hereunder shall be binding upon and inure to the benefit of and be enforceable by and against the
successors and permitted assigns of GPC Biotech or Licensee, as the case may be. In the event
either Party seeks and obtains the other Party’s consent to assign or delegate its rights or
obligations to another Party, the assignee or transferee shall assume all obligations of its
assignor or transferor under this Agreement

     15.5 Severability. If any provision of this Agreement is held to be illegal, invalid or
unenforceable under any present or future law, and if the rights or obligations of either Party
under this Agreement will not be materially and adversely affected thereby, (a) such provision
shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal,
invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions
of this Agreement shall remain in full force and effect and shall not be affected by the illegal,
invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal,
invalid or unenforceable provision, there shall be added automatically as a part of this Agreement
a legal, valid and enforceable provision as similar in terms to such illegal, invalid or
unenforceable provision as may be possible and reasonably acceptable to the Parties. To the
fullest extent permitted by applicable law, each Party hereby waives any provision of law that
would render any provision hereof illegal, invalid or unenforceable in any respect.

     15.6 Governing Law, Jurisdiction, Venue and Service

          15.6.1 Governing Law. This Agreement shall be governed by and construed in accordance with
the laws of the State of New York, excluding any conflicts or choice of law rule or principle that
might otherwise refer construction or interpretation of this Agreement to the substantive law of
another jurisdiction. The Parties agree to exclude the application to this Agreement of the United
Nations Convention on Contracts for the International Sale of Goods.

          15.6.2 Jurisdiction. Subject to Sections 15.7 and 15.12, the Parties hereby irrevocably and
unconditionally consent to the exclusive jurisdiction of the courts of the State of New York and
the United States District Court for the Southern District of New York for any action, suit or
proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and agree
not to commence any action, suit or proceeding (other than appeals therefrom) related thereto
except in such courts. The Parties irrevocably and unconditionally waive their right to a jury
trial.

86

 

          15.6.3 Venue. The Parties further hereby irrevocably and unconditionally waive any objection
to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out
of or relating to this Agreement in the courts of the State of New York or in the United States
District Court for the Southern District of New York, and hereby further irrevocably and
unconditionally waive and agree not to plead or claim in any such court that any such action, suit
or proceeding brought in any such court has been brought in an inconvenient forum.

          15.6.4 Service. Each Party further agrees that service of any process, summons, notice or
document by registered mail to its address set forth in Section 15.8.2 shall be effective service
of process for any action, suit or proceeding brought against it under this Agreement in any such
court.

     15.7 Dispute Resolution. Except with respect to any dispute governed by Section 7.12, if a
dispute arises between the Parties in connection with or relating to this Agreement or any document
or instrument delivered in connection herewith (a “Dispute”), it shall be resolved pursuant to this
Section 15.7.

          15.7.1 General. Except as otherwise provided in Sections 8.2.5, 15.7.2 or 15.7.3, either
Party shall have the right to refer any Dispute to the Chief Executive Officers of the Parties who
shall confer on the resolution of the issue. Any final decision mutually agreed to by such
representatives shall be conclusive and binding on the Parties. If such officers are not able to
agree on the resolution of any such issue within fifteen (15) Business Days after such issue was
first referred to them, either Party may, by written notice to the other Party, elect to initiate
arbitration pursuant to Section 15.7.4(a) for purposes of having the matter settled. For clarity,
any Disputes relating Section 14.2 or 14.3 shall be resolved pursuant to this Section 15.7.1 and
not pursuant to Section 15.7.2. Any Disputes concerning the proper characterization of a Dispute
subject to resolution under this Section 15.7 shall be submitted immediately to arbitration to be
resolved pursuant to Section 15.7.4(b).

          15.7.2 JEC Disputes.

               (a) In the event that a Dispute arises with respect to an issue within the jurisdiction of the
JEC, or a decision required to be made by the JEC that cannot be resolved in accordance with
Section 4.4.4, that relates to:

                  (i) Commercialization of the Licensed Product in the GPC Biotech Territory, such Dispute shall
be referred to the Chief Executive Officer of GPC Biotech who shall have the sole right to resolve
such Dispute;

                  (ii) the development of the Global Strategy pursuant to Section 3.1.3(a), such Dispute shall
be referred to the Chief Executive Officers of the Parties who shall confer on the resolution of
the issue. Any final decision mutually agreed to by such representatives with respect thereto
shall be conclusive and binding on the Parties. If such officers are not able to agree on the
resolution of an issue within fifteen (15) Business Days after such issue was first referred to
them, each Party shall have the right to determine the strategies relating to issues under Dispute
for such Party’s portion of the Territory; provided that any

87

 

Dispute relating to the development of elements of the Global Strategy relating to positioning,
branding or messaging of the Licensed Product shall be referred to the Chief Executive Officer of
GPC Biotech who shall have the sole right to resolve such Dispute.

                    (iii) Development of the Licensed Product in the Territory (other than the Licensee Activities
or Unilateral Activities of Licensee, or Disputes subject to subsections (iv) or (v) below), such
Dispute shall be referred to the Chief Executive Officer of GPC Biotech who shall have the sole
right to resolve such Dispute;

                    (iv) whether a proposed amendment to the Development Plan meets the criteria set forth in
Section 2.5.1 (regardless of whether such Dispute relates to a proposal to initiate such activity
or materially modify an activity included within the existing Development Plan), such Dispute shall
be referred to the Chief Executive Officers of the Parties who shall confer on the resolution of
the issue. Any final decision mutually agreed to by such representatives with respect thereto
shall be conclusive and binding on the Parties. If such officers are not able to agree on the
resolution of an issue within fifteen (15) Business Days after such issue was first referred to
them, either Party shall have the right, upon written notice to the other Party, to initiate
arbitration to resolve such Dispute pursuant to Section 15.7.4(b);

                    (v) whether under Section 2.5.3 the proposed protocol of any Clinical Study or Post Approval
Study with respect to the Licensed Product proposed by Licensee to be conducted for its portion of
the Territory creates an unreasonable risk of adverse results that could reasonably be expected to
have a material adverse effect on the Development or Commercialization of the Licensed Product in
GPC Biotech Territory, such Dispute shall be referred to the Chief Executive Officers of the
Parties who shall confer on the resolution of the issue. Any final decision mutually agreed to by
such representatives with respect thereto shall be conclusive and binding on the Parties. If such
officers are not able to agree on the resolution of an issue within fifteen (15) Business Days
after such issue was first referred to them, either Party shall have the right, upon written notice
to the other Party, to initiate arbitration to resolve such Dispute pursuant to Section 15.7.4(b);
or

                    (vi) whether under Section 3.1.3(b) the branding, positioning or messaging for the Licensed
Product in the Licensee Territory is consistent with the Global Strategy or whether any action of
the Licensee that is inconsistent with the Global Strategy with respect to the branding,
positioning and messaging for the Licensed Product could reasonably result in a material adverse
effect on the Commercialization of the Licensed Product in the GPC Biotech Territory, such Dispute
shall be referred to the Chief Executive Officers of the Parties who shall confer on the resolution
of the issue. Any final decision mutually agreed to by such representatives with respect thereto
shall be conclusive and binding on the Parties. If such officers are not able to agree on the
resolution of an issue within fifteen (15) Business Days after such issue was first referred to
them, either Party shall have the right, upon written notice to the other Party, to initiate
arbitration to resolve such Dispute pursuant to Section 15.7.4(b).

               (b) In the event that a Dispute arises with respect to an issue within the jurisdiction of the
JEC, or a decision required to be made by the JEC that cannot be resolved in accordance with
Section 4.4.4, that relates to:

88

 

                    (i) Commercialization of the Licensed Product in the Licensee Territory; or

                    (ii) Licensee Activities or Unilateral Activities of Licensee (other than Disputes subject to
subsection (a)(iv) or (a)(v) above);

such Dispute shall be referred to the Chief Executive Officer of Licensee who shall have the sole
right to resolve such Dispute.

          15.7.3 Intellectual Property Disputes. In the event that a Dispute arises with respect the
validity, scope, enforceability, inventorship or ownership of any Patent or Intellectual Property
Rights, and such Dispute cannot be resolved in accordance with Section 15.7.1, unless otherwise
agreed by the Parties in writing, such Dispute shall not be submitted to arbitration in accordance
with Section 15.7.4 and instead, either Party may initiate litigation in a court of competent
jurisdiction, notwithstanding Section 15.6, in the country in which such rights apply.

          15.7.4 Arbitration. Any arbitration under this Agreement (each an “Arbitration Matter”) shall
be administered by the American Arbitration Association under its Commercial Arbitration Rules then
in effect (the “Arbitration Rules”) and as otherwise described in this Section 15.7.4. The
arbitration shall take place at a location to be agreed by the Parties; provided, however, that in
the event that the Parties are unable to agree on a location for an arbitration under this
Agreement within five (5) days of the demand therefor, such arbitration shall be held in New York,
New York.

               (a) Full Arbitration. Unless Section 15.7.4(b) or 15.7.4(c) is applicable, the following
procedures shall apply:

                    (i) The Parties shall appoint an arbitrator by mutual agreement. If the Parties cannot agree
on the appointment of an arbitrator within thirty (30) days of the demand for arbitration, an
arbitrator shall be appointed in accordance with the Arbitration Rules.

                    (ii) Either Party may apply to the arbitrator for interim injunctive relief until the
arbitration decision is rendered or the Arbitration Matter is otherwise resolved. Either Party also
may, without waiving any right or remedy under this Agreement, seek from any court having
jurisdiction any injunctive or provisional relief necessary to protect the rights or property of
that Party pending resolution of the Arbitration Matter pursuant to this Section 15.7.4. The
arbitrator shall have the authority to grant any equitable and legal remedies that would be
available in any judicial proceeding instituted to resolve the Dispute submitted to such
arbitration in accordance with this Agreement; provided, however, that the arbitrator shall not
have the power to alter, amend or otherwise affect the terms or the provisions of this Agreement.
Judgment upon any award rendered pursuant to this Section may be entered by any court having
jurisdiction over the Parties’ other assets. The arbitrator shall have no authority to award
punitive or any other type of damages not measured by a Party’s compensatory damages.

                    (iii) Each Party shall bear its own costs and expenses and attorneys’ fees, and the Party that
does not prevail in the arbitration proceeding shall pay the arbitrator’s fees and any
administrative fees of arbitration.

89

 

                    (iv) Except to the extent necessary to confirm an award or decision or as may be required by
Applicable Law, neither Party may, and the Parties shall instruct the arbitrator not to, disclose
the existence, content, or results of an arbitration without the prior written consent of both
Parties. In no event shall an arbitration be initiated after the date when commencement of a legal
or equitable proceeding based on the Arbitration Matter would be barred by the applicable New York
statute of limitations.

                    (v) The Parties hereby agree that any payment to be made by a Party pursuant to a decision of
the arbitrator shall be made in United States dollars, free of any tax or other deduction. The
Parties further agree that subject to Section 15.7.5, the decision of the arbitrator shall be the
sole, exclusive and binding remedy between them regarding determination of the Arbitration Matters
presented and the Parties hereby waive the right to contest the award in any court or other forum.

               (b) Accelerated Arbitration. To the extent the Arbitration Matter involves a Dispute that is
submitted to arbitration by a Party under Section 2.6.2(c), 2.6.2(d), 3.1.3(b), 6.2, the final
sentence of Section 15.7.1, or 15.7.2(a)(iv through vi) or any other matter that is expressly
referred to accelerated arbitration elsewhere in this Agreement, the procedures set forth in
Section 15.7.4(a) shall apply, except that the following procedures shall also apply:

                    (i) For purposes of arbitration under this Section 15.7.4(b), the arbitrator shall be
appointed pursuant to Section 15.7.4(a)(i), but shall be a single independent, conflict-free
arbitrator (such arbitrator, the “Expert”), who shall have sufficient scientific background,
expertise and experience to resolve the Arbitration Matter.

                    (ii) Each Party shall prepare and submit a written summary of such Party’s position and any
relevant evidence in support thereof to the Expert within thirty (30) days of the selection of the
Expert. Upon receipt of such summaries from both Parties, the Expert shall provide copies of the
same to the other Party. Within fifteen (15) days of the delivery of such summaries by the Expert,
each Party shall submit a written rebuttal of the other Party’s summary and may also amend and
re-submit its original summary. Oral presentations shall not be permitted unless otherwise
requested by the Expert. The Expert shall make a final decision with respect to the Arbitration
Matter within thirty (30) days following receipt of the last of such rebuttal statements submitted
by the Parties.

               (c) Expedited Arbitration. To the extent the Arbitration Matter involves a Dispute pursuant
to the last two sentences of Section 14.5.3 or any other matter that is expressly referred to
expedited arbitration elsewhere in this Agreement, the procedures set forth in Section 15.7.4(b)
shall apply except that the Expert shall make a determination by selecting the resolution proposed
by one of the Parties that as a whole is the most fair and reasonable to the Parties in light of
the totality of the circumstances and shall provide the Parties with a written statement setting
forth the basis of the determination in connection therewith. For purposes of clarity, the Expert
shall only have the right to select a resolution proposed by one of the Parties in its entirety and
without modification.

          15.7.5 Interim Relief. Notwithstanding anything herein to the contrary, nothing in this
Section shall preclude either Party from seeking interim or provisional relief in a court of

90

 

competent jurisdiction, including a temporary restraining order, preliminary injunction or other
interim equitable relief concerning a Dispute, if necessary to protect the interests of such Party.
This Section shall be specifically enforceable.

     15.8 Notices.

          15.8.1 Notice Requirements. Any notice, request, demand, waiver, consent, approval or other
communication permitted or required under this Agreement shall be in writing, shall refer
specifically to this Agreement and shall be deemed given only if delivered by hand or sent by
facsimile transmission (with transmission confirmed) or by internationally recognized overnight
delivery service that maintains records of delivery, addressed to the Parties at their respective
addresses specified in Section 15.8.2 or to such other address as the Party to whom notice is to be
given may have provided to the other Party in accordance with this Section 15.8. Such Notice shall
be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with
transmission confirmed) or on the second business day (at the place of delivery) after deposit with
an internationally recognized overnight delivery service. Any notice delivered by facsimile shall
be confirmed by a hard copy delivered as soon as practicable thereafter. This Section 15.8 is not
intended to govern the day-to-day business communications necessary between the Parties in
performing their obligations under the terms of this Agreement.

          15.8.2 Address for Notice.

	 	 	 	 	 	 	 
	If to Licensee, to:	 	If to GPC Biotech, to:
	 
	 

	 	Pharmion GmbH
	 	 	 	GPC Biotech AG
	 

	 	Aeschenvorstadt 71,
	 	 	 	Fraunhoferstrasse 20
	 

	 	4051 Basel,
	 	 	 	82152 Martinsried/Munich, Germany
	 

	 	Switzerland
	 	 	 	Attention: Chief Executive Officer
	 

	 	Attention: Director
	 	 	 	Facsimile: +49 89 85 65 2610
	 

	 	Facsimile: +41 61 305 9899	 	 	 	 
	 

	 	 	 	 	 	with a copy to:
	 

	 	with a copy to:	 	 	 	 
	 

	 	 	 	 	 	GPC Biotech Inc.
	 

	 	Pharmion Corporation
	 	 	 	101 College Road East
	 

	 	2525 28th Street
	 	 	 	Princeton, NJ 08540, U.S.A.
	 

	 	Boulder, Colorado 80304, U.S.A.
	 	 	 	Attention: General Counsel
	 

	 	Attention: General Counsel
	 	 	 	Facsimile: +1 609 524 1050
	 

	 	Facsimile: +1 720 564 9191	 	 	 	 

     15.9 Entire Agreement. This Agreement, together with the Exhibits attached hereto, sets forth
and constitutes the entire agreement and understanding between the Parties with respect to the
subject matter hereof and

91

 

all prior agreements, understandings, promises and representations, whether written or oral, with
respect thereto are superseded hereby. Each Party confirms that it is not relying on any
representations or warranties of the other Party except as specifically set forth herein. No
amendment, modification, release or discharge shall be binding upon the Parties unless in writing
and duly executed by authorized representatives of both Parties.

     15.10 English Language. This Agreement shall be written and executed in, and all other
communications under or in connection with this Agreement shall be in, the English language. Any
translation into any other language shall not be an official version thereof, and in the event of
any conflict in interpretation between the English version and such translation, the English
version shall control.

     15.11 Equitable Relief. The Parties acknowledge and agree that the restrictions set forth in
Article 11 are reasonable and necessary to protect the legitimate interests of the other Party and
that such other Party would not have entered into this Agreement in the absence of such
restrictions, and that any breach or threatened breach of any provision of Article 11 may result in
irreparable injury to such other Party for which there will be no adequate remedy at law. In the
event of a breach or threatened breach of any provision of Article 11, the non-breaching Party
shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive
relief, whether preliminary or permanent, specific performance and an equitable accounting of all
earnings, profits and other benefits arising from such breach, which rights shall be cumulative and
in addition to any other rights or remedies to which such non-breaching Party may be entitled in
law or equity. Both Parties agree to waive any requirement that the other (a) post a bond or other
security as a condition for obtaining any such relief and (b) show irreparable harm, balancing of
harms, consideration of the public interest or inadequacy of monetary damages as a remedy. Nothing
in this Section 15.11 is intended, or should be construed, to limit either Party’s right to
equitable relief or any other remedy for a breach of any other provision of this Agreement.

     15.12 Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be
waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall
be effective unless set forth in a written instrument duly executed by or on behalf of the Party
waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the
failure to perform or of a breach by the other Party shall not be deemed a waiver of any other
right hereunder or of any other breach or failure by said other Party whether of a similar nature
or otherwise.

     15.13 No Benefit to Third Parties. The representations, warranties, covenants and agreements
set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and
permitted assigns, and they shall not be construed as conferring any rights on any other Persons.

     15.14 Further Assurance. Each Party shall duly execute and deliver, or cause to be duly
executed and delivered, such further instruments and do and cause to be done such further acts and
things, including the filing of such assignments, agreements, documents and instruments, as may be
necessary or as the other Party

92

 

may reasonably request in connection with this Agreement or to carry out more effectively the
provisions and purposes hereof, or to better assure and confirm unto such other Party its rights
and remedies under this Agreement.

     15.15 Relationship of the Parties. It is expressly agreed that GPC Biotech, on the one hand,
and Licensee, on the other hand, shall be independent contractors and that the relationship between
the two Parties shall not constitute a partnership, joint venture or agency. Neither GPC Biotech,
on the one hand, nor Licensee, on the other hand, shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall be binding on the
other, without the prior written consent of the other Party to do so, such consent not to be
unreasonably withheld or delayed. All persons employed by a Party shall be employees of such Party
and not of the other Party and all costs and obligations incurred by reason of any such employment
shall be for the account and expense of such Party.

     15.16 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument. This Agreement may be executed by facsimile signatures and such signatures shall be
deemed to bind each party hereto as if they were original signature.

     15.17 References. Unless otherwise specified, (a) references in this Agreement to any
Article, Section or Exhibit shall mean references to such Article, Section or Exhibit of this
Agreement, (b) references in any section to any clause are references to such clause of such
section and (c) references to any agreement, instrument or other document in this Agreement refer
to such agreement, instrument or other document as originally executed or, if subsequently varied,
replaced or supplemented from time to time, as so varied, replaced or supplemented and in effect at
the relevant time of reference thereto.

     15.18 Construction. Except where the context otherwise requires, wherever used, the singular
shall include the plural, the plural the singular, the use of any gender shall be applicable to all
genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement
are for convenience of reference only and in no way define, describe, extend or limit the scope or
intent of this Agreement or the intent of any provision contained in this Agreement. The term
“including” as used herein shall mean including, without limiting the generality of any description
preceding such term. The language of this Agreement shall be deemed to be the language mutually
chosen by the Parties and no rule of strict construction shall be applied against either Party
hereto.

[SIGNATURE PAGE FOLLOWS.]

93

 

THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first
written above.

	 	 	 
	GPC BIOTECH AG

	 	                PHARMION GMBH
	 
	 	 
	Signature : /s/ Elmar Maier, PhD

	 	Signature : /s/ Patrick J. Mahaffy
	 
	 	 
	Name : Elmar Maier, PhD

	 	Name : Patrick J. Mahaffy
	 
	 	 
	Title : SVP Business Development

	 	Title : Director
	 
	 	 
	Signature : /s/ Bernd R. Seizinger, M.D., PhD

	 	Signature : /s/ Erle T. Mast
	 
	 	 
	Name : Bernd R. Seizinger, M.D., PhD

	 	Name : Erle T. Mast
	 
	 	 
	Title : CEO

	 	Title : Director

94

 

Exhibit A

GPC Biotech Patents

	 	 	 	 	 
	Country	 	Application No	 	Grant No
	Austria
	 	89 300 787.2	 	EP 0 328 274
	Australia
	 	28971/89	 	AU 618310
	Belgium
	 	89 300 787.2	 	EP 0 328 274
	Brazil
	 	1100963-2	 	BR 1100963-2
	Canada
	 	589,796	 	CA 1,340,286
	Switzerland
	 	89 300 787.2	 	EP 0 328 274
	Germany
	 	89 300 787.2	 	EP 0 328 274
	Denmark
	 	0491/89	 	DK 175050
	Spain
	 	89 300 787.2	 	EP 0 328 274
	Finland
	 	89/0512	 	FI 91260
	France
	 	89 300 787.2	 	EP 0 328 274
	United Kingdom
	 	89 300 787.2	 	EP 0 328 274
	Greece
	 	89 300 787.2	 	EP 0 328 274
	Hungary
	 	52289	 	HU 205767
	Ireland
	 	31989	 	IE 65503
	Israel
	 	89119	 	IL 89119
	Italy
	 	89 300 787.2	 	EP 0 328 274
	Japan
	 	01/24751	 	JP 2781403
	Korea (South)
	 	89/1069	 	KR 147270
	Luxembourg
	 	89 300 787.2	 	EP 0 328 274
	Mexico
	 	9203596	 	MX 181357
	Netherlands
	 	89 300 787.2	 	EP 0 328 274
	Norway
	 	89/0426	 	NO 177569
	New Zealand
	 	227839	 	NZ 227839
	Portugal
	 	89608	 	PT 89608
	Romania
	 	C-20256	 	 
	Sweden
	 	89 300 787.2	 	EP 0 328 274
	Taiwan
	 	78/100752	 	TW 51931
	United States of America
	 	07/602,931	 	US 5,072,011
	South Africa
	 	89/0831	 	ZA 89/0831
	Hungary
	 	P/P00163	 	HU 210872
	United States of America
	 	07/723,971	 	US 5,244,919
	Austria
	 	95 302 629.1	 	EP 0 679 656
	Australia
	 	17661/95	 	AU 692521
	Belgium
	 	95 302 629.1	 	EP 0 679 656
	Canada
	 	2,147,567	 	 
	Switzerland
	 	95 302 629.1	 	EP 0 679 656
	Germany
	 	95 302 629.1	 	EP 0 679 656
	Denmark
	 	95 302 629.1	 	EP 0 679 656
	Spain
	 	95 302 629.1	 	EP 0 679 656
	France
	 	95 302 629.1	 	EP 0 679 656
	United Kingdom
	 	95 302 629.1	 	EP 0 679 656
	Greece
	 	95 302 629.1	 	EP 0 679 656
	Ireland
	 	95 302 629.1	 	EP 0 679 656
	Italy
	 	95 302 629.1	 	EP 0 679 656
	Japan
	 	7-100870	 	 
	Netherlands
	 	95 302 629.1	 	EP 0 679 656
	Portugal
	 	95 302 629.1	 	EP 0 679 656
	Sweden
	 	95 302 629.1	 	EP 0 679 656
	United States of America
	 	08/428,444	 	US 5,519,155
	Malta
	 	2893	 	 
	PCT
	 	PCT/US2005/24761	 	 
	Malta
	 	2636	 	 
	PCT
	 	PCT/EP2005/001733	 	 
	EPO
	 	05 005 380.0	 	 
	United States of America
	 	60/664,096	 	 

 

 

Exhibit B

Distributor Countries 

Austria

Switzerland

Turkey

Greece

New Zealand

Israel

Lebanon

Saudi Arabia

Malta

Egypt

Jordan

Syria

Oman

United Arab Emirates

Cyprus

Poland

Slovenia

Slovakia

Latvia

Lithuania

Hungary

Czech Republic

Estonia

 

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	ARTICLE 1 — DEFINITIONS	 	 	1	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 2 DEVELOPMENT AND REGULATORY	 	 	19	 	 	 
	 
	 	 	 	 	 	 	 	 
	2.1

	 	Development of the Licensed Product
	 	 	19	 	 	 
	2.2

	 	Development Plan and Implementation
	 	 	20	 	 	 
	2.3

	 	Development Budget
	 	 	21	 	 	 
	2.4

	 	Regulatory Matters
	 	 	22	 	 	 
	2.5	 	Unilateral Development
	2.6	 	Certain Development Activities Excluded From Licensee’s Opt-Out Rights
	2.7

	 	Supply of Licensed Product
	 	 	30	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 3 COMMERCIALIZATION	 	 	30	 	 	 
	 
	 	 	 	 	 	 	 	 
	3.1

	 	Commercialization of the Licensed Product
	 	 	30	 	 	 
	3.2

	 	Commercialization Plan and Implementation
	 	 	32	 	 	 
	3.4

	 	Non-Compete
	 	 	33	 	 	 
	3.4

	 	Promotional Materials and Activities
	 	 	33	 	 	 
	3.5

	 	Statements and Compliance with Applicable Law
	 	 	34	 	 	 
	3.6

	 	Use of Distributors
	 	 	35	 	 	 
	3.7

	 	Sales and Distribution in Licensee Territory
	 	 	35	 	 	 
	3.8

	 	Unauthorized Sales
	 	 	35	 	 	 
	3.9

	 	Reporting
	 	 	36	 	 	 
	3.10

	 	Commercialization Budget
	 	 	36	 	 	 
	3.11

	 	GPC Biotech Territory
	 	 	37	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 4 COLLABORATION MANAGEMENT	 	 	37	 	 	 
	 
	 	 	 	 	 	 	 	 
	4.1

	 	Joint Executive Committee (JEC).
	 	 	37	 	 	 
	4.2

	 	Joint Development Committee (JDC)
	 	 	38	 	 	 
	4.3

	 	Joint Commercialization Committee (JCC)
	 	 	39	 	 	 
	4.4

	 	General Provisions Governing Committees
	 	 	40	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 5 GRANT OF RIGHTS	 	 	42	 	 	 
	 
	 	 	 	 	 	 	 	 
	5.1

	 	Grants to Licensee
	 	 	42	 	 	 
	5.2

	 	Retention of Rights
	 	 	43	 	 	 
	5.3

	 	Sublicenses
	 	 	43	 	 	 
	5.4

	 	Right of First Negotiation
	 	 	44	 	 	 
	5.5

	 	Use of Trademarks and Corporate Names
	 	 	44	 	 	 
	5.6

	 	Grants to GPC Biotech
	 	 	45	 	 	 
	5.7

	 	No Implied Rights
	 	 	46	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 6 COLLABORATION COSTS	 	 	46	 	 	 
	 
	 	 	 	 	 	 	 	 
	6.1

	 	General
	 	 	46	 	 	 
	6.2

	 	Accounting Procedures
	 	 	49	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 7 CONSIDERATION	 	 	49	 	 	 

 

 

	 	 	 	 	 	 	 	 	 
	7.1

	 	Payments to GPC Biotech
	 	 	49	 	 	 
	7.2

	 	Royalties
	 	 	50	 	 	 
	7.3

	 	Royalty Term
	 	 	51	 	 	 
	7.4

	 	Royalty Adjustments
	 	 	51	 	 	 
	7.5

	 	Royalty Payments
	 	 	52	 	 	 
	7.6

	 	Royalty Statements
	 	 	52	 	 	 
	7.7

	 	Mode of Payment
	 	 	52	 	 	 
	7.8

	 	Taxes
	 	 	52	 	 	 
	7.9

	 	Interest on Late Payment
	 	 	53	 	 	 
	7.10

	 	Financial Records
	 	 	53	 	 	 
	7.11

	 	Audit
	 	 	53	 	 	 
	7.12

	 	Audit Dispute
	 	 	54	 	 	 
	7.13

	 	Confidentiality
	 	 	54	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 8 INTELLECTUAL PROPERTY	 	 	54	 	 	 
	 
	 	 	 	 	 	 	 	 
	8.1

	 	Ownership of Intellectual Property
	 	 	54	 	 	 
	8.2

	 	Maintenance and Prosecution of Patents and Trademarks
	 	 	56	 	 	 
	8.3

	 	Enforcement of Patents and Trademarks
	 	 	58	 	 	 
	8.4

	 	Potential Third Party Rights
	 	 	60	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 9 ADVERSE EVENT REPORTING	 	 	63	 	 	 
	 
	 	 	 	 	 	 	 	 
	9.1

	 	Complaints
	 	 	63	 	 	 
	9.2

	 	Adverse Event Reporting
	 	 	63	 	 	 
	9.3

	 	Pharmacovigilance
	 	 	63	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 10 Licensed Product Recall	 	 	64	 	 	 
	 
	 	 	 	 	 	 	 	 
	10.1

	 	Notification and Recall
	 	 	64	 	 	 
	10.2

	 	Recall Expenses
	 	 	64	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 11 Confidentiality AND Non-Disclosure	 	 	64	 	 	 
	 
	 	 	 	 	 	 	 	 
	11.1

	 	Confidentiality Obligations
	 	 	64	 	 	 
	11.2

	 	Permitted Disclosures
	 	 	65	 	 	 
	11.3

	 	Use of Name
	 	 	66	 	 	 
	11.4

	 	Press Releases
	 	 	66	 	 	 
	11.5

	 	Patient Information
	 	 	66	 	 	 
	11.6

	 	Publications
	 	 	67	 	 	 
	11.7

	 	Return of Confidential Inforamtion
	 	 	67	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 12 Representations and Warranties	 	 	68	 	 	 
	 
	 	 	 	 	 	 	 	 
	12.1

	 	Representations, Warranties and Covenants
	 	 	68	 	 	 
	12.2

	 	Additional Representations, Warranties and Covenants of Licensee
	 	 	69	 	 	 
	12.3

	 	Additional Representations, Warranties and Covenants of GPC Biotech
	 	 	69	 	 	 
	12.4

	 	Disclaimer of Warranty
	 	 	71	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 13 Indemnity	 	 	71	 	 	 
	 
	 	 	 	 	 	 	 	 
	13.1

	 	Indemnification of GPC Biotech
	 	 	71	 	 	 
	13.2

	 	Indemnification of Licensee
	 	 	72	 	 	 
	13.3

	 	Certain Losses
	 	 	72	 	 	 
	13.4

	 	Notice of Claim
	 	 	72	 	 	 

 

 

	 	 	 	 	 	 	 	 	 
	13.5

	 	Control of Defense
	 	 	72	 	 	 
	13.6

	 	Limitation on Damages and Liability
	 	 	74	 	 	 
	13.7

	 	Insurance
	 	 	74	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 14 TERM AND TERMINATION	 	 	75	 	 	 
	 
	 	 	 	 	 	 	 	 
	14.1

	 	Term
	 	 	75	 	 	 
	14.2

	 	Termination of this Agreement in its Entirety for Material Breach
	 	 	76	 	 	 
	14.3

	 	Termination of this Agreement in a Country or Major Market Region for Material Breach
	 	 	76	 	 	 
	14.4

	 	Termination by Licensee
	 	 	77	 	 	 
	14.5

	 	Termination by GPC Biotech
	 	 	77	 	 	 
	14.6

	 	Termination Upon Insolvency
	 	 	79	 	 	 
	14.7

	 	Rights in Bankruptcy
	 	 	79	 	 	 
	14.8

	 	Consequences of Termination
	 	 	80	 	 	 
	14.9

	 	Accrued Rights; Surviving Obligations
	 	 	84	 	 	 
	14.10

	 	Termination of Spectrum Agreement
	 	 	84	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 15 Miscellaneous	 	 	85	 	 	 
	 
	 	 	 	 	 	 	 	 
	15.1

	 	Force Majeure
	 	 	85	 	 	 
	15.2

	 	Export Control
	 	 	85	 	 	 
	15.3

	 	Non-Solicitation
	 	 	85	 	 	 
	15.4

	 	Assignment
	 	 	85	 	 	 
	15.5

	 	Severability
	 	 	86	 	 	 
	15.6

	 	Governing Law, Jurisdiction, Venue and Service
	 	 	86	 	 	 
	15.7

	 	Dispute Resolution
	 	 	87	 	 	 
	15.8

	 	Notices
	 	 	91	 	 	 
	15.9

	 	Entire Agreement
	 	 	91	 	 	 
	15.10

	 	English Language
	 	 	92	 	 	 
	15.11

	 	Equitable Relief
	 	 	92	 	 	 
	15.12

	 	Waiver and Non-Exclusion of Remedies
	 	 	92	 	 	 
	15.13

	 	No Benefit to Third Parties
	 	 	92	 	 	 
	15.14

	 	Further Assurance
	 	 	92	 	 	 
	15.15

	 	Relationship of the Parties
	 	 	93	 	 	 
	15.16

	 	Counterparts
	 	 	93	 	 	 
	15.17

	 	References
	 	 	93	 	 	 
	15.18

	 	Construction
	 	 	93	 	 	 

 

 

List of Exhibits

	 	 	 
	Exhibit A

	 	GPC Biotech Patents
	Exhibit B

	 	Distributor Countriesexv10w34

 

Exhibit 10.34

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN

THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN

OMITTED AND FILED SEPARATELY WITH THE

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO

RULE 24B-2 OF THE SECURITIES EXCHANGE

ACT OF 1934, AS AMENDED

SUPPLY AGREEMENT

          This Supply Agreement (the “Agreement”) is made and entered into effective as of December 19,
2005 (the “Effective Date”) by and between GPC Biotech AG, a German corporation, having its place
of business at Fraunhoferstrasse 20, 82152 Martinsried/Munich, Germany (“GPC Biotech”); and
Pharmion GmbH, a Swiss limited liability company and wholly-owned subsidiary of Pharmion
Corporation, a Delaware corporation, having a place of business at Aeschenvorstadt 71, 4051 Basel,
Switzerland (“Licensee”). GPC Biotech and Licensee are sometimes referred to herein individually
as a “Party” and collectively as the “Parties.”

RECITALS

          WHEREAS, the Parties have entered into a Co-Development and License Agreement of even date
herewith (the “License Agreement”), pursuant to which GPC Biotech grants a license to Licensee, and
Licensee obtains a license, to Develop and Commercialize the Licensed Product (each as defined
therein); and

          WHEREAS, in accordance with the terms of the License Agreement, the Parties are required to
enter into an agreement providing for the supply by GPC Biotech to Licensee of all of Licensee’s
requirements of the Licensed Product; and

          WHEREAS, GPC Biotech desires to supply the Licensed Product to Licensee, and Licensee desires
to purchase the Licensed Product, all on the terms and conditions set forth below.

          NOW, THEREFORE, in consideration of the foregoing premises, the mutual promises and covenants
of the Parties contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do
hereby agree as follows:

ARTICLE I

DEFINITIONS

          Unless otherwise specifically provided herein, the following terms shall have the following
meanings:

          1.1 “Affiliate” shall mean, with respect to a Party, any Person that, directly or indirectly,
through one or more intermediaries, controls, is controlled by or is under common control with such
Party. For purposes of this definition, “control” and, with correlative meanings, the terms
“controlled by” and “under common control with” shall mean (a) the possession, directly or
indirectly, of the power to direct the management or policies of a business entity, whether through
the ownership of voting securities, by contract relating to voting rights or corporate governance,
or otherwise, or (b) the ownership, directly or indirectly, of at least fifty percent (50%) of the
voting securities or other ownership interest of a business entity (or, with respect to a limited
partnership or other similar entity, its general partner or controlling entity).

1

 

          1.2 “Agreement” shall have the meaning set forth in the preamble to this Agreement.

          1.3 “API” shall mean the Licensed Compound as defined in the License Agreement.

          1.4 “API Facility” shall mean the Manufacturing facility of the API Subcontractor.

          1.5 “API Subcontractor” shall mean, as of the Effective Date, Johnson Matthey Inc. or any
other Person appointed by GPC Biotech thereafter and approved by Licensee in writing to supply API,
which approval shall not be unreasonably withheld or delayed.

          1.6 “Applicable Law” shall mean applicable laws, rules and regulations, including any rules,
regulations, guidelines or other requirements of the Regulatory Authorities, that may be in effect
from time to time.

          1.7 “Arbitration Rules” shall have the meaning set forth in Section 9.11.2.

          1.8 “Breaching Party” shall have the meaning set forth in Section 8.2.

          1.9 “Business Day” shall mean a day other than a Saturday or Sunday on which banking
institutions in Munich, Germany are open for business.

          1.10 “Calendar Quarter” shall mean each successive period of three (3) calendar months
commencing on January 1, April 1, July 1 and October 1.

          1.11 “Calendar Year” shall mean each successive period of twelve (12) calendar months
commencing on January 1 and ending on December 31.

          1.12 “cGMP” shall mean (a) the current good manufacturing practices for the methods used in,
and the facilities and controls used for, the Manufacture of the Licensed Product promulgated by
any Regulatory Authority including, without limitation, US cGMP, the EU Good Manufacturing
Guidelines, the International Conference on Harmonization Guidelines and any other applicable laws,
guidelines and/or regulations, together with the latest FDA and other applicable guidance documents
pertaining to manufacturing and quality control practice, all as updated, amended and revised from
time to time.

          1.13 “Claims” shall have the meaning set forth in Section 7.1.

          1.14 “CMC Sections” shall mean the Chemistry, Manufacturing and Controls sections of any
Regulatory Documentation, including all information included therein.

          1.15 “Complaining Party” shall have the meaning set forth in Section 8.2.

          1.16 “Dispute” shall have the meaning set forth in Section 9.11.1.

          1.17 “Distributor” shall have the meaning set forth in the License Agreement.

2

 

          1.18 “Drug Master File” shall have the meaning set forth in the License Agreement.

          1.19 “Effective Date” shall mean the effective date of this Agreement as set forth in the
preamble to this Agreement.

          1.20 “Exploitation” shall have the meaning set forth in the License Agreement.

          1.21 “Facilities” shall mean (a) the API Facility, (b) the Finishing Facility, and (c) any
Manufacturing facility of GPC Biotech or its Affiliates.

          1.22 “FDA” shall mean the United States Food and Drug Administration and any successor agency
thereto.

          1.23 “FFDCA” shall mean the United States Federal Food, Drug, and Cosmetic Act, as amended
from time to time.

          1.24 “Finishing Facility” shall mean the Manufacturing facility of the Finishing Subcontractor
or the Manufacturing facility of GPC Biotech or its Affiliate, as determined by GPC Biotech.

          1.25 “Finishing Subcontractor” shall mean, as of the Effective Date, [...***...], or any other
Person appointed by GPC Biotech thereafter to supply Licensed Product in bulk capsule form, and
approved by Licensee in writing, which approval shall not be unreasonably withheld or delayed.

          1.26 “Forecast(s)” shall have the meaning set forth in Section 2.2.1.

          1.27 “Full Product Batch” shall mean a specific quantity of Licensed Product equal to
approximately 480,000 units comprised of approximately [...***...] units of [...***...] capsules
and approximately [...***...] units of [...***...] capsules.

          1.28 “GPC Biotech” shall have the meaning set forth in the preamble to this Agreement.

          1.29 “Indemnification Claim Notice” shall have the meaning set forth in Section 7.3.

          1.30 “Indemnified Party” shall have the meaning set forth in Section 7.3.

          1.31 “Initial Forecast” shall have the meaning set forth in Section 2.2.1.

          1.32 “Joint Manufacturing Committee” or “JMC” shall have the meaning set forth in Section 2.1.4.

          1.33 “License Agreement” shall have the meaning set forth in the first recital to this Agreement.

 
 

*** Confidential Treatment Requested

3

 

          1.34 “Licensed Product” shall mean the “Licensed Product” as defined in the License Agreement
that has been Manufactured by or on behalf of GPC Biotech and delivered to Licensee pursuant to the
terms of this Agreement.

          1.35 “Licensee” shall have the meaning set forth in the preamble to this Agreement.

          1.36 “Licensee Territory” shall have the meaning set forth in the License Agreement.

          1.37 “Losses” shall have the meaning set forth in Section 7.1.

          1.38 “Major Market Country” shall have the meaning set forth in the License Agreement.

          1.39 “Manufacturing” shall mean all activities, steps and processes relating to the
production, manufacture, processing and holding of the Licensed Product or any intermediate
thereof, including stability testing, quality assurance and quality control. The terms
“Manufacture” and “Manufactured” refer to the act of Manufacturing.

          1.40 “Manufacturing Cost” shall have the meaning set forth in the License Agreement.

          1.41 “Manufacturing Process” shall mean any process or step thereof that is necessary or
useful for Manufacturing the Licensed Product or any intermediate thereof as evidenced in the batch
records or master batch records.

          1.42 “Materials” shall mean all raw materials, excipients, and containers required in
connection with the Manufacture of the Licensed Product, excluding API.

          1.43 “Notice Period” shall have the meaning set forth in Section 8.2.

          1.44 “Party” and “Parties” shall have the meaning set forth in the preamble to this Agreement.

          1.45 “Permits” shall have the meaning set forth in Section 6.1.1.

          1.46 “Person” shall mean an individual, sole proprietorship, partnership, limited partnership,
limited liability partnership, corporation, limited liability company, business trust, joint stock
company, trust, unincorporated association, joint venture or other similar entity or organization,
including a government or political subdivision, department or agency of a government.

          1.47 “Purchase Order” shall mean a written purchase order submitted by Licensee to GPC Biotech
in accordance with Section 2.2.2.

          1.48 “Quality Agreement” shall mean the quality assurance agreement between the Parties to be
agreed upon within ninety (90) days of the Effective Date.

4

 

          1.49 “Regulatory Authority” shall mean any applicable supra-national, federal, national,
regional, state, provincial or local regulatory agencies, departments, bureaus, commissions,
councils or other government entities regulating or otherwise exercising authority with respect to
the Exploitation of the Licensed Product in the Licensee Territory.

          1.50 “Regulatory Documentation” shall have the meaning set forth in the License Agreement.

          1.51 “Reserve Inventory” shall have the meaning set forth in Section 2.1.2.

          1.52 “Specifications” shall mean the list of tests, references to any analytical procedures
and appropriate acceptance criteria which are numerical limits, ranges or other criteria for tests
described in order to establish a set of criteria to which Licensed Product, at any stage of
Manufacture, should conform to be considered acceptable for its intended use as agreed to in
writing by the Parties within ninety (90) days of the Effective Date, as such specifications are
amended or supplemented from time to time in accordance with the terms hereof. Without limiting
the generality of the foregoing, the Specifications shall be consistent with all applicable
Regulatory Documentation filed prior to the Effective Date and shall specify that the Licensed
Products, when delivered to Licensee, shall have a minimum remaining shelf life of not less than
seventy five percent (75%) of the maximum shelf life that is available for the Licensed Products at
the time of Manufacture.

          1.53 “Subcontractor” shall mean either the API Subcontractor or the Finishing Subcontractor.

          1.54 “Sublicensee” shall have the meaning set forth in the License Agreement.

          1.55 “Supply Failure” shall have the meaning set forth in Section 8.5.

          1.56 “Supply Price,” with respect to any Licensed Product delivered hereunder, shall mean one
hundred and ten percent (110%) of the Manufacturing Costs for such Licensed Product.

          1.57 “Term” shall have the meaning set forth in Section 8.1.

          1.58 “Third Party” shall mean any Person other than GPC Biotech, Licensee and their respective
Affiliates and Sublicensees.

          1.59 “US cGMP” shall mean current good manufacturing practices for the methods used in, and
the facilities and controls used for, the Manufacture of the Licensed Products, all as set forth
from time to time by the FDA pursuant to the FFDCA and the rules and regulations promulgated
thereunder (including specifically Title 21, parts 210 and 211 of the Code of Federal Regulations
of the United States).

5

 

ARTICLE II

SUPPLY OF PRODUCT

          2.1 Purchase and Supply Obligations. Subject to the provisions of this Agreement, during the
Term Licensee shall, and Licensee shall cause its Sublicensees to, purchase one hundred percent
(100%) of their requirements of Licensed Product in bulk capsule form according to the
Specifications for sale in the Licensee Territory from GPC Biotech, and GPC Biotech shall
Manufacture and supply such quantities of Licensed Product to Licensee. GPC Biotech shall not
supply Licensed Products to any Third Party within the Licensee Territory. In the event that GPC
Biotech, at any time during the Term, has reason to believe that it or any Subcontractor will be
unable to perform the services hereunder or that there will be a material delay in performance
thereof, GPC Biotech shall (without limiting any other obligations GPC Biotech may have or rights
or remedies Licensee may have ) promptly notify Licensee thereof.

               2.1.1. Subcontracting. Licensee acknowledges and agrees that GPC Biotech may
subcontract or delegate any or all of its obligations hereunder to any Subcontractor;
provided that any change in Subcontractors requires Licensee’s prior written consent
and such subcontracting or delegation shall in no way relieve GPC Biotech of its
obligations hereunder except to the extent that such obligations are performed by a
Subcontractor. GPC Biotech shall ensure that any Subcontractor engaged by GPC Biotech
to Manufacture Licensed Product Manufactures the Licensed Product pursuant to the terms
of this Agreement.

               2.1.2. API and Materials; Reserve Inventory. GPC Biotech or its Subcontractors
shall obtain and provide all API, Materials and equipment required to Manufacture the
Licensed Products hereunder. During the Term of this Agreement, GPC Biotech shall
maintain, at its own expense, a reserve inventory of API and capsule shells to be used
in the future Manufacturing of Licensed Products (“Reserve Inventory”) in an amount
equal to twice Licensee’s Forecast for the then-current Calendar Quarter. When using
Reserve Inventory in order to Manufacture Licensed Products in accordance with this
Agreement, GPC Biotech and its Subcontractors shall manage such inventory with its own
inventories of API and Materials on a “first expiry, first out” basis to maximize shelf
life and minimize spoilage. GPC Biotech shall properly store all inventories of API
and Materials (including such Reserve Inventory) prior to use in accordance with cGMP
and the Specifications.

               2.1.3. Facilities. GPC Biotech shall Manufacture all Licensed Product hereunder
only at the Facilities. GPC Biotech shall maintain, or shall cause its Subcontractors
to maintain, at their own expense, the Facilities and all equipment required for the
Manufacture of the Licensed Product in a state of repair and operating efficiency
consistent with the requirements of cGMP and all other Applicable Law.

6

 

               2.1.4. Joint Manufacturing Committee. The JEC (as defined in the License
Agreement) will establish a Joint Manufacturing Committee comprising an equal number of
representatives of both Parties (the “JMC”). The JMC shall have the overall
responsibility for overseeing the Parties’ activities with respect to the Manufacture
of Licensed Product hereunder and, in particular, the JMC shall (a) discuss any
proposed changes to the Manufacturing Process or Specifications; (b) oversee and
coordinate regulatory activities relating to Manufacturing; (c) oversee and establish
work plans for analytical methods transfer; (d) coordinate product supply activities;
and (e) engage in any other activities or assume any other responsibilities delegated
to it by the JEC. The JEC will establish the meeting schedule and decision-making
rules that the JMC will follow in carrying out its responsibilities.

2.2 Forecasts and Purchase Orders.

               2.2.1. Not later than ninety (90) days following the Effective Date, Licensee
shall provide GPC Biotech with a good faith, written forecast of its anticipated
requirements of the Licensed Product and proposed delivery dates thereof for the period
beginning on the Effective Date and ending six (6) full Calendar Quarters thereafter
(“Initial Forecast”). Not later than thirty (30) days prior to the beginning of the
first full Calendar Quarter after the Initial Forecast and each subsequent full
Calendar Quarter of the Term, Licensee shall submit to GPC Biotech a good faith,
written forecast of its anticipated requirements of the Licensed Product and proposed
delivery dates thereof for such Calendar Quarter and the five (5) Calendar Quarters
thereafter (such forecasts, together with the Initial Forecast, the “Forecasts”) (for
example, not later than thirty (30) days prior to the Calendar Quarter that begins
April 1, 2007, Licensee shall submit a Forecast covering the period from April 1, 2007
through September 30, 2008). The quantities of Licensed Product and delivery dates
applicable to the first two (2) Calendar Quarters in each Forecast shall constitute a
binding obligation of Licensee to purchase and of GPC Biotech to supply such quantities
and shall not be subject to change without the prior written approval of both GPC
Biotech and Licensee.

               2.2.2. Licensee shall order Licensed Product by the issuance of Purchase Orders to
GPC Biotech at least one hundred twenty (120) days prior to the delivery date
specified in each respective Purchase Order. Each Purchase Order shall designate the
desired quantities of Licensed Product and the delivery date(s) thereof, and each
Purchase Order must be consistent with the binding portion of the most recently
delivered Forecast and shall constitute a binding commitment by Licensee to order from
GPC Biotech and by GPC Biotech to deliver to Licensee when placed. All Purchase Orders
shall be for Full Product Batch quantities of Licensed Product or integral multiples
thereof.

               2.2.3. GPC Biotech shall confirm acceptance of each Purchase Order submitted in
accordance with Section 2.2.2 within thirty (30) days after receipt thereof and shall
use commercially reasonable efforts to deliver

7

 

Licensed Product against each Purchase Order in accordance with the delivery date set forth
therein.

               2.2.4. Each Purchase Order shall be subject to all of the terms and conditions of
this Agreement. To the extent any terms or provisions of a Purchase Order or the
written acceptance thereof by GPC Biotech conflict with, or are in addition to, the
terms and provisions of this Agreement, the terms and provisions of this Agreement
shall control.

          2.3 Delivery Terms; Risk of Loss. GPC Biotech shall deliver all Licensed Product Manufactured
hereunder EXW (as defined in Incoterms 2000) the Finishing Facility. Title to all Licensed Product
shall pass to Licensee at the time of delivery.

          2.4 Regulatory Approvals. GPC Biotech shall, and shall cause its Subcontractors to, permit
any applicable Regulatory Authority to inspect the Facilities and otherwise cooperate fully with
such agencies and GPC Biotech shall, and shall cause its Subcontractors to, provide Licensee with
such information and assistance as Licensee may reasonably request in order for Licensee to comply
with the requirements of such Regulatory Authorities in regard to the Licensed Product. The
Parties further agree that GPC Biotech shall, and shall cause its Subcontractors to, use
commercially reasonable efforts, at Licensee’s expense, to cooperate in any registration process in
the Licensee Territory undertaken by Licensee in accordance with the License Agreement. On or
prior to the date agreed to by the Parties (in consultation with the JMC) in connection with the
Development of the Licensed Product, GPC Biotech shall, and shall cause its Subcontractors to, at
its expense, compile and file a Drug Master File with all Regulatory Authorities in the Major
Market Countries in the Licensee Territory that accept such filings. If any Regulatory Authorities
in the Licensee Territory do not allow for referencing Drug Master Files for purposes of obtaining
Regulatory Approval for the Licensed Product, GPC Biotech shall, and shall cause its Subcontractors
to, provide Licensee with all information required to complete the CMC Sections of any Regulatory
Documentation required to be submitted in the Major Market Countries in the Licensee Territory as
soon as reasonably practicable.

          2.5 Change Control. GPC Biotech shall Manufacture Licensed Product according to cGMP and the
applicable Specifications. GPC Biotech shall notify Licensee of any and all changes it proposes in
its Manufacturing (including API and Materials), Subcontractors, Facilities, Manufacturing Process
or Specifications relating to Licensed Product. GPC Biotech or Licensee may, at any time, request
a change to the Manufacturing Process or the Specifications related to the Licensed Product. GPC
Biotech and its Subcontractors agree to implement any change to the Manufacturing Process or
Specifications that is required by a Regulatory Authority or by Applicable Law in the Licensee
Territory. In the event of any other request to modify the Manufacturing Process or
Specifications, both Licensee and GPC Biotech shall promptly meet to evaluate such proposed changes
including the effect of such changes on the regulatory filings related to the Licensed Product and
the costs associated with Manufacturing. No such change shall be made without the approval of both
Parties; provided that such approval shall not be unreasonably withheld. To the extent that any
change is required by Regulatory Authorities in both the GPC Biotech Territory and the Licensee
Territory, the costs associated with implementing such change will be considered Collaboration
Costs under

8

 

the License Agreement. The costs associated with implementing all other changes will be the
responsibility of (a) GPC Biotech, if GPC Biotech or its Subcontractors requested the change or the
change was required by Regulatory Authorities anywhere in the GPC Biotech Territory, or (b)
Licensee, if Licensee requested the change or the change was required by Regulatory Authorities
anywhere in the Licensee Territory.

          2.6 Lot Numbers. GPC Biotech shall imprint the lot numbers and expiration dates on Licensed
Product containers, as required by cGMP, for each Licensed Product delivered. Such lot numbers and
expiration dates shall be assigned to each lot by GPC Biotech based on GPC Biotech’s or its
Subcontractor’s standard operating procedures.

          2.7 Analytical Methods Transfer. Licensee shall be responsible for primary and secondary
packaging and release testing for Licensed Products to be sold by Licensee in the Licensee
Territory. In accordance with a work plan and budget to be agreed upon by Licensee and GPC
Biotech, GPC Biotech shall provide Licensee with (a) validated analytical methods and reference
standards; (b) details of the packaging materials that GPC Biotech has used for its stability
studies; and (c) technical support required to transfer the methods to a Third Party laboratory
selected by Licensee to perform release testing of Licensed Product provided to Licensee hereunder.
The transfer of analytical methods and other related technology hereunder shall be under the
supervision and direction of the JMC. Licensee shall pay GPC Biotech’s actual out-of-pocket
expenses in connection with conducting the activities described in this Section 2.7.

          2.8 Licensed Product Failure and Rejection; Latent Defects. With each delivery of Licensed
Product hereunder, GPC Biotech shall provide a Certificate of Analysis and a Certificate of
Compliance, in a form agreed to by the Parties, along with all other documentation required
pursuant to the Quality Agreement. Within thirty (30) days following delivery to Licensee of such
Licensed Product and all such documentation, Licensee shall have the right to give GPC Biotech
notice of rejection of any batch of Licensed Product that, in whole or part, fails to meet the
applicable Specifications at the time of delivery. Failure by Licensee to give notice of rejection
within the period set forth above shall be deemed acceptance by it of the Licensed Product to which
the notice of rejection would have otherwise applied. GPC Biotech retains the right of appeal to
an independent laboratory as provided in Section  2.16 of this
Agreement. Notwithstanding the foregoing, the requirement for Licensee to provide notice of
rejection within the period set forth above shall not apply to any defect not readily discoverable
by Licensee within such thirty (30) day period. In the event of any Licensed Product with defects
not readily discoverable by Licensee within such thirty (30) day period, notwithstanding anything
to the contrary contained herein, Licensee may reject such Licensed Product by delivering notice of
rejection to GPC Biotech no later than the earlier of: (a) thirty (30) days after the date of
discovery of such defect or (b) expiration of the shelf life of the Licensed Product. If Licensee
fails to notify GPC Biotech of such defect within such time period, Licensee shall be deemed to
have accepted such Licensed Product. Licensee shall promptly supply GPC Biotech with any evidence
it has that relates to whether any Licensed Product delivered to Licensee by GPC Biotech fails to
meet the applicable Specifications.

          2.9 Inspection. Licensee shall have the right, no more than once during any Calendar Year
during the Term, except for any additional “for cause” inspections where Licensee has been informed
of quality issues at any of the Facilities, to enter the Facilities upon

9

 

reasonable advance notice and during normal business hours for the purpose of inspecting the
Facilities, procedures and any relevant records relating to the Manufacture of Licensed Product
(including all batch sheets and records for all Manufacturing steps); provided, however, that, with
respect to any audit of a Subcontractor’s facility, Licensee agrees to enter into a customary
confidentiality agreement reasonably acceptable to such Subcontractor prior to such audit and upon
such Subcontractor’s request; and provided further, that any inspection of the API Facility or
Finishing Facility shall be coordinated with any inspection planned by GPC Biotech. No such
inspection shall diminish or increase GPC Biotech’s obligations hereunder, except that GPC Biotech
shall, and shall cause its Subcontractors to, undertake to use commercially reasonable efforts to
correct promptly any deficiencies reasonably identified by Licensee in such inspection. In the
event that any Facility used in the Manufacturing of Licensed Product hereunder is inspected by
representatives of any Regulatory Authority in connection with the Manufacture of the Licensed
Product, GPC Biotech shall notify Licensee immediately by telephone and follow up in writing, upon
learning of such inspection, and shall promptly supply Licensee with copies of any reports or
responses prepared by the Regulatory Authority, GPC Biotech or the applicable Subcontractor
relating to such inspection. Licensee may send representatives to such Facility and Licensee may
participate in any portion of such inspection relating to the Licensed Product of which GPC Biotech
receives advance notice.

          2.10 Manufacturing Records. GPC Biotech shall, and shall cause its Subcontractors to,
maintain adequate and accurate books and records with respect to its and their activities
hereunder, including Manufacturing records and lot traceability records, with respect to each
Licensed Product lot delivered hereunder. These records shall be retained until Licensee gives GPC
Biotech written consent for records to be destroyed, which consent shall not be unreasonably
withheld; provided, however, that in no event shall records be destroyed at any time when such
records are required to be retained by Applicable Law. Notwithstanding the foregoing, GPC Biotech
shall, prior to discarding any documentation related to the Manufacture of Licensed Product, make
such documentation available for collection by Licensee at Licensee’s expense.

          2.11 Batch Records. Upon request by Licensee, GPC Biotech shall make available for review
copies of the individual and master batch records received from Subcontractors and used for any
step in the Manufacture of Licensed Product delivered hereunder. Licensee may use the information
in such batch records as provided in the License Agreement, including in regulatory submissions in
order to gain or maintain regulatory approvals.

          2.12 Deviations. GPC Biotech agrees that it or its Subcontractor’s quality assurance function
shall review the Manufacturing records for all steps and all lots of Licensed Product delivered
hereunder. Upon discovery of any deviation from cGMP or from any warranty hereunder, GPC Biotech
shall promptly notify Licensee and conduct an appropriate investigation to determine the cause of
such deviation and take appropriate action at its expense to avoid recurrence. GPC Biotech shall
provide Licensee with the applicable documentation of such deviations and report to Licensee on the
results of the subsequent investigation and corrective actions taken to address such deviations.

10

 

          2.13 Warning Letters. Each Party shall promptly notify the other Party of, and provide the
other Party with copies of, any correspondence and/or other documentation received or prepared by
the Party in connection with receipt of any warning letter or other regulatory correspondence from
the FDA or any other Regulatory Authority in connection with the Manufacture of the Licensed
Product; provided that GPC Biotech may redact from such communications portions thereof which it is
required to keep confidential pursuant to binding agreements with Third Parties.

          2.14 Annual Reports. GPC Biotech shall supply, on a Calendar Year basis, Licensed Product data
related to applicable complaint test results, all investigations (regarding Manufacturing) and the
like, at Licensee’s expense, which Licensee reasonably requires in order to complete any filing
under any applicable regulatory regime, including any annual product review report that Licensee is
required to file with any applicable Regulatory Authority.

          2.15 Communication With Governmental Agencies. Subject to the rights and obligations set
forth in the License Agreement, each Party may communicate with any governmental agency, including
but not limited to governmental agencies responsible for granting regulatory approval for the
Licensed Product, regarding such Licensed Product if, in the opinion of that Party’s counsel, such
communication is necessary to comply with the terms of this Agreement or the requirements of any
law, governmental order or regulation; provided, however, that, unless in the reasonable opinion of
its counsel there is a legal prohibition against doing so, such Party shall permit the other Party
to accompany and take part in relevant communications with the agency, to receive copies of all
such communications from the agency and to review and provide comments on any written communication
with any Regulatory Authority or other government agency prior to submitting such communication.

          2.16 Quality Claims.

                    2.16.1. Independent Laboratory. In the event of any disagreement between GPC
Biotech and Licensee relating to Licensed Product conformance to the Specifications at
the time of delivery thereof by GPC Biotech to Licensee, the Parties shall use good
faith efforts to reach an amicable resolution of such disagreement. In the event that
resolution cannot be reached by the Parties within fifteen (15) Business Days, a
mutually agreed upon, neutral, independent laboratory meeting the requirements of cGMP
shall be brought in to resolve the disagreement upon the request of either Party. Such
laboratory shall use the test methods contained in the applicable Specifications. The
cost of such laboratory shall be borne by the Party determined by the laboratory to be
the non-prevailing Party in such disagreement. The findings of such laboratory shall
be binding on Licensee and GPC Biotech solely with respect to determining whether a
particular batch, portion of a batch, or multiple batches of Licensed Product conform
with the Specifications. Notwithstanding anything set forth in this Agreement to the
contrary, GPC Biotech expressly understands and agrees that Licensee shall have the
sole and final authority to determine whether all or a portion of any batch of Licensed
Product is suitable for release and distribution. In those instances where Licensee
has rejected any Licensed Product which has otherwise, according to the provisions of
this Section 2.16.1, been deemed suitable for use, Licensee shall pay

11

 

GPC Biotech for such Licensed Product in accordance with the terms of this Agreement.

                    2.16.2. Certain Remedies for Non-Conforming Licensed Product. In the event that
any Licensed Product delivered hereunder is determined to be not in conformance with
the applicable Specifications at the time of delivery, such Licensed Product shall be
returned by Licensee to GPC Biotech at GPC Biotech’s expense and GPC Biotech shall use
commercially reasonable efforts to replace such nonconforming Licensed Product within
sixty (60) days of such return at no extra charge to Licensee. In the event GPC Biotech
cannot replace such nonconforming Licensed Product within such sixty (60) day period,
it shall refund to Licensee the amount paid therefor. GPC Biotech shall also reimburse
Licensee for freight and any other shipment expenses incurred by Licensee in connection
with the disposition or return of any rejected Licensed Product. Licensee acknowledges
and agrees that in no event shall GPC Biotech have any liability of any kind for
Licensed Product that fails to conform to the applicable Specifications due to acts,
omissions or circumstances occurring after the delivery thereof.

          2.17 Second Source; Allocation of Inventory and Supply.

                    2.17.1. The Parties intend to have identified and qualified one or more second
source manufacturers for the Licensed Products and API during the term of this
Agreement. Except as set forth in Section 8.5 in the event of a Supply Failure, the
second source manufacturer shall be selected and qualified by GPC Biotech, with
Licensee’s written approval, in accordance with the terms of GPC Biotech’s existing
agreements with its Subcontractors; provided that any such second source shall be
approved by applicable Regulatory Authorities and shall comply with the provisions of
Section 2.4 hereof with respect to the completion of a Drug Master File or, if
applicable, CMC Sections of any Regulatory Documentation required to be submitted in
the Licensee Territory. The schedule for the qualification of the second source will
be agreed upon by the JMC promptly after the Effective Date.

                    2.17.2. In addition to the requirements of Section 2.1.2 hereof with respect to
Reserve Inventory levels, in the event of any shortage of available supply of API,
Materials or Licensed Product for any reason, GPC Biotech shall, during the period of
any such shortage, allocate at least [...***...] of its available Manufacturing
capacity at the Facilities to supply Licensed Product to Licensee under this Agreement.

 

*** Confidential Treatment Requested

12

 

ARTICLE III

CONSIDERATION

          3.1 Payment Terms; Price.

                    3.1.1. Invoicing. Concurrently with or promptly following the delivery of any
Licensed Product hereunder, GPC Biotech shall submit to Licensee an invoice covering
such Licensed Product. Each such invoice shall, to the extent applicable, identify
Licensee’s Purchase Order number, Licensed Product and lot numbers, names and
quantities, unit price and the total amount to be remitted by Licensee. In addition,
each invoice shall include documentation that, in reasonable detail, supports GPC
Biotech’s calculation of Manufacturing Cost in a format to be agreed upon by the
Parties. Licensee shall pay all such invoices within forty five (45) days after
receipt thereof.

                    3.1.2. Purchase Price. The purchase price to be paid by Licensee for all Licensed
Product delivered hereunder shall be an amount equal to the Supply Price for such
Licensed Product.

                    3.1.3. Use of Product From Validation Batches. The Parties intend that where
Licensed Product Manufactured in any validation batches produced by GPC Biotech or its
Subcontractors satisfies all of the requirements set forth in Article 6 hereof, such
product may be provided to Licensee under the terms of this Agreement for sale in the
Licensee Territory. In this event, where the Manufacturing Costs for the Licensed
Products produced in such validation batches were included in Collaboration Costs under
the License Agreement, Licensee shall be entitled to a credit applicable against the
Supply Price in an amount equal to the portion of such Collaboration Costs specifically
attributable to the Manufacture of such validation batches paid by Licensee under the
License Agreement.

                    3.1.4. Estimate of Future Manufacturing Costs; Audits. On or before the date that
is twelve (12) months prior to the anticipated date of commercial launch of the
Licensed Products in the Licensee Territory and annually thereafter, GPC Biotech shall
notify Licensee of its estimated Manufacturing Cost for the Licensed Product that will
apply for the next one-year period and provide supporting documentation for such
Manufacturing Cost calculations. The JMC shall meet to review the estimated
Manufacturing Costs provided hereunder and to consider any actions that might be taken
to reduce such Manufacturing Costs. GPC Biotech shall maintain reasonably detailed
and complete records of its Manufacturing Costs in accordance with generally accepted
accounting principles applicable in the United States during the term of this Agreement
and for a period of not less than three (3) years from the expiration date of each
batch to which such records pertain or such longer period as may be required by
Applicable Law. Licensee shall have the right, no more than once during any Calendar
Year during the Term, to conduct an audit of GPC Biotech’s books and records upon
reasonable advance notice and during normal business

13

 

          hours for the purpose of verifying Manufacturing Costs invoiced to Licensee hereunder.

          3.2 Mode of Payment. All payments to GPC Biotech under this Agreement shall be made by
deposit of Euros in the requisite amount to such bank account as GPC Biotech may from time to time
designate by notice to Licensee.

          3.3 Taxes. The purchase price payable by Licensee for Licensed Product in accordance with
Section 3.1.2 excludes all sales, use, value added or other similar taxes or duties payable in
connection with the sale of such Licensed Product; any and all of which shall be the sole
responsibility of Licensee.

          3.4 Interest on Late Payment. If any payment due to GPC Biotech under this Agreement is
overdue on any amounts invoiced that are not subject to a good faith dispute by Licensee, then
Licensee shall pay interest thereon (before and after any judgment) at an annual rate (but with
interest accruing on a daily basis) of the lesser of four percent (4%) above the prime rate as
reported in The Wall Street Journal, Eastern Edition, and the maximum rate allowed by Applicable
Law, such interest to run from the date upon which payment of such sum became due until payment
thereof in full together with such interest.

ARTICLE IV

INTELLECTUAL PROPERTY

          4.1 Ownership of Specifications and Manufacturing Process. Licensee acknowledges and agrees
that, as between the Parties, the Specifications and Manufacturing Processes for the Licensed
Product shall be the sole and exclusive property of GPC Biotech, subject to the licenses granted to
Licensee under the License Agreement.

ARTICLE V

CONFIDENTIALITY

          5.1 Confidentiality and Non-Disclosure. Each Party acknowledges and agrees that any
information furnished or otherwise made known to it, directly or indirectly, by the other Party in
connection with this Agreement shall constitute Confidential Information of the other Party for all
purposes of the License Agreement, except to the extent that any such information is not included
in the Definition of Confidential Information pursuant to Section 11.1 of the License Agreement.
Notwithstanding anything in the foregoing sentence to the contrary, Licensee acknowledges and
agrees that Specifications and Manufacturing Processes for the Licensed Product shall constitute
the Confidential Information of GPC Biotech subject to all applicable terms and conditions set
forth in the License Agreement.

ARTICLE VI

REPRESENTATIONS AND WARRANTIES

          6.1 Representations and Warranties of GPC Biotech. GPC Biotech represents, and warrants to
Licensee that:

14

 

                    6.1.1. It or its Subcontractors have obtained (or shall obtain prior to
Manufacturing Licensed Product), and shall remain in compliance with during the Term,
all permits, licenses and other authorizations (the “Permits”) which are required by
Applicable Law to the Manufacture Licensed Product as specified by this Agreement and
for qualification of the Facilities for such purposes; provided, however, GPC Biotech
shall have no obligation under this Agreement to obtain Permits relating to the sale,
marketing, distribution or use of API or Licensed Product or with respect to the
labeling of Licensed Product;

                    6.1.2. All Manufacturing under this Agreement shall be conducted in accordance in
all respects with cGMP, including (i) availability of adequate personnel and facilities
to comply with such requirements and (ii) all other processes, methods and requirements
necessary for compliance with cGMP and all other Applicable Laws, the Manufacturing
Process, the Quality Agreement and the Specifications. In addition, all Manufacturing
shall be conducted in accordance with GPC Biotech’s or its Subcontractor’s standard
operating procedures;

                    6.1.3. At the time of delivery thereof to Licensee, the Licensed Product
Manufactured under this Agreement, shall be in conformance with the applicable
Specifications and shall not be adulterated or misbranded within the meaning of the
FFDCA or any substantially similar definition under other Applicable Law;

                    6.1.4. It has not been debarred, nor is it subject to a pending debarment, and
shall not use the services of any Persons debarred pursuant to section 306 of the
FFDCA, 21 U.S.C. § 335(a) or (b) in any capacity associated with or related to the
Manufacture of the Licensed Product. GPC Biotech shall promptly inform Licensee in
writing of any debarment, or the commencement of any debarment or like proceedings
against GPC Biotech, its employees, officers, agents or Subcontractors, during the
Term. GPC Biotech also warrants that neither GPC Biotech nor any of its officers or
employees has been convicted of a felony under the U.S. federal law for conduct
relating to the development or approval, including the process for development or
approval, of any drug product, new drug application or abbreviated new drug application
and neither GPC Biotech nor any of its officers or employees has been convicted of a
felony under the U.S. federal law for conduct relating to the regulation of any product
under the FFDCA; and

                    6.1.5. To GPC Biotech’s Knowledge, as of the Effective Date, GPC Biotech is in
compliance in all material respects with the terms of its agreements with
Subcontractors relating to the Facilities (the “Subcontractor Agreements”). GPC
Biotech covenants to Licensee and agrees that it shall use all commercially reasonable
efforts not to take any action or omit to take any action that would constitute a
breach of the Subcontractor Agreements or enter into any amendment to the Subcontractor
Agreements, which amendment would be reasonably likely to have a material adverse
effect on the Manufacturing of the

15

 

Licensed Product in the Licensee Territory or GPC Biotech’s ability to perform its
obligations under this Agreement. GPC Biotech shall provide Licensee promptly with
notice of the occurrence of any such breach or any notice alleging that GPC Biotech has
committed any such breach.

          6.2 Representations and Warranties of Each Party. Each Party represents and warrants to the
other Party that it has the full power and right to enter into this Agreement and that there are no
outstanding agreements, assignments, licenses, encumbrances or rights of any kind held by other
parties, private or public, inconsistent with the provisions of this Agreement.

          6.3 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTIONS 6.1 AND
6.2, GPC BIOTECH MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN
FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND GPC BIOTECH SPECIFICALLY DISCLAIMS ANY
OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF
QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE
VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD
PARTIES. LICENSEE’S EXCLUSIVE REMEDY FOR BREACH OF WARRANTY BY GPC BIOTECH SHALL BE DIRECT
DAMAGES AND GPC BIOTECH’S OBLIGATION TO REPAIR OR REPLACE THE LICENSED PRODUCT AND RESUBMIT IT TO
LICENSEE IN ACCORDANCE WITH THE PROVISIONS OF SECTION 2.8.

ARTICLE VII

INDEMNITY

          7.1 Indemnification of GPC Biotech. Licensee agrees to indemnify, defend and hold harmless
GPC Biotech, its Affiliates and their respective directors, officers, employees and agents from and
against any and all losses, damages liabilities, lawsuits, proceedings, costs and expenses arising
therefrom, including without limitation, reasonable attorneys’ fees and the cost of recalls
(collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of
Third Parties (collectively, “Claims”) arising from or occurring as a result of (a) the breach by
Licensee of this Agreement or (b) the negligence or willful misconduct on the part of Licensee in
performing its obligations under this Agreement, except for those Losses for which GPC Biotech has
an obligation to indemnify Licensee pursuant to Section 7.2 hereof, as to which Losses each Party
shall indemnify the other to the extent of their respective liability; provided, however, that
Licensee shall not be obligated to indemnify GPC Biotech for any Losses to the extent that such
Losses arise as a result of gross negligence or willful misconduct on the part of GPC Biotech or
any of its Affiliates.

          7.2 Indemnification of Licensee. Subject to Section 7.4, GPC Biotech agrees to indemnify,
defend and hold harmless Licensee, its Affiliates and their respective directors, officers,
employees and agents from and against any and all Losses in connection with any and all Claims
arising from or occurring as a result of (a) the breach by GPC Biotech or any Subcontractor of this
Agreement or (b) the negligence or willful misconduct on the part of GPC

16

 

Biotech or any Subcontractor in performing its obligations under this Agreement or a Subcontract,
except for those Losses for which Licensee has an obligation to indemnify Licensee pursuant to
Section 7.1 hereof, as to which Losses each Party shall indemnify the other to the extent of their
respective liability; provided, however, that GPC Biotech shall not be obligated to indemnify
Licensee for any Losses to the extent that such Losses arise as a result of gross negligence or
willful misconduct on the part of Licensee or any of its Affiliates, Sublicensees or Distributors.

          7.3 Indemnification Procedures.

                    7.3.1. All indemnification claims in respect of a Party, its Affiliates or their
respective directors, officers, employees and agents shall be made solely by such Party
to this Agreement (the “Indemnified Party”). The Indemnified Party shall give the
indemnifying Party prompt written notice (an “Indemnification Claim Notice”) of any
Losses or discovery of fact upon which such indemnified Party intends to base a request
for indemnification under Section 7.1 or 7.2, but in no event shall the indemnifying
Party be liable for any Losses that result from any delay in providing such notice.
Each Indemnification Claim Notice must contain a description of the claim and the
nature and amount of such Loss (to the extent that the nature and amount of such Loss
is known at such time). The Indemnified Party shall furnish promptly to the
indemnifying Party copies of all papers and official documents received in respect of
any Losses and Claims.

                    7.3.2. At its option, the indemnifying Party or, if GPC Biotech is the
indemnifying Party and at GPC Biotech’s option, any Subcontractor, may assume the
defense of any Claim by giving written notice to the Indemnified Party within thirty
(30) days after the indemnifying Party’s receipt of an Indemnification Claim Notice,
which notice shall include an express agreement to undertake the defense of such Claim
in accordance with the provisions of this Article 7. The assumption of the defense of
a Claim by the indemnifying Party shall not be construed as an acknowledgment that the
indemnifying Party is liable to indemnify the Indemnified Party in respect of the
Claim, nor shall it constitute a waiver by the indemnifying Party of any defenses it
may assert against the Indemnified Party’s claim for indemnification. Upon assuming
the defense of a Claim, the indemnifying Party may appoint as lead counsel in the
defense of the Claim any legal counsel selected by the indemnifying Party. In the
event the indemnifying Party assumes the defense of a Claim, the Indemnified Party
shall immediately deliver to the indemnifying Party all original notices and documents
(including court papers) received by the Indemnified Party in connection with the
Claim. Should the indemnifying Party assume the defense of a Claim, except as provided
in Section 7.3.1, the indemnifying Party shall not be liable to the Indemnified Party
for any legal expenses subsequently incurred by such Indemnified Party in connection
with the analysis, defense or settlement of the Claim. In the event that it is
ultimately determined that the indemnifying Party is not obligated to indemnify, defend
or hold harmless the Indemnified Party from and against the Claim, the Indemnified
Party shall reimburse the indemnifying

17

 

Party for any and all costs and expenses (including attorneys’ fees and costs of suit)
incurred by the indemnifying Party in its defense of the Third Party Claim.

          7.3.3. Without limiting Section 7.3.2 above, any Indemnified Party shall be
entitled to participate in, but not control, the defense of such Claim and to employ
counsel of its choice for such purpose; provided, however, that such employment shall
be at the Indemnified Party’s own expense unless (i) the employment thereof has been
specifically authorized by the indemnifying Party in writing, (ii) the indemnifying
Party has failed to assume the defense and employ counsel in accordance with Section
7.3.2 (in which case the Indemnified Party shall control the defense) or (c) the
interests of the Indemnified Party and the indemnifying Party (or, if applicable, an
indemnifying Subcontractor) with respect to such Claim are sufficiently adverse to
prohibit the representation by the same counsel of both parties under applicable law,
ethical rules or equitable principles.

          7.3.4. With respect to any Loss relating solely to the payment of money damages in
connection with a Claim that shall not result in the Indemnified Party’s becoming
subject to injunctive or other relief or otherwise adversely affecting the business of
the Indemnified Party in any manner, and as to which the indemnifying Party shall have
acknowledged in writing the obligation to indemnify the Indemnified Party hereunder,
the indemnifying Party shall have the sole right to consent to the entry of any
judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as
the indemnifying Party, in its sole discretion, shall deem appropriate; provided that
such disposition includes as an unconditional term thereof the giving by the claimant
or plaintiff to the Indemnified Party of a release of all liability in respect thereof.
With respect to all other Losses in connection with any Claim, where the indemnifying
Party has assumed the defense of the Claim in accordance with Section 7.3.2, the
indemnifying Party shall have authority to consent to the entry of any judgment, enter
into any settlement or otherwise dispose of such Loss provided it obtains the prior
written consent of the Indemnified Party (which consent shall not be unreasonably
withheld or delayed). Regardless of whether the indemnifying Party chooses to defend
or prosecute any Claim, no Indemnified Party shall admit any liability with respect to
or settle, compromise or discharge, any Third Party Claim without the prior written
consent of the indemnifying Party, such consent not to be unreasonably withheld or
delayed.

          7.3.5. If the indemnifying Party chooses to defend or prosecute any Claim, the
Indemnified Party shall, and shall cause each Indemnified Party to, cooperate in the
defense or prosecution thereof and shall furnish such records, information and
testimony, provide such witnesses and attend such conferences, discovery proceedings,
hearings, trials and appeals as may be reasonably requested in connection therewith.
Such cooperation shall include access during normal business hours afforded to
indemnifying Party to, and reasonable retention by the Indemnified Party of, records
and information that are reasonably relevant to such Claim, and making indemnified
Parties and other

18

 

employees and agents available on a mutually convenient basis to provide additional
information and explanation of any material provided hereunder, and the indemnifying
Party shall reimburse the Indemnified Party for all its reasonable out-of-pocket
expenses in connection therewith.

                    7.3.6. Except as provided above, the costs and expenses, including fees and
disbursements of counsel, incurred by the Indemnified Party in connection with any
Claim shall be reimbursed on a Calendar Quarter basis by the indemnifying Party,
without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s
right to indemnification and subject to refund in the event the indemnifying Party is
ultimately held not to be obligated to indemnify the Indemnified Party.

          7.4 Limitations.

                    7.4.1. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A
PARTY OR ITS AFFILIATES (OR WITH RESPECT TO LICENSEE, ITS SUBLICENSEES OR
DISTRIBUTORS), OR WITH RESPECT TO CLAIMS UNDER SECTION 7.1 OR 7.2, NO PARTY OR ANY OF
THEIR RESPECTIVE AFFILIATES SHALL BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE
OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, WHETHER IN CONTRACT, WARRANTY,
NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF ANY BREACH OF OR
FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT.

                    7.4.2. NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE PARTIES AGREE THAT THE
AGGREGATE MONETARY LIABILITY OF GPC BIOTECH FOR ANY BREACH OF THE TERMS OF THIS
AGREEMENT BY A SUBCONTRACTOR SHALL BE SUBJECT TO ANY LIMITATIONS ON LIABILITY SPECIFIED
IN GPC BIOTECH’S AGREEMENT WITH SUCH SUBCONTRACTOR; PROVIDED, HOWEVER, THAT NOTHING IN
THIS SECTION 7.4.2 SHALL OPERATE TO LIMIT GPC BIOTECH’S LIABILITY OR LICENSEE’S
REMEDIES SPECIFIED IN THE LICENSE AGREEMENT OR ANY NON-MONETARY REMEDIES EXPRESSLY
PROVIDED IN THIS AGREEMENT.

ARTICLE VIII

TERM AND TERMINATION

          8.1 Term. Unless earlier terminated as provided herein, the term of this Agreement (the
“Term”) shall commence on the Effective Date and shall expire on a country-by-country basis on the
date of expiration or termination of the License Agreement for any reason with respect to such
country or countries.

19

 

          8.2 Termination of this Agreement for Material Breach. In the event that either Party (the
“Breaching Party”) shall be in material default in the performance of any of its material
obligations under this Agreement, in addition to any other right and remedy the other Party (the
“Complaining Party”) may have, the Complaining Party may terminate this Agreement, in its entirety
by sixty (60) days’ prior written notice (the “Notice Period”) to the Breaching Party, specifying
the breach and its claim of right to terminate; provided always that the termination shall not
become effective at the end of the Notice Period if the Breaching Party cures the breach complained
about during the Notice Period (or, if such default cannot be cured within such sixty (60)-day
period, if the Breaching Party commences actions to cure such default within the Notice Period and
thereafter diligently continues such actions; provided further that such default is cured within
one hundred eighty (180) days after the receipt of such notice), except in the case of a payment
default (with respect to amounts invoiced by GPC Biotech that are not subject to a good faith
dispute by Licensee), as to which the Breaching Party shall have only a ten (10)-day cure period.

          8.3 Termination by Either Party. Either Party shall have the right to terminate this Agreement
by written notice to the other Party upon the occurrence of any of the following: (a) the other
Party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies
for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit
of creditors, or becomes subject to involuntary proceedings under any bankruptcy or insolvency law
(which proceedings remain undismissed for sixty (60) days) or (b) a force majeure event pursuant to
Section 9.6.

          8.4 Accrued Rights; Surviving Obligations.

                    8.4.1. Accrued Rights. Termination or expiration of this Agreement for any reason
shall be without prejudice to any rights that shall have accrued to the benefit of a
Party prior to such termination or expiration. Such termination or expiration shall
not relieve a Party from obligations that are expressly indicated to survive the
termination or expiration of this Agreement.

                    8.4.2. Materials. Upon termination of this Agreement for any reason except
termination by Licensee pursuant to Section 8.2, Licensee promptly shall reimburse GPC
Biotech for the actual costs of all API, Materials and work in process in the
possession of GPC Biotech or its Subcontractors, or which GPC Biotech or its
Subcontractors have committed to purchase (unless cancelable); provided that the
amounts of such API, Materials and work in process shall not exceed the quantities
necessary to Manufacture the amount of Licensed Product specified in the binding
portion of the most recently submitted Forecast (as provided in Section 2.2.2), unless
the Parties mutually agree that inventory levels of API and Materials may exceed the
requirements for such periods; provided further that Licensee shall only be liable for
any such inventory of API, Materials and work in process including excess inventory
mutually agreed by the Parties, that is not otherwise usable by GPC Biotech in the
ordinary course of business.

20

 

                    8.4.3. Survival. Without limiting the foregoing, Sections 2.8, 2.10, 2.16, 3.2,
3.3, 3.4, 6.3, 9.1, 9.2, 9.3, 9.5, 9.7, 9.8, 9.9, 9.10, 9.11, 9.12, 9.13, 9.15, 9.16,
this Section 8.4, and Articles IV, V and VII of this Agreement shall survive the
termination or expiration of this Agreement for any reason.

          8.5 Failure of Supply. In the event of a Supply Failure (as defined below), Licensee shall
have the right to identify, establish and maintain a Third Party manufacturer as a second source
for the supply of Licensed Product or API, as applicable (a “Second Source”). No later than ten
(10) Business Days after a Supply Failure, the JMC shall establish a schedule and budget for
activities and responsibilities of the parties, including technology transfer, required to
establish the Second Source. Promptly after the selection of a Second Source for the Licensed
Product by Licensee and such Second Source enters into a written agreement with GPC Biotech, GPC
Biotech shall commence transfer to such Second Source of technology relating to the Manufacturing
Process for the Licensed Product which transfer shall be completed as soon as practicable
thereafter, subject to the applicable terms of such agreement. Such agreement shall include (a)
licenses under Intellectual Property Rights Controlled by GPC Biotech to the extent required to
enable the Second Source to Manufacture the Licensed Products for Licensee and (b) adequate
protection for the trade secrets and other confidential information of GPC Biotech relating to
transferred technology. GPC Biotech shall bear the expenses (including any payments to Third
Parties) associated with the activities under this Section 8.5, unless the cause of the Supply
Failure is a Force Majeure event (as described in Section 9.6) in which case such costs and
expenses shall be deemed “Collaboration Costs” subject to the terms of the License Agreement. For
purposes of this Section 8.5, a “Supply Failure” shall be deemed to occur if, at any time during
the term of this Agreement, GPC Biotech fails to deliver to Licensee an amount of Licensed Product
conforming to the requirements of Article 6 hereof of less than (i) [...***...] of the quantities
specified in Purchase Orders over a period of [...***...]; or (ii) [...***...] of the quantities
specified in Purchase Orders over a period of [...***...], where in each case such quantities were
properly forecast and ordered by Licensee in accordance with this Section 2. In addition, if
either Party becomes aware of any conditions or circumstances affecting the supply of Licensed
Products or the Facilities that could reasonably be expected to lead to a Supply Failure, such
Party will inform the other Party thereof. In such event, Licensee may then begin the process of
identifying and contacting potential Second Sources and Licensee shall work with the JMC in
establishing a contingency plan for the technology transfer activities specified herein.

ARTICLE IX

MISCELLANEOUS

          9.1 Notices.

                    9.1.1. Notice Requirements. Any notice, request, demand, waiver, consent,
approval or other communication permitted or required under this Agreement shall be in
writing, shall refer specifically to this Agreement and shall be deemed given only if
delivered by hand or sent by facsimile transmission (with transmission confirmed) or by
internationally recognized overnight delivery service that maintains records of
delivery, addressed to the

 

*** Confidential Treatment Requested

21

 

Parties at their respective addresses specified in Section 9.1.2 or to such other
address as the Party to whom notice is to be given may have provided to the other Party
in accordance with this Section 9.1. Such Notice shall be deemed to have been given as
of the date delivered by hand or transmitted by facsimile (with transmission confirmed)
or on the second business day (at the place of delivery) after deposit with an
internationally recognized overnight delivery service. Any notice delivered by
facsimile shall be confirmed by a hard copy delivered as soon as practicable
thereafter. This Section 9.1 is not intended to govern the day-to-day business
communications necessary between the Parties in performing their obligations under the
terms of this Agreement.

                    9.1.2. Address for Notice

If to Licensee, to:

Pharmion GmbH

Aeschenvorstadt 71,

4051 Basel,

Switzerland

Attention: Director

Facsimile: +41 61 305 9899

with a copy to:

Pharmion Corporation

2525 28th Street

Boulder, Colorado 80301

Attention: VP and General Counsel

Facsimile: 720 564 9191

If to GPC Biotech, to:

GPC Biotech AG

Fraunhoferstrasse 20

82152 Martinsried/Munich, Germany

Attention: Chief Executive Officer

Facsimile: +49 89 85 65 2610

with a copy to:

GPC Biotech Inc.

101 College Road East

Princeton, NJ 08540, U.S.A.

Attention: General Counsel

Facsimile: +1 609 524 1050

22

 

          9.2 Governing Law, Jurisdiction, Venue and Service.

                    9.2.1. Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, excluding any conflicts or choice of
law rule or principle that might otherwise refer construction or interpretation of this
Agreement to the substantive law of another jurisdiction. The Parties agree to exclude
the application to this Agreement of the United Nations Convention on Contracts for the
International Sale of Goods.

                    9.2.2. Jurisdiction. Subject to Sections 9.3 and 9.11, the Parties hereby
irrevocably and unconditionally consent to the exclusive jurisdiction of the courts of
the State of New York and the United States District Court for the Southern District of
New York for any action, suit or proceeding (other than appeals therefrom) arising out
of or relating to this Agreement, and agree not to commence any action, suit or
proceeding (other than appeals therefrom) related thereto except in such courts. The
Parties irrevocably and unconditionally waive their right to a jury trial.

                    9.2.3. Venue. The Parties further hereby irrevocably and unconditionally waive
any objection to the laying of venue of any action, suit or proceeding (other than
appeals therefrom) arising out of or relating to this Agreement in the courts of the
State of New York or in the United States District Court for the Southern District of
New York, and hereby further irrevocably and unconditionally waive and agree not to
plead or claim in any such court that any such action, suit or proceeding brought in
any such court has been brought in an inconvenient forum.

                    9.2.4. Service. Each Party further agrees that service of any process, summons,
notice or document by registered mail to its address set forth in Section 9.1.2 shall
be effective service of process for any action, suit or proceeding brought against it
under this Agreement in any such court.

          9.3 Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be
waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall
be effective unless set forth in a written instrument duly executed by or on behalf of the Party
waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the
failure to perform or of a breach by the other Party shall not be deemed a waiver of any other
right hereunder or of any other breach or failure by said other Party whether of a similar nature
or otherwise.

          9.4 Assignment. Without the prior written consent of the other Party hereto, neither Party
shall sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily,
involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties
hereunder; provided, however, that (a) GPC Biotech may, without such consent, delegate its
obligations hereunder in accordance with Section 2.1.1, (b) either Party may, without such consent,
assign this Agreement and its rights and obligations hereunder in connection with any assignment of
the License Agreement as permitted under Section 15.4 of the License Agreement;

23

 

provided that in the case of such assignment to an Affiliate, such assigning Party shall remain
responsible for the performance by such Affiliate of the rights and obligations hereunder. Any
attempted assignment or delegation in violation of the preceding sentence shall be void and of no
effect. All validly assigned and delegated rights and obligations of the Parties hereunder shall
be binding upon and inure to the benefit of and be enforceable by and against the successors and
permitted assigns of GPC Biotech or Licensee, as the case may be. In the event either Party seeks
and obtains the other Party’s consent to assign or delegate its rights or obligations to another
Party, the assignee or transferee shall assume all obligations of its assignor or transferor under
this Agreement.

          9.5 Severability. If any provision of this Agreement is held to be illegal, invalid or
unenforceable under any present or future law, and if the rights or obligations of either Party
under this Agreement shall not be materially and adversely affected thereby, (a) such provision
shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal,
invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions
of this Agreement shall remain in full force and effect and shall not be affected by the illegal,
invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal,
invalid or unenforceable provision, there shall be added automatically as a part of this Agreement
a legal, valid and enforceable provision as similar in terms to such illegal, invalid or
unenforceable provision as may be possible and reasonably acceptable to the Parties. To the
fullest extent permitted by applicable law, each Party hereby waives any provision of law that
would render any provision hereof illegal, invalid or unenforceable in any respect.

          9.6 Force Majeure. Notwithstanding anything to the contrary contained herein, neither Party
shall be deemed to be in breach hereof or be liable for non-performance, defective or late
performance of any of its obligations under this Agreement (other than obligations to pay money) to
the extent and for such periods of time as such non-performance, defective or late performance is
due to reasons of strike, riots, war, act of God, invasion, fire, explosion, floods, delay of
carrier, shortage in the supply of Materials, acts of government or governmental agencies or
instrumentalities (other than such acts that arise from or relate to violations of Applicable Law
by the affected Party) and any other contingencies beyond the Parties’ or any Subcontractor’s
reasonable control. The Party affected shall give written notice to the other Party of any
material delay due to such causes. In the event a force majeure event prevents a Party’s
performance under this Agreement for one hundred eighty (180) consecutive days, the other Party may
(in addition to all other rights of such Party under this Agreement, including Section 8.5)
terminate this Agreement upon thirty (30) days prior written notice to the other Party, but such
termination shall not be deemed a breach by the Party affected by the force majeure condition.

          9.7 No Benefit to Other Persons. The representations, warranties, covenants and agreements
set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and
permitted assigns, and they shall not be construed as conferring any rights on any other Persons.

          9.8 Export Control. This Agreement is made subject to any restrictions concerning the export
of products or technical information from the United States or other countries that may be imposed
on related to the Parties from time to time. Each Party agrees that

24

 

it shall not export, directly or indirectly, any technical information acquired from the other
Party under this Agreement or any products using such technical information to a location or in a
manner that at the time of export requires an export license or other governmental approval,
without first obtaining the written consent to do so from the appropriate agency or other
governmental entity in accordance with Applicable Law.

          9.9 Relationship of the Parties. It is expressly agreed that GPC Biotech, on the one hand,
and Licensee, on the other hand, shall be independent contractors and that the relationship between
the two Parties shall not constitute a partnership, joint venture or agency. Neither GPC Biotech,
on the one hand, nor Licensee, on the other hand, shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall be binding on the
other, without the prior written consent of the other Party to do so, such consent not to be
unreasonably withheld or delayed. All persons employed by a Party shall be employees of such Party
and not of the other Party and all costs and obligations incurred by reason of any such employment
shall be for the account and expense of such Party.

          9.10 References. Unless otherwise specified, (a) references in this Agreement to any Article
or Section shall mean references to such Article or Section of this Agreement, (b) references in
any section to any clause are references to such clause of such section and (c) references to any
agreement, instrument or other document in this Agreement refer to such agreement, instrument or
other document as originally executed or, if subsequently varied, replaced or supplemented from
time to time, as so varied, replaced or supplemented and in effect at the relevant time of
reference thereto.

          9.11 Dispute Resolution.

                    9.11.1. General. Except with respect to Section 2.16, if a dispute arises between
the Parties in connection with or relating to this Agreement or any document or
instrument delivered in connection herewith (a “Dispute”), then either Party shall have
the right to refer such dispute to the Chief Executive Officer of GPC Biotech and the
Chief Executive Officer of Licensee who shall confer on the resolution of the issue.
Any final decision mutually agreed to by such representatives shall be conclusive and
binding on the Parties. If such officers are not able to agree on the resolution of an
issue within twenty (20) Business Days after such issue was first referred to them,
either Party may, by written notice to the other Party, elect to initiate arbitration
pursuant to Section 9.11.2 for purposes of having the matter settled.

                    9.11.2. Arbitration. Any arbitration under this Agreement shall take place at a
location to be agreed by the Parties; provided, however, that in the event that the
Parties are unable to agree on a location for an arbitration under this Agreement
within five (5) days of the demand therefor, such arbitration shall be held in New
York, New York. Any arbitration under this Agreement shall be administered by the
American Arbitration Association under its Commercial Arbitration Rules then in effect
(the “Arbitration Rules”). The Parties shall appoint an arbitrator by mutual
agreement. If the Parties cannot agree on the appointment of an arbitrator within
thirty (30) days of the demand for arbitration,

25

 

an arbitrator shall be appointed in accordance with the Arbitration Rules. The
arbitrator shall have the authority to grant any equitable and legal remedies that
would be available in any judicial proceeding instituted to resolve the Dispute
submitted to such arbitration in accordance with this Agreement; provided, however,
that the arbitrator shall not have the power to alter, amend or otherwise affect the
terms or the provisions of this Agreement. Judgment upon any award rendered pursuant
to this Section may be entered by any court having jurisdiction over the Parties’ other
assets. The arbitrator shall have no authority to award punitive or any other type of
damages not measured by a Party’s compensatory damages. Each Party shall bear its own
costs and expenses and attorneys’ fees and an equal share of the arbitrator’s fees and
any administrative fees of arbitration, unless the arbitrator shall otherwise allocate
such costs, expenses and fees between the Parties. The Parties agree that all
arbitration awards shall be final and binding on the Parties and their Affiliates. The
Parties hereby waive the right to contest the award in any court or other forum.
Except to the extent necessary to confirm or enforce an award or as may be required by
law, neither a Party nor an arbitrator may disclose the existence, content or results
of an arbitration without the prior written consent of both Parties.

                    9.11.3. Interim Relief. Notwithstanding anything herein to the contrary, nothing
in this Section shall preclude either Party from seeking interim or provisional relief,
including a temporary restraining order, preliminary injunction or other interim
equitable relief concerning a dispute, if necessary to protect the interests of such
Party. This Section shall be specifically enforceable.

          9.12 Entire Agreement. This Agreement sets forth and constitutes the entire agreement and
understanding between the Parties with respect to the subject matter hereof and all prior
agreements, understandings, promises and representations, whether written or oral, with respect
thereto are superseded hereby. Notwithstanding the foregoing, in event of any conflict between the
terms of this Agreement and the terms of the License Agreement, the terms of the License Agreement
shall control and take precedence. Each Party confirms that it is not relying on any
representations or warranties of the other Party except as specifically set forth herein. No
amendment, modification, release or discharge shall be binding upon the Parties unless in writing
and duly executed by authorized representatives of both Parties.

          9.13 English Language. This Agreement shall be written and executed in, and all other
communications under or in connection with this Agreement shall be in, the English language. Any
translation into any other language shall not be an official version thereof, and in the event of
any conflict in interpretation between the English version and such translation, the English
version shall control.

          9.14 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument. This Agreement may be executed by facsimile signatures and such signatures shall be
deemed to bind each Party hereto as if they were original signature.

26

 

          9.15 Further Assurance. Each Party shall duly execute and deliver, or cause to be duly
executed and delivered, such further instruments and do and cause to be done such further acts and
things, including the filing of such assignments, agreements, documents and instruments, as may be
necessary or as the other Party may reasonably request in connection with this Agreement or to
carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto
such other Party its rights and remedies under this Agreement.

          9.16 Construction. Except where the context otherwise requires, wherever used, the singular
shall include the plural, the plural the singular, the use of any gender shall be applicable to all
genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement
are for convenience of reference only and in no way define, describe, extend or limit the scope or
intent of this Agreement or the intent of any provision contained in this Agreement. The term
“including” as used herein shall mean including, without limiting the generality of any description
preceding such term. The language of this Agreement shall be deemed to be the language mutually
chosen by the Parties and no rule of strict construction shall be applied against either Party
hereto.

[SIGNATURE PAGE FOLLOWS.]

27

 

     THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first
written above.

	 	 	 
	GPC BIOTECH AG

	 	          PHARMION GMBH
	 
	 	 
	Signature : /s/ Elmar Maier, PhD

	 	Signature : /s/ Patrick J. Mahaffy
	 
	 	 
	Name : Elmar Maier, PhD

	 	Name : Patrick J. Mahaffy
	 
	 	 
	Title : SVP Business Development

	 	Title : Director
	 
	 	 
	Signature : /s/ Bernd R. Seizinger, M.D., PhD

	 	Signature : /s/ Erle T. Mast
	 
	 	 
	Name : Bernd R. Seizinger, M.D., PhD

	 	Name : Erle T. Mast
	 
	 	 
	Title : CEO

	 	Title : Director

28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]